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Summary 
The 3’-untranslated regions (3’-UTRs) of protein coding transcripts play a well-
established role as cis regulators of RNA stability and protein translation. Recent 
findings also point to functions in the nucleus. This thesis reports on the analysis of a 
specific 3’-UTR, referred to here as CU-RNA, originating from the CDV3 gene 
(carnitine deficiency-associated gene expressed in ventricle 3) that was previously 
identified as a 3’-UTR with a putative nuclear function. In an initial characterization of 
CU-RNA it was shown that it has nuclear functions due to the following criteria: (i) the 
transcript was able to rescue RNase A-induced chromatin aggregation, (ii) the 
transcript remained within the nucleus after microinjection, (iii) the endogenous 
transcript was present in the nucleus, (iv) by immobilizing the RNA at a specific 
genomic locus it was shown that locally tethered CU-RNA induces chromatin 
compaction, demonstrating its chromatin modifying activity. This chromatin 
recruitment system was subsequently used to investigate the mechanism of action of 
CU-RNA. It was found that CU-RNA derived fragments recruit enhancer of zeste 
homolog 2 (EZH2), the enzyme that sets trimethylation of histone H3 at lysine 27 
(H3K27me3). By deletion analysis a CU-RNA sequence element, CU-RNA-T0, was 
identified that was necessary to also induce H3K27me3. The splicing regulators 
PTBP1 (polypyrimidine tract binding protein 1) and U2AF2 (U2 small nuclear RNA 
auxiliary factor 2), and the H3K27me3-promoting factor HNRNPK (heterogeneous 
nuclear ribonucleoprotein K) were found to specifically interact with CU-RNA-T0. In 
contrast, an alternative splicing variant of CDV3 that lacks the T0 element 
(CU-RNA-ΔT0) and did not induce H3K27me3, bound the splice factor HNRNPC 
(heterogeneous nuclear ribonucleoprotein C). It was therefore investigated whether 
the H3K27me3 inducing activity of CU-RNA-T0 affects splicing. Reducing the 
H3K27me3 level at the CDV3 locus by inhibition of EZH2 enzymatic activity indeed 
changed the ratio of the CDV3 transcript variant levels. Based on these results a 
model is proposed, in which the CU-RNA-T0 element regulates alternative splicing of 
its own transcript, the CDV3, via a feedback loop that establishes a specific 
chromatin signature. Thereby stable steady-state levels between the splicing variants 
are regulated that might be distinct with respect to their 3’-UTR sequence dependent 
cytoplasmic activities. This contribution to the understanding of the mechanism 
governing alternative splicing is of great importance to be able to develop novel 
drugs targeting deregulated alternative splicing in cancer. 
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Zusammenfassung 
Die 3’-untranslatierten Regionen (3’-UTRs) von proteinkodierenden Transkripten 
spielen eine wichtige Rolle als cis-regulatorische Elemente von RNA-Stabilität und 
Proteintranslation. Neuere Erkenntnisse weisen darauf hin, dass sie darüber hinaus 
auch Funktionen im Zellkern haben könnten. In dieser Arbeit wurde eine bestimmte 
3’-UTR, genannt CU-RNA, analysiert, die vom CDV3 Gen (carnitine deficiency-
associated gene expressed in ventricle 3) stammt, und in vorhergehenden 
Publikationen als 3’-UTR mit vermeintlich nukleärer Funktion identifiziert wurde. In 
einer anfänglichen Charakterisierung wurde anhand der folgenden Kriterien 
festgestellt, dass die CU-RNA eine Funktion im Zellkern hat: Erstens konnte das 
Transkript RNase A-induzierter Chromatinverdichtung entgegenwirken, zweitens 
lokalisierte es nach Mikroinjektion im Zellkern, drittens konnte das endogene 
Transkript im Zellkern nachgewiesen werden und viertens führte die Rekrutierung 
von CU-RNA an einen bestimmten genomischen Lokus zu Chromatinverdichtung, 
was seine Fähigkeit Chromatin zu modifizieren demonstrierte. Dieses 
Rekrutierungssystem wurde im Weiteren dazu verwendet den Wirkmechanismus der 
CU-RNA zu untersuchen. Dabei wurde herausgefunden, dass Fragmente der 
CU-RNA das Enzym EZH2 (enhancer of zeste homolog 2) rekrutieren, welches für 
die Trimethylierung des Lysins an Position 27 von Histon 3 (H3K27me3) 
verantwortlich ist. Deletionsstudien zeigten, dass ein spezifisches Element der 
CU-RNA, CU-RNA-T0, notwendig ist um auch H3K27me3 am Chromatin zu 
induzierten. Die Spleißfaktoren PTBP1 (polypyrimidine tract binding protein 1) und 
U2AF2 (U2 small nuclear RNA auxiliary factor 2) und der H3K27me3-fördernde 
Faktor HNRNPK (heterogeneous nuclear ribonucleoprotein K) wurden zudem als 
CU-RNA-T0 interagierende Proteine identifiziert. Eine alternative Spleißvariante des 
CDV3 Gens, die das T0 Element nicht enthält (CU-RNA-ΔT0) und nicht H3K27me3 
induzierte, interagierte hingegen mit dem Spleißfaktor HNRNPC (heterogeneous 
nuclear ribonucleoprotein C). Folglich wurde untersucht, ob die H3K27me3-
fördernde Aktivität von CU-RNA-T0 alternatives Spleißen beeinflusst. Tatsächlich 
verschob sich das Verhältnis der CU-RNA Transkriptvarianten, wenn die H3K27me3 
Level mittels EZH2-Inhibitierung verringert wurden. Basierend auf diesen 
Ergebnissen wird ein Model aufgestellt, in welchem das CU-RNA-T0 Element das 
alternative Spleißen des eigenen Transkripts, CDV3, reguliert, indem es eine 
spezifische Chromatinsignatur etabliert. Dadurch wird das „steady-state“ Verhältnis 
der Transkriptvarianten reguliert, die sich zum Beispiel im Bezug auf ihre 3’-UTR 
x  
 
 
sequenzabhängigen zytoplasmatischen Aktivitäten unterscheiden können. Dieser 
Beitrag zum Verständnis des Mechanismus zur Regulation von alternativem 
Spleißen ist von großer Bedeutung, um gezielt Medikamente gegen dereguliertes 
alternatives Spleißen in Krebszellen zu entwickeln. 
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Introduction 
Gene expression can be regulated at many steps throughout the pathway leading 
from the information encoded in the DNA to the functional protein. At each of 
these steps, the process can be modulated to influence which particular genes 
are expressed and how much is expressed. Thus, cells can control transcription, 
RNA processing, RNA localization, RNA stability, translation, protein activity, and 
protein degradation. Besides its function as the messenger conveying genetic 
information from DNA to the ribosome, RNA is also an essential player in 
controlling gene expression at all levels in cis or in trans (Figure 1).  
Extensive studies of the diverse roles of RNA in all of these steps have led to the 
identification of various RNA species that are classified according to their 
functions in the cell. Examples of how different types of RNAs regulate gene 
expression include the following: On the level of chromatin modulation, a wide 
range of models of how RNAs exert their function has been suggested (Rinn & 
Chang, 2012): RNAs have been proposed i) to be the scaffold molecules of 
higher order chromatin organizing ribonucleoprotein complexes (Guttman et al, 
2011; Hung et al, 2011; Khalil et al, 2009; Kino et al, 2010; Kotake et al, 2011; 
Pandey et al, 2008; Yap et al, 2010), ii) to be at the center of chromatin modifying 
complexes by targeting them to chromatin and regulating their enzymatic 
activities (Gupta et al, 2010; Huarte et al, 2010; Rinn et al, 2007), iii) to act as 
decoys that titrate away DNA-binding proteins (Spitale et al, 2011; Zappulla & 
Cech, 2006), or iv) to foster chromosome looping (Yao et al, 2010). One famous 
example of a chromatin modifying RNA is the X inactivation specific transcript 
(XIST). It is involved in the processes of X chromosome inactivation in female 
mammalian cells where it plays a crucial role in the recruitment and regulation of 
the polycomb repressive complex 2 (PRC2) (for more details see introduction, 
section 2.1) (Brockdorff, 2013; Brockdorff et al, 1992). As a mode of controlling 
transcription RNAs have recently been proposed to assist transcription factors in 
finding their binding sites, as described for example for the Epstein-Barr virus 
encoded RNA 2 (EBER2) (Lee et al, 2015). Splicing of primary messenger RNA 
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(pre-mRNA) has long been known to be controlled by small nuclear RNAs 
(snRNAs) (Maniatis & Reed, 1987). The nuclear export of RNAs is directly linked 
to the process of mRNA maturation and polyadenylation thus, it also involves cis 
and trans acting signals encoded in RNA (Chekanova & Belostotsky, 2003; Luo & 
Reed, 1999). Likewise, the complex control of RNA stability and decay is 
influenced by cis-regulatory RNA elements, such as AU-rich elements (AREs) 
(Stoecklin & Muhlemann, 2013), and by microRNAs regulating the abundance of 
specific mRNAs in the cell (Valencia-Sanchez et al, 2006). In addition, translation 
regulation involves cis-regulatory RNA elements such as the 5’ cap structure and 
the 3’ poly(A) tail. Lastly, the processes of translation requires transfer RNAs 
(tRNAs) that are loaded with the amino acids (Gebauer & Hentze, 2004), and the 
ribosomal RNAs (rRNAs) as building blocks of the ribosomes (Yusupov et al, 
2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Role of RNA within the flow of information from DNA to protein in a eukaryotic 
cell. Examples of RNAs and elements within the RNAs that play a role in controlling each of 
these steps either in cis or in trans are indicated with the arrows on the left. XIST: X inactivation 
specific transcript, EBER: Epstein-Barr virus encoded RNA 2, snRNAs: small nuclear RNAs, 
poly(A) tail: poly-adenylated tail, miRNA: microRNAs, ARE: AU-rich elements, tRNA: transfer 
RNA, rRNA: ribosomal RNA. 
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While more and more RNA species with regulatory roles in gene expression 
particularly at the level of chromatin organization are identified, little is known 
about the chromatin-regulatory functions of the mRNA itself. This thesis focuses 
on the role of the 3’ untranslated regions (3’-UTRs) of mRNAs in regulating 
chromatin organization. It is examined how 3’-UTRs can influence chromatin, and 
thereby how they can regulate RNA splicing and determine expression of 
different splice variants of the same transcript. The regulation of gene expression 
by chromatin modifications, the role of RNA as a regulatory factor of this process 
and the regulation of RNA splicing will therefore be introduced in more detail in 
the following.  
 
1 Covalent modifications of histones regulate gene expression 
The genomic DNA of eukaryotic cells is highly packaged into a dynamic 
nucleoprotein complex called chromatin (van Holde, 1989). The structure of 
chromatin plays an important regulatory role in defining cellular identity and 
function (Fisher, 2002; Hsieh & Gage, 2004; Jaenisch & Bird, 2003; Valk-
Lingbeek et al, 2004). Although all cells of an organism have the same genomic 
information, various transcriptional programs, resulting from the up- and down-
regulation of specific genes, participate in defining the nature and function of 
each cell. The transcriptional program can be selected by regulating chromatin 
structure in response to internal or external stimuli.  
 
1.1 Nucleosomes as the molecular building blocks of chromatin 
The basic building block of chromatin is the nucleosome, consisting of an 
octamer of two of each of the core histones H2A, H2B, H3, and H4 (Baltimore, 
2001), wrapped by 146 base pairs (bp) of DNA. Histones are small basic proteins 
consisting of a globular domain and a flexible, charged N-terminus, called the 
histone tail that protrudes out from the nucleosome (Luger et al, 1997; Marino-
Ramirez et al, 2011). These tails interact with the DNA outside the nucleosome 
particles or with the linker DNA between the histones (Zheng & Hayes, 2003).  
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1.2 The role of histone posttranslational modifications in gene 
expression 
The N-terminal tails of histones are subject to a vast number of posttranslational 
modifications (Kouzarides, 2007). An ever-increasing number of modifications at 
more than 128 different residues have been identified so far (Dawson & 
Kouzarides, 2012; Huang et al, 2014; Khare et al, 2012). Acetylation of lysines, 
methylation of lysines and arginines, and phosphorylation of serines and 
theronines and in particular modifications of the tail of histone H3 are amongst 
the best-studied histone modifications. A map of well-known modifications of the 
histone H3 tail and the enzymes setting and removing these modifications is 
depicted in Figure 2. 
 
 
Histone modifications influence chromatin structure by different mechanisms: 
They can affect interactions between adjacent nucleosomes and between 
nucleosomes and DNA (Rippe, 2012; Rippe et al, 2008). Lysine acetylation, for 
Figure 2: Histone H3 modification maps. The most common methylation, phosphorylation, 
acetylation, and isomerization sites are marked, and the corresponding enzymes setting or 
removing these modifications are indicated. Numbers denote amino acid positions. Adapted from 
Abcam. 
Introduction  5 
 
 
example, leads to higher chromatin accessibility since it neutralizes the positive 
charge of lysines and weakens the electrostatic interactions with the negatively 
charged DNA (Görisch et al, 2005; Shogren-Knaak et al, 2006; Wang & Hayes, 
2006). Furthermore, histone modifications can facilitate the binding of certain 
proteins with specific reader domains, while other modifications prevent their 
binding. For example, the heterochromatin protein 1 (HP1) is involved in the 
formation and maintenance of transcriptionally inactive chromatin and binds 
trimethylated histone H3 at lysine 9 (H3K9me3) (Grewal & Jia, 2007; Jacobs & 
Khorasanizadeh, 2002; Kouzarides, 2007). However, it is ejected from its binding 
site by phosphorylation of serine 10, which is a mark of mitotic chromatin (Fischle 
et al, 2005; Mateescu et al, 2004). Thus, by steering the recruitment of proteins 
that bind to histone tails, posttranslational modifications of histones regulate 
genomic functions (Jenuwein & Allis, 2001). Thereby, they define different 
domains of chromatin, e.g. the more open and transcriptionally active 
euchromatin in contrast to the more densely packed and transcriptionally inactive 
heterochromatin. Typical euchromatic marks include trimethylation of histone H3 
at lysines 4 and 36 (H3K4me3 and H3K36me3), and acetylation of histone H3 
lysines 9 and 27 (H3K9ac and H3K27ac) (Dawson & Kouzarides, 2012). 
Trimethylation of lysines 9 and 27 of histone H3 (H3K9me3 and H3K27me3) are 
classically associated with heterochromatin although more diverse functions have 
also been described (Gonzalez et al, 2015; Mikkelsen et al, 2007; Vakoc et al, 
2005).  
 
1.3 H3K27me3 and the polycomb repressive complex 2 
H3K27me3 is one of the most extensively studied histone modifications. It was 
originally identified as a histone mark that is associated with gene silencing (Cao 
et al, 2002). However, additional functions became apparent more recently, such 
as its involvement in regulating alternative splicing (see introduction, section 2.2) 
(Gonzalez et al, 2015). Monomethylation of H3K27 has been suggested to be set 
by the Arabidopsis trithorax-related proteins 5 and 6 (ATXR5 and ATXR6) in 
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Arabidopsis thaliana (Jacob et al, 2009). Furthermore, the histone 
methyltransferase G9a that controls methylation of H3K9 (Tachibana et al, 2001) 
was shown to also contribute to monomethylation of H3K27 in vitro and in vivo in 
embryonic stem cells (Wu et al, 2011). However, trimethylation of H3K27 is 
distinct in that it has only one known methyltransferase, the enhancer of zeste 2 
(EZH2) (Kuzmichev et al, 2004). EZH2 is part of the PRC2 complex, which is 
known for its functions in development and cell differentiation (Boyer et al, 2006; 
Bracken et al, 2006). The PRC2 complex is build up by four core components: 
EZH1/2, suppressor of zeste 12 homolog (SUZ12), embryonic ectoderm 
development (EED), and retinoblastoma binding protein 4 (RBAP46/48) (Figure 
3). EED binds to H3K27me3 and enhances the enzymatic activity of EZH2 
(Margueron et al, 2009). SUZ12 is crucial for the stability of the complex and has 
regulatory functions (Cao & Zhang, 2004). Both EZH2 and SUZ12 contain RNA-
binding domains (Cifuentes-Rojas et al, 2014). The histone chaperones RBAP46 
and RBAP48 interact with histones H3 and H4 (Song et al, 2008).  
 
 
 
 
 
 
 
 
 
 
The core units interact with various other components depending on the cellular 
state and environmental cues. Examples of PRC2 accessory subunits are the 
adipocyte enhancer-binding protein 2 (AEBP2) and Jumonji AT rich interactive 
domain 2 (JARID2). AEBP2 is a zinc finger protein that is known for its PRC2 
targeting activity (Kim et al, 2009). JARID2 is a member of the Jumonji C family 
of lysine demethylases, but lacks the catalytic activity (Nayak et al, 2011). 
Figure 3: Scheme of polycomb 
repressive complex 2 (PRC2). The 
core components, EZH2, EED, 
SUZ12, and RBAP46/48, with 
putative RNA-binding domains 
(RBD) and the catalytic histone 
methyltransferase domain (SET) are 
illustrated. Accessory factors such 
as JARID2 or RNA are found 
together with the complex in a 
context-dependent manner. 
Adapted from Brockdorff, 2013.  
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Different studies demonstrated the importance of JARID2 for recruiting PRC2 to 
specific chromatin sites, and its essential role in differentiation and self-renewal of 
embryonic stem cells (Pasini et al, 2010; Peng et al, 2009; Shen et al, 2009). The 
probably best studied function of H3K27me3 and the PRC2 complex is the 
inactivation of one of the X chromosomes in female mammalian cells (Rougeulle 
et al, 2004). This process will be introduced in more detail in section 2.1 of the 
introduction.  
Besides its function as the protein complex that sets H3K27me3, the PRC2 
complex also modulates chromatin independently of its methyltransferase activity. 
Several studies have reported on the chromatin compacting activity of the PCR2 
complex (Naughton et al, 2010; Rego et al, 2008). In agreement with these 
findings, experiments by Margueron and colleagues revealed that the PCR2 
complex with EZH2 as the catalytically active component is mainly responsible 
for setting of the H3K27me3 mark.  However, when in complex with EZH1, PCR2 
it is mainly responsible for repressing transcription by chromatin compaction 
(Margueron et al, 2008). Thus, PCR2 is a multifunctional protein complex whose 
activity is highly dependent on its composition and accessory binding factors. 
 
2 RNA as a regulatory factor of gene expression and RNA 
processing 
Over the past decades, RNA transcripts not primarily dedicated to protein 
synthesis have emerged as key factors in diverse nuclear activities and as 
regulators of nuclear function and organization (Batista & Chang, 2013; 
Bergmann & Spector, 2014; Caudron-Herger & Rippe, 2012; Mercer & Mattick, 
2013). As such, they play important roles in the organization of sub-nuclear 
structures (Mao et al, 2011; Shevtsov & Dundr, 2011), in altering chromatin 
states (Caudron-Herger et al, 2011; Caudron-Herger et al, 2015; Deng et al, 
2009; Wong et al, 2007; Yang et al, 2011) and in regulating gene expression 
(Bergmann & Spector, 2014; Mercer & Mattick, 2013; Yang et al, 2013; Yao et al, 
2010). They mainly exert this function by interacting with effector proteins and 
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modulating their activity. The involvement of XIST and PRC2 in X chromosome 
inactivation will be introduced as an example of RNA-regulated chromatin 
organization. Furthermore, the connection between chromatin and alternatives 
splicing will be established. In this process the local chromatin signature, partly 
resulting from its histone modification composition and influence by RNA, directly 
affects expression of alternative transcripts (Haque & Oberdoerffer, 2014). 
 
2.1 RNA-mediated chromatin modification 
XIST and the PRC2 complex in X chromosome inactivation 
The role of the PRC2 complex has most extensively been described in the 
process of X chromosome inactivation (Xi) in female mammalian cells. Besides 
the PRC2 complex and its accessory protein factors, this process involves a 
number of cis-acting RNAs: the 17 kilobases long XIST (Brockdorff et al, 1992), 
its antisense transcript TSIX (Jeon & Lee, 2011) and the RepA transcript (Zhao et 
al, 2008). The latter originates from the first exon of XIST and contains the so 
called A repeats, which form a very specific stem loop structure and are essential 
for XIST-mediated chromosome silencing (Brockdorff, 2013; Margueron & 
Reinberg, 2011). The coordinated expression of these transcripts regulates the 
recruitment of chromatin modifying factors that eventually render one of the X 
chromosomes in female mammalian cells inactive. The current model involves 
the following steps (Figure 4): Before X inactivation, the antisense transcript of 
XIST, TSIX, is transcribed from the X chromosome and titrates away RepA and 
PRC2, blocking RepA-PRC2 interactions. Upon the onset of X chromosome 
inactivation, TSIX is down regulated. PRC2 then contacts RepA via the EZH2 and 
SUZ12 subunits. This recruitment takes place co-transcriptionally and leads to 
PRC2 loading onto chromatin. However, as long as the RNA is bound to the 
PRC2 complex its enzymatic activity is blocked. When in complex with JARID2, 
the RNA-PCR2 interaction is loosened and the methyltransferase activity is 
unblocked. EZH2 then sets the H3K27me3 leading to a cascade of events 
including further histone modifications such as ubiquitylation of histone H2AK119, 
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which eventually results in X chromosome inactivation (Cifuentes-Rojas et al, 
2014). The involvement of JARID2 in this process has been reported by several 
studies independently (da Rocha et al, 2014; Kaneko et al, 2014a). Another 
publication demonstrates the necessity of the presence of the heterogeneous 
nuclear ribonucleoprotein K (HNRNPK) for the PCR2 complex to be able to set 
H3K27me3 (Chu et al, 2015).  
 
 
The PRC2 complex and its regulation by RNA 
As illustrated in Figure 4, PRC2 recruitment and regulation is controlled by RNA. 
In agreement with this, PRC2 has been shown to bind RNA of human origin as 
well as irrelevant transcripts from ciliates and bacteria in vitro in a size dependent 
manner, with lower affinity for shorter transcripts (Davidovich et al, 2013). A 
quantitative binding study showed that while EZH2 alone binds RNA 
promiscuously, the whole PRC2 complex binds the RepA transcript in a highly 
specific manner compared to other transcripts (Cifuentes-Rojas et al, 2014). In a 
more detailed analysis conducted in the same study, the PRC2 components 
SUZ12, JARID2 and EZH2 have specifically been identified as RNA-binding 
Figure 4: Model for the 
interaction of PRC2 with RNA 
and JARID2. (A) RNA binding 
recruits the complex to a 
chromatin target site, but the 
methyltransferase activity is 
blocked. (B) JARID2 interacts 
with the complex leading to a 
weakening of the RNA binding 
and unblocks the enzymatic 
activity. This results in 
H3K27me3 deposition. Histones 
are shown in grey, the DNA in 
black, and the RNA in red.  
(Cifuentes-Rojas et al, 2014; 
Kretz & Meister, 2014) 
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components. EED is suggested to positively influence the affinity of EZH2 for 
RNA, while JARID2 is proposed to weaken PRC2 binding to RNA. Moreover the 
RNA-binding capacity of EZH2 is also regulated by its cell-cycle dependent 
phosphorylation state (Kaneko et al, 2010). 
Many studies suggest that also in vivo the binding of PRC2 to RNA is rather 
promiscuous. While candidate-based approaches have identified for example 
XIST (Brockdorff et al, 1992), RepA (Zhao et al, 2008), HOX (homeobox protein) 
transcript antisense RNA (HOTAIR) (Rinn et al, 2007; Tsai et al, 2010), KCNQ1 
(potassium channel, voltage gated KQT-like subfamily Q, member 1) overlapping 
transcript 1 (Kcnq1ot1) (Pandey et al, 2008) or Braveheart (Klattenhoff et al, 
2013) as RNAs that interact with the PRC2 complex in vivo, several unbiased 
approaches advocate the promiscuous role of RNAs in PRC2 binding and 
regulation. Immunoprecipitations of PRC2 have identified interacting RNAs such 
as antisense, intergenic and promoter-associated RNAs (Zhao et al, 2010), 
lincRNAs (Khalil et al, 2009), the 5’ ends of nascent transcripts (Kaneko et al, 
2013; Kanhere et al, 2010), full nascent transcripts (Kaneko et al, 2014b), intronic 
RNAs (Guil et al, 2012) and all mRNAs in general (Karapetyan et al, 2013). 
Finally, a recent study discusses whether indeed the PRC2 interactions are 
specific, promiscuous or non-specific (Davidovich et al, 2015). They clearly 
distinguish promiscuity from unspecificity and find that PRC2 exhibits both 
specificity and promiscuity in RNA-binding in vitro. It is concluded that these two 
features are not mutually exclusive. Models to explain the biological relevance of 
the promiscuous RNA-binding capacity of PRC2 have been suggested by several 
groups: Davidovich and colleagues suggested a “junk-mail” model in which PCR2 
binding to RNA allows the complex to scan for target genes that have escaped 
repression and thereby leading to the maintenance of the repressed state 
(Davidovich et al, 2013). Kaneko and colleagues proposed a mechanism, by 
which PRC2 interacts with RNA to sense the transcriptional state of a given locus 
to then translate it into epigenetic information (Kaneko et al, 2014b; Kaneko et al, 
2013). Having all controversies and different models in mind, the binding 
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specificity of RNA to PRC2 remains to be demonstrated in more detail and the 
function of the promiscuous RNA-binding capacity awaits further analyses.  
 
2.2 Alternative splicing and its regulation by the local chromatin 
surrounding 
RNA splicing and alternative splicing 
Typical human genes consist of exons with an average lengths of 145 
nucleotides (nt) in length that are divided by introns reaching up to ten times this 
length (International Human Genome Sequencing et al, 2001). In order to obtain 
a functional mRNA transcript, the introns have to be removed from the primary 
transcripts in a co-transcriptional process called RNA splicing (Black, 2003). To 
allow for proper identification of exons and introns, each exon is defined by 
specific sequences that mark the splice site at the boundaries between the intron 
and exon (5’ splice site, 3’ splice site, and branch site, Figure 5A). The 
components of the splicing machinery recognize these splice sites, which leads 
to the assembly of a multiprotein complex, named the spliceosome. Besides its 
function in recognizing the intron/exon boundaries, the spliceosome’s major role 
is to catalyze the “cut-and-paste” reaction, cutting out the introns and re-joining 
the exons. Depending on the context, the spliceosome can consist of more than 
one hundred proteins with regulatory functions (Faustino & Cooper, 2003). The 
core components consist of the five small nuclear ribonulceoproteins (snRNPs) 
U1, U2, U4, U5, and U6. Each of these snRNPs consists of a single uridine-rich 
small nuclear RNA (snRNA) and several proteins. The U1 snRNP binds the 5’ 
splice site, whereas the U2 snRNP contacts the branch site via RNA-RNA 
interactions between the snRNA and the pre-mRNA (Figure 5B). Through 
rearrangements of RNA-RNA, RNA-protein, and protein-protein interactions 
within the spliceosome (Du & Rosbash, 2002; Lallena et al, 2002; Liu et al, 2002; 
Liu, 2002) the pre-mRNA is ultimately spliced by the catalytic activity of the 
U4/U6/U5 complex (Faustino & Cooper, 2003; Villa et al, 2002). 
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Via a process called alternative splicing mRNA isoforms with different stability 
and coding potential can be produced. Particular exons of a gene may be 
included within or excluded from the final mRNA. Thereby, several transcript 
isoforms can be produced from the same locus significantly increasing the 
diversity of transcripts in the cell. For example, the Drosophila melanogaster 
gene Dscam has over 38,000 possible alternative splice forms (Black, 2000; 
Celotto & Graveley, 2001; Graveley, 2001; Schmucker et al, 2000). Furthermore, 
alternative splicing can also affect protein production by regulation of the stability 
of the resulting mRNA (Hughes, 2006). Finally, related proteins with qualitatively 
different functions can be synthesized. Alternative splicing of the nucleosome-
remodeling factor subunit SNF2L, for example, removes the nuclear localization 
signal (NLS) from the protein and thereby alters its subcellular distribution 
(Lazzaro et al, 2008). Interestingly, this gene also contains an alternative exon, 
which, when expressed, renders the enzyme catalytically inactive (Barak et al, 
2004). Thus, alternative splicing has far reaching implications for protein diversity, 
stability, localization and function. 
Figure 5: Schematic representation of classic and auxiliary splicing signals (n = G, A, U, or 
C; y = pyrimidine; r = purine). (A) The classical splicing signals, which in most human introns 
are required for recognition of exons (Tarn & Steitz, 1997). (B) Factors that bind both classical 
and auxiliary splicing elements. Auxiliary elements within exons (ESEs) and introns (ISEs and 
ISSs) are often required for the efficient splicing of both constitutive and alternative exons. The 
intronic elements have a function in modulating the cell-specific use of alternative exons by 
binding multicomponent regulatory complexes. (Faustino & Cooper, 2003) 
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To regulate alternative splicing, there is a large number of splicing regulatory 
proteins that recognize distinct RNA sequences across the transcriptome in 
addition to the basic components of the spliceosome (Fu & Ares, 2014). The cell 
type-specific expression levels of these RNA-binding proteins (RBPs) control 
each alternative splicing event. Well-studied examples are various 
heterogeneous nuclear ribonucleoproteins (hnRNPs), such as HNRNPC (Konig 
et al, 2010), the polypyrimidine tract binding protein 1 (PTBP1) (Licatalosi et al, 
2012; Xue et al, 2009), the U2 small nuclear RNA auxiliary factors U2AF1 (Shao 
et al, 2014) and U2AF2 (Wahl et al, 2009) (also referred to as U2AF35 and 
U2AF65), the T-cell-restricted intracellular antigen-1 (TIA1) (Wang et al, 2010), 
and T-cell-restricted intracellular antigen-1 like (TIAL/TIAR) (Le Guiner et al, 
2001). The ensemble of these proteins has been suggested to act as the so 
called “splicing code” (Fu, 2004) although attempts to “read” this code and predict 
alternative splicing events have so far been limited.  
 
Regulation of alternative splicing by the local histone modification 
signature 
Since chromatin is the template for transcription, changes in its structure and in 
the reading and writing of local histone modifications can modulate splicing 
decisions (Haque & Oberdoerffer, 2014; Kornblihtt et al, 2013; Luco & Misteli, 
2011; Luco et al, 2010; Schwartz & Ast, 2010). Both nucleosome positioning and 
histone modifications were reported to influence splicing decisions. Different 
models have been described to explain the influence of chromatin on alternative 
splicing: It has been suggested that the elongation rate of RNA polymerase II 
(RNA Pol II) affects recruitment of the splicing machinery, with fast elongation 
favoring inclusion of a downstream exon. A change in chromatin conformation 
such as localized modifications of specific histones could slow down RNA Pol II. 
This would favor recruitment of specific splicing factors to weaker exons and 
induce exon inclusion (Kornblihtt et al, 2013). Moreover, histone modifications 
could directly recruit splicing factors via a chromatin-adaptor system that consists 
of a chromatin-binding protein to read the histone mark and a splicing factor to 
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modulate splicing of the pre-mRNA (Luco & Misteli, 2011). In agreement with this, 
DNA methylation has been shown to affect RNA splicing by a mechanism 
involving HP1 (Yearim et al, 2015).  
Histone modifications such as H3K36me3, H3K79me1, H2BK5me1 (Schwartz et 
al., 2009) and H3K4me1 (Spies et al, 2009) but also mono-, di-, and 
trimethylation of H3K27 (Andersson et al, 2009) have been suggested to mark 
exons. In particular, the balance between H3K27me3 and H3K36me3 at specific 
loci has been suggested to play a role in the establishment and maintenance of 
specific splicing patterns (Gonzalez et al, 2015; Luco & Misteli, 2011). A 
mechanism has been proposed, by which the expression of an anti-sense 
transcript of the fibroblast growth factor receptor 2 (FGFR2) induces recruitment 
of PRC2 in cis to lead to enrichment of H3K27me3 and the H3K36me3 
demethylase KDM2a. The combination of these two events in turn inhibits 
recruitment of the chromatin-adaptor complex of mortality factor 4 like 1 (MRG15) 
and PTBP1 (MRG15-PTBP1) thereby favoring specific exon inclusion. Given that 
the PCR2 complex binds to RNA promiscuously and is vastly regulated by RNA 
(see introduction, section 2.1), its recruitment to loci where RNA is being 
produced and its involvement in RNA splicing is of particular interest for this study.  
 
3 Cellular functions of 3’-UTRs 
In eukaryotes mature mRNAs have a tripartite structure consisting of a 5’-UTR, a 
coding region, and a 3’-UTR (Mignone et al, 2002). The UTRs are known to play 
crucial roles in the post-transcriptional regulation of gene expression. Since this 
thesis focuses on 3’-UTRs, a more detailed introduction on their cytoplasmatic 
and nuclear functions is given in the following.  
The 3’-UTR begins at the stop codon and its end is defined by the poly(A) tail 
(Zhao et al, 2011). The cis-regulatory elements within 3’-UTRs can influence 
polyadenylation, translation efficiency (van der Velden & Thomas, 1999), 
localization (Jansen, 2001) and stability of the transcript (Bashirullah et al, 2001). 
For some genes, alternative splicing results in the use of an alternative final exon 
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that produces variation in both the 3’-UTR length and sequence, leading to 
variation in the expression of the gene (Hughes, 2006). 
 
3.1 Cytoplasmic functions of 3’-UTRs 
Classically, 3’-UTRs are known for their roles that take place in the cytoplasm 
(Matoulkova et al, 2012). These include the following: First, 3’-UTRs contain 
binding sites for microRNAs (miRNAs). MiRNAs are short trans-acting RNAs that 
regulate the expression of the majority of protein-coding genes post-
transcriptionally. Their binding to the 3’-UTR promotes destabilization and 
degradation of mRNA or inhibits translation (Farazi et al, 2011; Friedman et al, 
2009). Second, many 3’-UTR contain AU-rich elements (AREs) which influence 
mRNA decay, stability, or translation (Xu et al, 1997). These functions are 
mediated by ARE-binding proteins that recognize the AREs in a cell type-, timing-, 
and cellular localization-dependent manner. Third, the poly(A) tail attached to 3’-
UTRs is bound by poly(A) tail-binding proteins which also contribute to regulation 
of mRNA translation, stability and export (Mandel et al, 2008). For example, 
proteins that bind the poly(A) tail interact with factors involved in translation 
initiation, causing circularization of the transcript and promoting translation. The 
absence of the poly(A) tail in many cases leads to exonuclease-mediated 
degradation of the mRNA (Pichon et al, 2012). Finally, secondary structure 
motives found in 3’-UTRs aid binding of specific RBPs. Attracting these proteins 
can be of importance for example to relocalize the transcript to specific 
subcellular compartments and again to regulate translation (Barrett et al, 2012). 
In summary, the 3’-UTR of protein-coding transcripts is highly important for 
posttranscriptional regulation of gene expression. Varying length and sequence 
of the 3’-UTR is therefore one of many mechanisms to alter gene expression.  
 
3.2 Nuclear functions of 3’-UTRs 
Besides their functions in regulating mRNA stability, localization and translation, 
3’-UTRs have been suggested to have alternative roles. Mercer and colleagues 
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found that a large number of 3’-UTRs in human, mouse and fly are also 
expressed independently from their associated protein-coding sequences, to 
which they are normally linked. It is proposed that they are produced by post-
transcriptional cleavage from the rest of the mRNA transcript and that they have 
nuclear localizations (Furuno et al, 2006; Mercer et al, 2011). In another study, 
Caudron-Herger and colleagues suggested that a nuclear RNA fraction enriched 
in long 3’-UTR sequences maintains higher order chromatin in an open 
configuration (Caudron-Herger et al, 2011). Both findings point to a nuclear 
function of 3’-UTR sequences in chromatin organization. Interestingly, a 
systematic analysis of known long non-coding RNAs (lncRNAs) revealed 
similarities between 3’-UTRs and lncRNAs in terms of structural features and 
sequence composition (Niazi & Valadkhan, 2012). So far a vast number of 
lncRNAs have been linked to chromatin organization whereas very little is known 
about the nuclear activities of 3’-UTRs. Their direct link to chromatin organization 
and function and whether and how this is linked to the translation of the 
associated protein-coding sequence remains to be investigated. 
 
4 Methods to detect and functionally characterize nuclear RNAs 
in single cells 
A multitude of biochemical and deep sequencing-based methods are nowadays 
available to detect and functionally characterize nuclear RNAs. While these 
methods offer great advantages in terms of high-throughput analyses, they suffer 
from their limitations in studying individual cells. Microscopy-based readouts, on 
the other hand, have the advantage that samples can be studied at the single-cell 
level and individual observations do not get lost due to population averaging. The 
first method described here is microinjection used as a tool to monitor the 
subcellular localization of RNAs and to link this to their function. The second 
technique termed the “MS2/LacI-mediated recruitment system” is used to recruit 
a transcript of interest to a specific chromatin locus and to examine its effect on 
the local chromatin environment. In both approaches it is an important issue to be 
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able to detect the transcripts because endogenous or ectopically expressed 
RNAs, unlike proteins, so far cannot be directly tagged with fluorescent proteins 
to observe their behavior in living cells. 
 
4.1 Microinjection of RNA into the nuclei of living cells 
To examine the effect of overrepresentation of a specific RNA in cells and to 
introduce a visible label to an RNA of interest one can either transfect a plasmid 
encoding for the RNA, transfect the RNA itself or use microinjection. The method 
introduced here is microinjection of RNAs directly into the nuclei of living cells 
(Figure 6A).  
 
 
Figure 6: The principle of computer assisted microinjection. (A) Schematic illustration of the 
basic principle of microinjection: A needle with a tip diameter is loaded with the desired RNA. 
Using the computer assisted microinjection system, the RNA is injected directly into the nucleus. 
(B) Photograph of the computer assisted microinjection system that was used to microinject 
RNAs directly into the nuclei of living cells. 
 
This has a number of advantages over parallel methods that are available to 
deliver high amounts of RNA transcripts into living cells: First, the RNAs can be 
used at any desired concentration, a parameter that can be very closely 
controlled by microinjections. Second, morphology and physiology can be directly 
correlated on the minutes-time scale after microinjection. Third, a whole pool of 
RNAs of known or even unknown identity can be examined. Lastly, RNAs can 
also be microinjected at high concentrations to cells that are difficult to transfect. 
The main disadvantage is, however, that microinjection is an extremely laborious 
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technique and only a restricted number of cells can be treated. Computer 
assisted microinjection systems such as the one used in this study (Figure 6B) 
are a vast improvement to this point. Although the number of microinjected cells 
is still too small to be able to perform classical biochemical studies, it is large 
enough to obtain statistically significant results from single cell imaging data.  
 
4.2 Recruitment of RNA to a specific genomic locus 
To investigate the influence of proteins on chromatin a chromatin-tethering 
systems has been developed and employed in several studies. It involves a 
stable integration of the bacterial lacO sequence into mammalian genomes 
(Belmont & Straight, 1998; Robinett et al, 1996) and makes use of the fact that 
the interaction of the LacI protein with the lacO sequence is highly specific and 
affine (Figure 7A). Transfecting these cells with the LacI protein fused to a 
fluorescent protein has facilitated studying the dynamics of chromatin in living 
cells (Chuang & Belmont, 2007; Jegou et al, 2009; Straight et al, 1996). 
Furthermore, the system has been exploited to investigate protein-protein 
interactions in the nuclei of living mammalian cells and to recruit proteins of 
interest to chromatin (Chung et al, 2011). One main advantage of the system is 
that while the lacO sequence is naturally part of the E.coli lac operon, it offers a 
unique, well-defined binding site once it is artificially incorporated into the 
genome of mammalian cells.  
Instead of recruiting proteins, another well-described nucleic acid-protein 
interaction system has been introduced to recruit RNA transcripts to the 
chromatin. It employs the MS2 bacteriophage protein, which binds to an RNA 
hairpin, the MS2 stem loops, with high affinity and specificity (Johansson et al, 
1998). In this recruitment system, the MS2 coat protein is fused to both a 
fluorescent protein and the LacI (Figure 7B). Furthermore the RNA of interest is 
tagged with several MS2 stem loop sequences. This allows for enrichment of the 
RNA at the chromatin and studying its influence on the local chromatin 
surrounding. A previous study made use of a similar system to immobilize RNAs 
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at the chromatin. It was observed that RNA can function as a structural element 
and a nucleator of nuclear bodies (Shevtsov & Dundr, 2011), suggesting that the 
MS2/LacI-mediated recruitment system can indeed be used to study the 
mechanism of action of nuclear RNAs.  
This model system can have far reaching applications, two of which are of 
particular interest to this study: investigation of the effect of RNA on the state of 
the chromatin in terms of its compaction and posttranslational modifications of 
histones and examination of the RNA’s protein interaction partners. In all cases 
the visualization of RNA at the lacO array can be accomplished by several 
methods as described in section 4.3 of the introduction.  
 
 
 
 
 
Figure 7: Scheme of the 
MS2/LacI-mediated recruitment 
system. (A) Arrays of the lacO 
repeats are stably integrated into 
the genome of mammalian cells. 
The LacI fused to GFP or a similar 
fluorescent protein binds with high 
affinity and specificity to these 
arrays. Transfection of LacI-GFP 
can therefore be used to visualize 
these genomic loci. (B) 
Experimental approach to tether 
MS2 stem loop-tagged RNAs via 
MS2-GPF-LacI to stably integrated 
lacO arrays. For simplicity only one 
of the MS2 stem loops sequences 
is depicted here. In the experiments 
described in this thesis plasmids 
encoding for 18 MS2 loops were 
used. The RNA can for example be 
visualized by RNA-FISH as 
depicted schematically. Its putative 
protein interaction partners can be 
assessed by immunofluorescence. 
GFP: green fluorescent protein. 
Adapted from Jegou et al., 2009 
and Shevtsov and Dundr, 2011. 
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4.3 Labeling and visualization of RNAs 
Labeling and visualization of microinjected RNA 
In order to observe RNAs after microinjection or recruitment to the lacO arrays 
they need to be labeled. Unlike proteins, RNAs cannot be directly labeled in living 
cells. Nonetheless, for visualization of RNA after microinjection, a number of 
methods have been developed in the recent years that have significantly 
expanded the possibilities to visualize RNAs in living cells. For example, RNAs 
can be tagged with specific sequence motives, which are recognized by RBPs 
fused to GFP. For example, the same RNA-protein interactions as described 
above involving the MS2 coat protein (see introduction, section 4.2) could also be 
exploited for RNA labeling (Bertrand et al, 1998; Daigle & Ellenberg, 2007; 
Ozawa et al, 2007; Valencia-Burton & Broude, 2007; Valencia-Burton et al, 2007). 
Alternatives with similar characteristics as the MS2 coat protein would include 
another bacteriophage protein, the lambda N protein (Daigle & Ellenberg, 2007; 
De Gregorio et al, 1999), the Tat (trans-activator) peptide from the bovine 
immunodeficiency virus (Wakiyama et al, 2012), or the MS2 coat protein-related 
PP7 coat protein, which binds a stem loop in the PP7 RNA (Lim et al, 2001). All 
of these might, however, change the natural behavior of the RNA due to the 
relatively large size of the GFP fusion protein in comparison to the RNA itself. 
A number of small-molecule-based RNA imaging methods have been developed 
to circumvent this: These methods have in common that they use an aptamer 
sequence introduced into the transcript. For example, RNAs can be tagged with 
sequences, which bind molecules that only fluoresce when in complex with the 
RNA (Arora et al, 2015; Paige et al, 2011). Similarly to using aptamers that are 
specifically bound by RNA-binding proteins, this method can be a disadvantage 
for several reasons: First, the aptamer sequence, even though it is usually rather 
short, presents a foreign sequence and thus potentially introduces changes to the 
RNA in terms of structure, binding affinities to proteins, mobility and function. 
Second, the RNAs of interest have to be cloned together with the aptamer 
sequence, which can be laborious when investigating large numbers of 
transcripts. Third, only RNAs of known sequence can be investigated, so that 
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these techniques make it impossible to study for example pools of unknown 
RNAs. To avoid cloning and transfecting the RNA of interest with an aptamer 
sequence, stem-loop shaped oligonulceotides, called molecular beacon probes, 
can be used. They have an internally quenched fluorophore whose fluorescence 
is restored upon hybridization of the probe with the RNA. This methods and its 
derivatives, however, suffer from challenges in delivery and stability of the probes 
(Tyagi, 2009).  
To circumvent also these limitations alternative RNA labeling methods make use 
of direct labeling of the RNA of interest. This can be done for example by 
producing the RNA of interest in vitro in the presence of a fluorescently labeled 
nucleotide. Fluorescein, for example, is a small, auto-fluorescent molecule that 
should not hinder the RNA to adopt is physiological secondary structure and is 
readily incorporated into the RNA by T7 polymerase in vitro (Proudnikov & 
Mirzabekov, 1996). When labeling purified RNA pools of unknown sequences, 
propidium iodide (PI) can be used. It preferentially stains RNA but also DNA in 
case of low RNA concentrations (Suzuki et al, 1997). On the one hand, it is thus 
a well-suited agent to stain and observe the microinjected RNA. On the other 
hand, it is also a suitable localization marker to identify the microinjected cells. 
The main advantage is that it can be used to simultaneously label an entire pool 
of RNAs. 
 
Visualization of RNA recruited to chromatin 
To label RNAs that have been recruited to the lacO array, one possibility involves 
the incorporation of ethynyl-uridine (EU) into RNA. This compound can be added 
to the cell culture medium and is readily incorporated into all freshly produced 
RNA by RNA Pol II. After fixation of the cells, the transcripts with incorporated EU 
are made visible by attaching a fluorophore to the EU using an azide-alkyne 
cycloaddition reaction, also called “click” reaction (Liang & Astruc, 2011). Thus, 
detection of RNA at the arrays is based on the assumption that the enrichment at 
the arrays is strong enough to be distinguishable it from the nuclear background 
where nascent RNAs are being produced constantly.  
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The second, more specific, possibility to label lacO-immobilized RNA is to 
perform RNA-FISH directed against either the MS2 stem loops (Goodier et al, 
2010) or directly against the RNA of interest (Figure 7B). The LacI/MS2-mediated 
recruitment system theoretically leads to a clear enrichment of the RNA-FISH 
signal at the lacO arrays because of the high affinity of the MS2 stem loops to the 
MS2 coat protein. It is expected that most of the MS2 stem loop-tagged RNA is 
found at the array and only very little is distributed over the nuclear background. 
Both methods are tested and compared in the course of the present thesis. 
 
5 Scope of the thesis 
Alternative splicing of pre-mRNA is a crucial step in the expression of many 
genes and provides an important control layer affecting transcript and proteome 
diversity in a specific cell type (Chen & Manley, 2009). Numerous studies showed 
that cancer cells take advantage of alternative splicing to produce aberrant 
proteins harboring altered, added, or deleted functional domains, which drives 
tumorigenesis (David & Manley, 2010; Oltean & Bates, 2014; Zhang & Manley, 
2013). A detailed understanding of the principles that govern alternative splicing 
and the mechanisms that cells use to stably maintain their splicing pattern is thus 
essential to discover novel drug targets for therapeutic interventions.  
While it has been described in much detail how the outcome of alternative 
splicing is controlled by the combination of multiple cis-acting RNA elements 
within the pre-mRNA (Barash et al, 2010), the recruitment of regulatory splicing 
factors can also be influenced by chromatin modifications (Alló et al, 2009; Haque 
& Oberdoerffer, 2014; Kornblihtt et al, 2013; Luco & Misteli, 2011; Luco et al, 
2010; Schwartz & Ast, 2010). These chromatin modifications are well known to 
be influenced by nuclear lncRNAs that play roles in guiding and regulating the 
activity of chromatin modifying enzymes (Rinn & Chang, 2012). As a novel player 
for RNA-dependent chromatin modifications specific 3’-UTRs have been 
suggested to exert nuclear functions besides their well-described role in 
regulating mRNA stability and protein translation in the cytoplasm (Caudron-
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Herger et al, 2011; Mercer et al, 2011). Moreover, 3’-UTRs resemble lncRNAs in 
terms of structural features and sequence composition (Niazi & Valadkhan, 2012). 
Given that 3’-UTRs are part of the pre-mRNA, as well as the spliced transcript, it 
seems conceivable that they could be involved in modifying the chromatin and 
thereby regulating alternative splicing. However, to date, it remains unknown how 
3’-UTRs can affect chromatin modifications and whether this activity is linked to 
alternative splicing decisions.  
To address these open questions, I investigated whether 3’-UTRs are linked to 
chromatin modifications and nuclear RNA processing as an additional circuit by 
which RNA feeds back on its own production. Towards this goal, this thesis 
focused on the analysis of a particular 3’-UTR transcript, CU-RNA, originating 
from the 3000 nucleotide (nt) long 3’-UTR of the CDV3 gene. A number of 
methodological advances had to be performed in order to be able to detect and 
characterize nuclear RNAs. Using these techniques, CU-RNA was found to 
compact chromatin and could be linked to the recruitment and regulation of EZH2 
and thus the setting of H3K27me3, the latter being specific for one of the two 
transcript isoforms of CDV3. In a second set of experiments, the H3K27me3-
promoting activity of CU-RNA could be linked to its own alternative splicing. A 
model is proposed, in which CU-RNA regulates its own alternative splicing via a 
feedback loop that establishes a splicing specific chromatin signature. According 
to this model, stable steady-state levels between CU-RNA splicing variants are 
established that might be distinct with respect to their 3’-UTR sequence-
dependent cytoplasmic activities. 
Thus, this thesis aims at unraveling a novel mechanism, which extends the 
previously known scope of functions of 3’-UTRs in the cell. A mechanism is 
suggested, by which a 3’-UTR modulates chromatin modifications and regulates 
alternative splicing. Furthermore, it is concluded from this work that a chromatin 
dependent splicing regulatory system could control the abundance of certain 
transcript isoforms by an epigenetic-based mechanism. Through the involvement 
of EZH2 in this process, a direct link to deregulation of H3K27me3 and alternative 
splicing in cancer could be made, since both H3K27me3 and EZH2 have been 
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shown to be deregulated in many cancer types (Chase & Cross, 2011; Plass et al, 
2013).  
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Materials and Methods 
1 Materials 
1.1 Biological materials 
Bacterial strains 
The E. coli chemocompetent strains DH5α (Thermo Fisher Scientific, USA) and 
SURE 2 (Stratagene, USA) were used to amplify and prepare plasmid DNA. 
 
Cell lines 
The HeLa, HeLa S3 and U2OS osteosarcoma cell lines were used (DSMZ, 
Braunschweig, Germany). For establishment of LacI-mediated RNA recruitment 
studies the U2OS cells line with a single telomeric lacO integration was used 
(Jegou et al, 2009). The CHO hamster cell line AO3, also with a stable integration 
of a lacO array, was employed for recruitment studies (Luijsterburg et al, 2012; 
Tumbar et al, 1999).  
 
Primers 
Synthetic DNA oligonucleotides were used as primers for creating DNA 
fragments for molecular cloning, quantitative real-time PCR analysis, and for 
producing templates for RNA in vitro transcription. All primers were purchased 
from Eurofins MWG Operon (Germany) and are listed in Table 1.  
 
Table 1: Primers used in this study. Restriction sites and T7 promoter sequences are 
highlighted. Ctrl: control, iv txn: in vitro transcription, ssRT-PCR: strand specific RT-PCR. 
Name Sequence (5’ à  3’) Application 
NotI-CDV3a-fwd AAAGCGGCCGCTGCTACCTGGAATTAAATG cloning 
NotI-CDV3a-rev AAAGCGGCCGCACAGTCCAAAATCCATATATTTAC cloning 
NotI-CDV3-H1-fwd AAAGCGGCCGCGGGTGGCTTTTAGAATAAATCCC cloning 
NotI-CDV3-H1-ref AAAGCGGCCGCACAAATCACAGCCCTACACAG cloning 
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Name Sequence (5’ à  3’) Application 
NotI-CDV3-H2-fwd AAAGCGGCCGCGGAAGGGGAAGGGAGAGAAT cloning 
NotI-CDV3-H2-rev AAAGCGGCCGCGCCAAACCATGCCTGAGAAT cloning 
NotI-CORO1C-fwd AAAGCGGCCGCGCAAGAACTTGTGCTTG cloning 
NotI-CORO1C-rev AAAGCGGCCGCCTCTGAAAATGGAAGCAAG cloning 
NotI-STARD7-fwd AAAGCGGCCGCCAGGCTTTGGGATAAGAAG cloning 
NotI-STARD7-rev AAAGCGGCCGCTACCAATCTTTATGTATTTATTC cloning 
NotI-SSR3-fwd AAAGCGGCCGCACCATGTCAGCTTCACC cloning 
NotI-SSR3-rev AAAGCGGCCGCCAGATGAATCTTTTATTTC cloning 
NotI-Ctrl-fwd AAAGCGGCCGCTGCGGGACTACCTCTCAAAC cloning 
NotI-Ctrl-rev AAAGCGGCCGCGCAAACGGGAACACGATATT cloning 
NotI-RepA-fwd AAAGCGGCCGCCACTCTCTTTTCTATATTTT cloning 
NotI-RepA-rev AAAGCGGCCGCTTCATCCATAAAAAGCACCGA cloning 
T7-CORO1C-fwd TAATACGACTCACTATAGGGCAAGAACTTGTGCTTG iv txn 
T7-CORO1C-rev GACAGAACACTATGGCCAC iv txn 
T7-CDV3a-fwd TAATACGACTCACTATAGGGGCTACCTGGAATTAAATGAC iv txn 
T7-CDV3a-rev CTTGCACTGCCAAACCATGCC iv txn 
T7-STARD7-fwd TAATACGACTCACTATAGGGCAGGCTTTGGGATAAGAAGGG iv txn 
T7-STARD7-fwd GTAACTGTACAGACAGACCCCAAG iv txn 
T7-AS-STARD7-fwd CAGGCTTTGGGATAAGAAGGG iv txn 
T7-AS-STARD7-fwd TAATACGACTCACTATAGGGTAACTGTACAGACAGACCCCAAG iv txn 
T7-SSR3-fwd TAATACGACTCACTATAGGGCTGGCTTTGTGTCTATGG iv txn 
T7-SSR3-rev GAGTAGGTCGCATCTCTGTG iv txn 
T7-SURF4-fwd TAATACGACTCACTATAGGGCAGTCACAGATCCCTACCTG iv txn 
T7-SURF4-rev GCC AGA ATC AAT TGG TAG ATC C iv txn 
T7-EIF4B-fwd TAATACGACTCACTATAGGGCCTCTACATCCTGTGCTT iv txn 
T7-EIF4B-rev CATCAAGACATCTCCCAGG iv txn 
T7-FADS-fwd TAATACGACTCACTATAGGGCAACAGCCACCCTGCCCAGTC iv txn 
T7-FADS-rev TGC CTC TGG CCA GGT TGT AAA  iv txn 
T7-DDXD21-fwd TAATACGACTCACTATAGGGAGCACATTGTGCCTCCTTTTG iv txn 
T7-DDXD21-rev ACCCATGGCTTGATGGGAAGC iv txn 
T7-EIF2S3-fwd TAATACGACTCACTATAGGGCGGATGGATTTGGAAGTTGGA iv txn 
T7-EIF2S3-ref CCTCATGCTACAACACAACC iv txn 
T7-PTTG1IP-fwd TAATACGACTCACTATAGGGAGCGCTCCAGCACATCAGT iv txn 
T7-PTTG1IP-rev CGAAGACCGACCTTACAGAC iv txn 
T7-FAM38A-fwd TAATACGACTCACTATAGGGCTGTCTACAGCAACCTG iv txn 
T7-FAM38A-ref GTTCCTGCCTGCAGGTTCTCC iv txn 
T7-Ctrl-RNA-1-fwd TAATACGACTCACTATAGGGGATCTCAGCTCACTGGAACC iv txn 
T7- Ctrl -RNA-1-ref CCAGATCCTTATACTCAACAG iv txn 
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Name Sequence (5’ à  3’) Application 
T7- Ctrl -RNA-2-fwd TAATACGACTCACTATAGGGGAGTACGGGCACCATCCATA iv txn 
T7- Ctrl -RNA-2-ref TGTGGCACTGCAGAAAGTG iv txn 
T7- Ctrl -RNA-3-fwd TAATACGACTCACTATAGGGTCCGGTTTGGCCGATTCTG iv txn 
T7- Ctrl -RNA-3-ref CAAGAGTGAAACTCCGTCC iv txn 
T7-RepA-fwd TAATACGACTCACTATAGGGCACTCTCTTTTCTATATTTT iv txn 
T7-RepA-rev TTCATCCATAAAAAGCACCGA iv txn 
CDV3a/CDV3b-fwd CCAAGCATGTAGAAAGCCGG qRT-PCR 
CDV3a-rev AGTGGTGAAAAGGCTGGGAT qRT-PCR 
CDV3b-rev TGTGAGTGGCTGCTTTTCTG qRT-PCR 
ACTB-fwd TCCCTGGAGAAGAGCTACGA (Arnoult et al, 2012) qRT-PCR 
ACTB-rev AGCACTGTGTTGGCGTACAG (Arnoult et al, 2012) qRT-PCR 
CU-RNA -fwd TAATACGACTCACTATAGGGTGTTAATGTTACAGAATTCTTGCACTG ssRT-PCR 
CU-RNA-rev TGCTACCTGGAATTAAATGACTACA ssRT-PCR 
 
Expression vectors 
The following expression plasmid vectors were used for transfection of cells 
(Table 2). 
 
Table 2: Expression vectors used in this study 
Plasmid Reference 
pcDNA3.1-MS2loops this study 
pcDNA3.1-MS2loops-CORO1C-3’-UTR this study 
pcDNA3.1-MS2loops-CDV3a-3’-UTR/CU-RNA this study 
pcDNA3.1-MS2loops-STARD7-3’-UTR this study 
pcDNA3.1-MS2loops-SSR3-3’-UTR this study 
pcDNA3.1-MS2loops-CU-RNA-H1 this study 
pcDNA3.1-MS2loops-CU-RNA-H2 this study 
pcDNA3.1-MS2loops-CU-RNA-Q1 this study 
pcDNA3.1-MS2loops-CU-RNA-Q2 this study 
pcDNA3.1-MS2loops-CU-RNA-T0 this study 
pcDNA3.1-MS2loops-CU-RNA-T1 this study 
pcDNA3.1-MS2loops-CU-RNA-T2 this study 
pcDNA3.1-MS2loops-CU-RNA-ΔT0 this study 
pcDNA3.1-MS2loops-RepA this study 
pSV2-MS2-GFP-LacI (Caudron-Herger et al, 2015) 
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G-blocks 
The following G-blocks were used as PCR-templates for molecular cloning, for in 
vitro transcription and as templates in quantitative real-time PCR to validate 
qRT-PCR primers. All were purchased from Integrated DNA Technologies (IDT, 
USA) and are listed in Table 3. 
 
Table 3: G-blocks used as PCR-templates for molecular cloning. 
Name Sequence (5’ à  3’) Application 
CDV3-Q1	
CACACCTACAGCTACGTTGAGCGGCCGCGGGTGGCTTTTAGAATAA
ATCCCAGCCTTTTCACCACTTTGAGAGCACAGCTGGCTTGAATTTAA
ACCTCCACGTGGACTTGCTCCTCTGCTCTGTCTTAAAAAATGTGTAA
GGGACCTTGGGGTGGCTTTTAGAATAAATCCCGGAGGGCAGTGATT
CACCACACTCGAGTTTCTTTACCTGATCTAATCAGATCCACTCCCACA
AAATCGATGTGAGGAGAAATCATTGACTAATGAGTAGAATTTACTTGA
ATGAGAAAATTGTTACCCTTGTGCATAAAGAGAGAGATGTATTATCTA
TTACTTGCTAAAAGTAAGAGTCTTAGGAGGAATGTCATTACACAGCTT
TTAACAGTTTTCTTCAAGTTTGTCCTGAAATAGGGTCACAGTTAATAC
TGTTCAGTAGAAGATAGGACCCTAGAGCTTCAATACAGCGTTCTGTG
TTTTCTGTTTGAATTGAAGCCTTAAAATGGTTTGATAAGGATTTTCTAT
ATGCCTCCACTCCTACCCCTCCCCAGGATTCTTCTAAGGGGTGGCTT
TTTTTTAAATTCAAGGACGAATATTTTCAAAAACCCTAGTGAAGAAGA
AATATTTACTGATTACATTTCTTTTCCCTTAGGGATAAAGAAATGGAG
AAGAGCTTTGAAGTAGTAAGACACGCGGCCGCGTGGCTGCATCTGC
TCGAAG 
Cloning 
CDV3-Q2	
CACACCTACAGCTACGTTGAGCGGCCGCGATGAGGTTTCAAAAAAC
CAGGCCCTTAAACTTCAGCTAGACAACCAATATGCTGTGCTTGAAAA
TCAGAAAAGCAGCCACTCACAATACAATTAAGGAATGGGCTTTGCTA
ACCCTTCTGAGGTAACTAGACTGCAGCTAACCACCACCAACAGCCAT
TCATCATCTGATCTCTGCTGGATCTACAGACACCGATGCAGACCACT
CGATTTCATGACCGGCCCTATTGCACTATGGAAGTTAAAGTGTCACG
ACTGCTCTATGCATATTGGATTTAGGGGAATTTTCATTGTTACATAAA
TGTGTGAACTAGTTTCAACAGTGTTCTTTCATATTTACTCTGCAAATA
CAAAAAACCAAAACCTGCAGCCAGTGGTCATTTCAAAATCTTTTTATG
TTCAGATACTGAGCCTTCATAAGGGTTGACTACCTCAGATTTGCTGC
ACTCATTGTGGACTTCATGTGGATCACAACTTCTGGATAAGAAGATTA
CAACTATTAAGTGTCGATGTGAACCTTGCAACCAGCTCTACTGGATT
CTTATCAGAAATCCTGCATAAAAAGTCAGCCATCTGGGTTCTGATCT
GCTGTAAAAGATGAAGATTTAAGTGACCTTAATTAACCTGTCCTGTGC
CCTACCCTTAAGGAATACTCTCTGTAGTAGGCTGTTGTTATATTAGAC
TTCCTGGAACACACTGCTGAAAAGAACTGATGTGTTCAGATCATCTG
TGTAGGGCTGTGATTTGTAATTTAAACTAATTGTATTCTGAGGTAGCG
GCCGCGTGGCTGCATCTGCTCGAAG 
Cloning 
CDV3-T0 
(CU-RNA-T0)	
CACACCTACAGCTACGTTGAGCGGCCGCAAATTCAAGGACGAATATT
TTCAAAAACCCTAGTGAAGAAGAAATATTTACTGATTACATTTCTTTTC
CCTTAGGGATAAAGAAATGGAGAAGAGCTTTGAAGTAGTAAGACACA
AAAATAGAGGTAGGGATGAGGTTTCAAAAAACCAGGCCCTTAAACTT
CAGCTAGACAACCAATATGCTGTGCTTGAAAATCAGAAAAGCAGCCA
CTCACAATACAATTAAGGAATGGGCTTTGCTAACCCTTCTGAGGTAA
CTAGCGGCCGCGTGGCTGCATCTGCTCGAAG 
Cloning 
CDV3-T1	
CACACCTACAGCTACGTTGAGCGGCCGCGATGAGGTTTCAAAAAAC
CAGGCCCTTAAACTTCAGCTAGACAACCAATATGCTGTGCTTGAAAA
TCAGAAAAGCAGCCACTCACAATACAATTAAGGAATGGGCTTTGCTA
ACCCTTCTGAGGTAACTAGACTGCAGCTAACCACCACCAACAGCCAT
TCATCATCTGATCTCTGCTGGATCTACAGACACCGATGCAGACCACT
CGATTTCATGACCGGCCCTATTGCACTATGGAAGTTAAAGTGTCACG
ACTGCGCGGCCGCGTGGCTGCATCTGCTCGAAG 
Cloning 
CDV3-T2	
CACACCTACAGCTACGTTGAGCGGCCGCTCTATGCATATTGGATTTA
GGGGAATTTTCATTGTTACATAAATGTGTGAACTAGTTTCAACAGTGT
TCTTTCATATTTACTCTGCAAATACAAAAAACCAAAACCTGCAGCCAG
TGGTCATTTCAAAATCTTTTTATGTTCAGATACTGAGCCTTCATAAGG
GTTGACTACCTCAGATTTGCTGCACTCATTGTGGACTTCATGTGGAT
CACAACTTCTGGATAAGAAGATTACAACTATTAAGTGTCGATGTGAAC
GCGGCCGCGTGGCTGCATCTGCTCGAAG 
Cloning 
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Name Sequence (5’ à  3’) Application 
CDV3-T3	
CACACCTACAGCTACGTTGAGCGGCCGCCTTGCAACCAGCTCTACT
GGATTCTTATCAGAAATCCTGCATAAAAAGTCAGCCATCTGGGTTCT
GATCTGCTGTAAAAGATGAAGATTTAAGTGACCTTAATTAACCTGTCC
TGTGCCCTACCCTTAAGGAATACTCTCTGTAGTAGGCTGTTGTTATAT
TAGACTTCCTGGAACACACTGCTGAAAAGAACTGATGTGTTCAGATC
ATCTGTGTAGGGCTGTGATTTGTAATTTAAACTAATTGTATTCTGAGG
TAGCGGCCGCGTGGCTGCATCTGCTCGAAG 
Cloning 
CDV3-ΔT0 
(CU-RNA-ΔT0)	
CACACCTACAGCTACGTTGAGCGGCCGCGACCACCAGAAATCTACA
GTGATACACAGTTCCCATCCCTGCAGTCAACTGCCAAGCATGTAGAA
AGCCGGAAGGATAAAGAAATGGAGAAGAGCTTTGAAGTAGTAAGAC
ACAAAAATAGAGGTAGGGATGAGGTTTCAAAAAACCAGGCCCTTAAA
CTTCAGCTAGACAACCAATATGCTGTGCTTGAAAATCAGAAAAGCAG
CCACTCACAATACAATTAAGGAATGGGCTTTGCTAACCCTTCTGAGG
TAACTAGCGGCCGCGTGGCTGCATCTGCTCGAAG 
Cloning 
CDV3-S1	
CACACCTACAGCTACGTTGAGCGGCCGCAAATTCAAGGACGAATATT
TTCAAAAACCCTAGTGAAGAAGAAATATTTACTGATTACATTTCTTTTC
CCTTAGGGATAAAGAAATGCGGCCGCGTGGCTGCATCTGCTCGAAG 
Cloning 
CDV3-S2	
CACACCTACAGCTACGTTGAGCGGCCGCGGAGAAGAGCTTTGAAGT
AGTAAGACACAAAAATAGAGGTAGGGATGAGGTTTCAAAAAACCAGG
CCCTTAAACTTCAGCTAGACAGCGGCCGCGTGGCTGCATCTGCTCG
AAG 
Cloning 
CDV3-S3	
CACACCTACAGCTACGTTGAGCGGCCGCACCAATATGCTGTGCTTG
AAAATCAGAAAAGCAGCCACTCACAATACAATTAAGGAATGGGCTTT
GCTAACCCTTCTGAGGTAACTAGCGGCCGCGTGGCTGCATCTGCTC
GAAG 
Cloning 
CDV3a	
AACTGGGAAGAAGGTGGAGGTGGTGGTGGAGGTATGGAAAAATCTT
CAGGTCCCTGGAATAAAACAGCTCCAGTACAAGCACCTCCTGCTCCA
GTAATTGTTACAGAAACCCCAGAACCAGCGATGACTAGTGGTGTGTA
TAGGCCTCCTGGGGCCAGGTTAACCACAACAAGGAAAACACCACAA
GGACCACCAGAAATCTACAGTGATACACAGTTCCCATCCCTGCAGTC
AACTGCCAAGCATGTAGAAAGCCGGAAGTACTTAAAATGAATGCTAC
CTGGAATTAAATGACTACATATGGCACATCTACATCTTACTTTAGGGA
CATGAATTTTTTAAAATAAATAAAATGGGAAGAAATGTAAATGACATC
AGATGGAAATGTGTTTTTTGGGGTGGCTTTTAGAATAAATCCCAGCC
TTTTCACCACTTTGAGAGCACAGCTGG 
qRT-PCR 
validation 
CDV3b	
GGTGATAACTGGGAAGAAGGTGGAGGTGGTGGTGGAGGTATGGAAA
AATCTTCAGGTCCCTGGAATAAAACAGCTCCAGTACAAGCACCTCCT
GCTCCAGTAATTGTTACAGAAACCCCAGAACCAGCGATGACTAGTGG
TGTGTATAGGCCTCCTGGGGCCAGGTTAACCACAACAAGGAAAACA
CCACAAGGACCACCAGAAATCTACAGTGATACACAGTTCCCATCCCT
GCAGTCAACTGCCAAGCATGTAGAAAGCCGGAAGGATAAAGAAATG
GAGAAGAGCTTTGAAGTAGTAAGACACAAAAATAGAGGTAGGGATGA
GGTTTCAAAAAACCAGGCCCTTAAACTTCAGCTAGACAACCAATATG
CTGTGCTTGAAAATCAGAAAAGCAGCCACTCACAATACAATTAAGGA
ATGGGCTTTGCTAACCCTTCTGAGGTAACTAGACTGCAGCTAACCAC
CACCAACAGCCATTCATCATCTGA 
qRT-PCR 
validation 
 
siRNAs 
Silcencer select siRNAs were purchased from Ambion (Thermo Fisher Scientific, 
USA) and used for silencing of the respective genes (Table 4).  
 
Table 4: siRNAs used in this study. 
siRNA siRNA ID # 
HNRNPK  s6739 
MRG15 s21501 
Negative control Negative control #1 (catalog #: 4390844) 
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Antibodies 
Antibodies were used for immunofluorescent stainings, RNA-FISH, western and 
northern blotting. All primary antibodies (Table 5) were specific to the protein of 
interest. The secondary antibodies (Table 6) were directed against the primary 
antibodies and coupled to a fluorescent dye or horseradish peroxidase. 
 
Table 5: Primary antibodies used in this study. IF: immunofluorescence, FACS: fluorescence 
activated cell sorting, WB: western blot, NB: northern blot. 
Antibody Host Source IF/FACS WB/NB 
DIG Mouse Roche, clone 1.71.256 1:100 1:10000 
EZH2 Rabbit Active Motif, AM39933 -  1:100 
EZH2 Mouse Active Motif, AM39875 1:50 - 
H3 Rabbit Abcam, ab1791 - 1:5000 
H3K27me3 Rabbit Active Motif, AM39535 1:600 1:600 
HNRNPC Mouse Santa Cruz, sc-32308 - 1:200 
HNRNPK Mouse Santa Cruz, sc-32307 - 1:200 
JARID2 Rabbit Abcam, ab192252 1:100 1:1000 
JARID2 Rabbit NovusBio, nb100-2214 1:1000 1:1000 
MRG15 Rabbit Active Motif, AM39362 - 1:500 
PTBP1 Rabbit Cell Signaling, 8776 - 1:1000 
U2AF2 Mouse Sigma-Aldrich, U4758 - 1:5000 
 
Table 6: Secondary antibodies used in this study. IF: immunofluorescence, FACS: 
fluorescence activated cell sorting, WB: western blot, NB: northern blot. 
Antibody Host Source IF/FACS WB/NB 
Alexa 568-anti-mouse IgG Goat Thermo Fisher Scientific, USA 1:500 - 
Alexa 568-anti-rabbit IgG  Goat Thermo Fisher Scientific, USA 1:500 - 
Alexa 633-anti-mouse IgG Goat Thermo Fisher Scientific, USA 1:500 - 
Alexa 633-anti-rabbit IgG Goat Thermo Fisher Scientific, USA 1:500 - 
HRP-linked-anti-mouse IgG Goat Cell Signaling, USA - 1:2000 
HRP-linked-anti-rabbit IgG Goat Cell Signaling, USA - 1:2000 
 
Enzymes 
The following enzymes were used for cloning, PCR, in vitro transcription, 
qRT-PCR, protein, RNA and DNA extracts (Table 7). 
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Table 7: Enzymes used in this study. 
Enzyme Source 
FastAP Thermo Fisher Scientific, USA 
Proteinase K Genaxxon, Germany 
Polymerase (qRT) Roche, Germany 
Q5 polymerase New England Biolabs, Germany 
Restriction enzymes (FastDigest) Thermo Fisher Scientific, USA 
RNase A Thermo Fisher Scientific, USA 
RNase H New Enlgand, Biolabs, Germany 
RQ1 DNase I Promega, Germany 
T4 DNA ligase Thermo Fisher Scientific, USA 
 
1.2 Media and solutions 
Bacterial culture media 
Bacterial culture media used in this study are depicted in Table 8.  
 
Table 8: Bacterial culture media used in this study. 
Medium Composition 
Luria Bertani (LB) medium	 1 % (w/v) tryptone 0.5 % (w/v) yeast extract  86 mM NaCl 
pH = 7.0	
LB medium with antibiotics LB + 100 µg/ml ampicillin  
LB + 50 µg/ml kanamycin 
LB agar plates 
1000 ml LB 
15 g agar 
antibiotics 
SOC medium New England Biolabs, Germany 
 
Cell culture media and reagents 
Cell culture media and reagents used in the study are listed in Table 9. The use 
of the different media is explained in section 2.2 of the materials and methods. 
 
Table 9: Cell culture media and reagents used in this study. 
Medium/Reagents Source 
DMEM (without phenol red)	 Thermo Fisher Scientific, USA	
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Medium/Reagents Source 
DMEM high glucose (without phenol red) Thermo Fisher Scientific, USA 
DMEM/F-12 (without phenol red) Thermo Fisher Scientific, USA 
DMSO Sigma-Aldrich, Germany 
Fetal Bovine Serum (FBS)  PAN Biotech, Germany 
L-glutamine   PAA, Germany 
Leibovitz’s L-15 medium (without phenol red) Thermo Fisher Scientific, USA 
Opti-MEM I reduced serum medium Thermo Fisher Scientific, USA 
Penicillin/Streptomycin PAN Biotech, Germany 
RPMI (without phenol red) GE Healthcare, Germany 
Trypsin PAN Biotech, Germany 
 
Transfections reagents 
All cells were transfected with Lipofectamine 2000 (Thermo Fisher Scientific, 
USA).  
 
Nucleic acid staining dyes and mounting reagents 
4’,6-Diamidin-2-phenylindol (DAPI) and propidium iodide (PI) were used in this 
study to stain DNA and RNA, respectively. Mowiol was used to mount 
microscopy slides (Table 10).  
 
Table 10: DNA staining dyes and mounting reagents 
Dye / mounting reagent Source / composition 
DAPI	 Sigma-Aldrich, Germany	
PI Thermo Fisher Scientific, USA 
Mowiol 
2.4 g of Mowiol 4-88  
6 g of glycerol  
6 mL of H2O  
12 mL of 0.2 M Tris-Cl (pH 8.5)  
 
Small molecule inhibitors 
To inhibit histone H3 lysine 27 methlyation the small molecule inhibitor GSK343 
(BioVision, USA) was dissolved in DMSO at a stock concentration of 10 mM and 
used at a final concentration of 5 µM or 1 µM.  Pre-mRNA splicing was inhibited 
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with 100 nM pladienolide B (PlaB, BioAustralis, USA) dissolved in ethanol with a 
stock concentration of 1 mM. 
 
Buffers 
The composition of all non-commercial buffers used in this study is listed in Table 
11.  
 
Table 11: Buffers used in this study. 
Buffer Composition 
Buffer A (nucleoli preparation) 
10 nM Hepes, pH 7.9 
10 mM KCl 
1.5 mM MgCl2 
0.5 mM DTT 
Cell lysis buffer 
(nuclear extract preparation)	 85 mM KCl 0.5 % NP-40 
5 mM HEPES pH 7.4	
Covaris sonication buffer 
10mM Tris pH8.0 
200mM NaCl 
1mM EDTA 
0.1% Na-Deoxycholate 
0.5% n-Lauroylsarcosine 
+ Protease Inhibitor Complete 
CSK buffer 
100 mM NaCl  
300 mM sucrose  
3 mM MgCl2  
10 mM PIPES pH 6.8  
0.5 % Triton X 100 
Elution buffer (ChIP) 
50mM Tris pH 8.0 
1mM EDTA 
1% SDS 
50mM NaHCO3 
High salt buffer (ChIP) 
50mM Hepes pH 7.9 
500mM NaCl 
1mM EDTA 
1% Triton X-100 
0.1% Na-deoxycholate 
0.1% SDS 
Laemmli buffer 
0.1% (v/v) 2-Mercaptoethanol 
0.0005% (w/v) Bromophenol blue 
10% (v/v) Glycerol 
2% (w/v) SDS  
63 mM Tris-HCl pH 6.8 
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Buffer Composition 
Li buffer (ChIP) 
20mM Tris pH 8.0 
1mM EDTA 
250mM LiCl 
0.5% NP-40 
0.5% Na-deoxycholate 
methylation buffer (4X) 
50 mM Tris-HCl pH 8.5 
5 mM MgCl2 
4 mM DTT 
NaP buffer	 12.2 mM Na2HPO4-7H2O  7.8 mM NaH2PO4	
Nuclei lysis buffer 
(nuclear extract preparation) 
300 mM NaCl 
20 mM Tris-HCl pH 8.0 
0.2 % Tween-20 
1mM EDTA 
1 mM EGTA 
PBS (pH 7.2) 1x 
1.7 mM KH2PO4 
137 mM NaCl 
10 mM Na2HPO4 
2.7 mM KCl 
RNA-FISH hybridization buffer 
30% dextran sulfate 
2 mg/mL BSA 
4x SSC 
RIPA buffer (1X) 
150 mM NaCl 
1 % NP40 
0.5 % Na-Desoxy-cholate, 
0.1 % SDS 
50 mM Tris pH 8.0 
1X Complete 
Protease Inhibitor Cocktail (Roche, 
Switzerland) 
SSC buffer, 1x 
150 mM NaCl 
15 nM Na3Citrate 
SDS running buffer (pH 8.3) 1x 
25 mM Tris 
192 mM glycine 
0.1 % (w/v) SDS 
TAE  
40 mM Tris 
13.8 mM C2H4O2  
1 mM EDTA, pH 8.0 
TE buffer (pH 8.0) 
10 mM Tris 
1 mM EDTA 
TBS (pH 7.5) 1x 50 mM Tris-CL 
150 mM NaCl 
Transfer buffer 1x 
25 mM Tris 
192 mM glycine  
0.5 % (w/v) SDS  
20 % MeOH (v/v) (freshly added before use) 
washing buffer (RNA affinity purification) 
5 mM Tris-HCl 
pH 7.5 
0.5 mM EDTA 
0.5 M NaCl 
0.05 % Tween-20 
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1.3 Commercial kits 
The following commercial kits were used in this study (Table 12).  
 
Table 12: Commercial kits used in this study. 
Kit Source 
EZH2 Assay Kit BPS Bioscience, USA 
Click-it RNA imaging Kit Thermo Fisher Scientific, USA 
Light Cycler 480 SybrGreen I Master Roche, Germany 
NEBNext Ultra DNA Library Prep Kit  Illumina, USA 
NucleoSpin plasmid purification kit	 Macherey Nagel, Germany	
Pierce BCA Protein Assay Kit Thermo Fisher Scientific, USA 
RNeasy Mini kit Qiagen, Germany 
SuperScript III Reverse Transcriptase Thermo Fisher Scientific, USA 
T7 High Yield RNA Synthesis Kit New England Biolabs, Germany 
TeloTAGGG Telomere Length Assay Roche, Germany 
Wizard SV Gel and PCR Clean-Up System Promega, Germany 
 
1.4 Instruments 
All non-standard instruments used in this study are listed in Table 13. 
 
Table 13: Instruments used in this study.  
Instrument Source 
Chemi Doc Gel documentation system BioRad, Germany 
Covaris sonicator Covaris, USA 
FACSCanto II  BD Bioscience, USA 
FemtoJet microinjection module Eppendorf, Germany 
Leica TCS SP5 Confocal Laser Scanning Microscope	 Leica Microsystems, Germany 
LUNA automated cell counter Logos Biosystems, USA 
Mastercycler Eppendorf, Germany 
Qubit fluorometer Thermo Fisher Scientific, USA 
StepOne Plus RT-qPCR Applied Biosystems, Germany 
Spectrophotometer NanoDrop Thermo Fisher Scientific, USA 
SemiDry Blotter VWR, Germany 
TECAN Infinite M200 plate reader Tecan, Switzerland 
2200 Tape Station Instrument Agilent Technologies, USA 
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1.5 Software 
All non-standard software applications used in this study are listed in Table 14. 
 
Table 14: Software used in this study. 
Software Source 
Adobe Illustrator Adobe Systems, USA 
Adobe Photoshop Adobe Systems, USA 
BEDtools (Quinlan & Hall, 2010) 
bowtie (Langmead et al, 2009) 
Excel Microsoft, USA 
Fastqc (Andrews, 2010) 
ImageJ National Institutes of Health, USA 
Integrative Genome Viewer (Robinson et al, 2011) 
KaleidaGraph Synergy Software, USA 
LAS AF Leica Microsystems, Germany 
MCORE (Molitor et al, 2015) 
R www.r-project.org 
Scaffold Proteome Software, USA 
Serial Cloner serialbasics.free.fr 
Sicer (Zang et al, 2009) 
 
2 Methods 
2.1 Molecular cloning 
All RNAs sequences expressed from the pcDNA3.1 plasmid containing the MS2 
stem loop sequences (Schmidt et al, 2011) were amplified by PCR using the 
Q5 polymerase and primers containing the NotI restriction site. Total HeLa cDNA 
or g-blocks were used as templates for PCR. PCR-products were purified using 
the Wizard SV Gel and PCR Clean-Up System. Restriction digestion of both 
insert and target vector were carried out using FastDigest enzymes. Phosphate 
residues of the vector were removed by FastAP phosphatase for 30 min at 37°C. 
Both inserts and vector fragments were purified by agarose gel extraction and 
ligated using the T4 DNA ligase. To amplify the ligated products, they were 
transformed into E.coli SURE2 chemocompetent cells, which were grown in 
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LB-ampicillin medium at 30°C over night. Plasmids were then isolated using the 
NuceolSpin plasmid purification kit. All kits and enzymes were used according to 
the manufacturer’s instructions. All cloned expression plasmids were checked by 
DNA sequencing using the over-night-express GATC services (Germany). 
Plasmid amplification of pSV2-MS2-GFP-LacI were carried out in DH5α 
chemocompetent bacteria. 
 
2.2 Cell culture techniques 
Cultivation of mammalian cell lines 
HeLa cells were cultured in RPMI medium supplemented with 2 mM L-Glutamine, 
10% FCS and 100 µg/ml penicillin/streptomycin. HeLa S3 cells were grown in 
DMEM medium supplemented with 2 mM L-Glutamine, 10 % FCS and 1% 
penicillin/streptomycin (v/v). AO3 cells were grown in DMEM/F-12 medium 
supplemented with 2 mM fresh L-Glutamine, 20% FCS and 1% 
penicillin/streptomycin (v/v). EC4 and F4BII8 cells were cultured in DMEM 
medium supplemented with 2 mM L-Glutamine, 10 % FCS and 1% 
penicillin/streptomycin (v/v). For microinjection experiments cells were kept in 
Leibovitz’s L15-medium supplemented with 2 mM L-Glutamine, 10 % FBS and 
1% penicillin/streptomycin (v/v). All cells were grown at 37°C in 5% CO2.  
 
Transient transfections 
Transient transfection of plasmids into cells was conducted with Lipofectamine 
2000 (Thermo Fisher Scientific, USA) according to the manufacturer’s 
instructions. Briefly, cells were seeded 24 h prior to transfection to reach a 
confluence of 80-90% at the time point of transfection. The 
penicillin/streptomycin-containing medium was replaced by antibiotic-free 
medium. Plasmid DNA was diluted in Opti-MEM, mixed with lipofectamine, also 
diluted in Opti-MEM, stirred rigorously and incubated at room-temperature for 
20 min. Lipofectamine-DNA complexes were then added to the cells. The 
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transfection mixes were removed from the cells 6-8 h after transfection and cells 
were fixed 24 h after transfection.  
 
siRNA transfection 
For siRNA-mediated knockdown of HNRNPK and MRG15 1.5 x 105 cells were 
reverse-transfected with Lipofectamin 2000 (Thermo Fisher Scientific, USA) and 
siRNAs against HNRNPK or MRG15 (see Table 4). Silencer select negative 
control #1 siRNA (Ambion, #3490844) was used as a non-target control. 72 h 
after transfection, cells were processed for western blot and qRT-PCR analysis. 
 
2.3 Inhibition of EZH2, pre-mRNA splicing and RNA Pol II 
To inhibit methylation of histone H3 at lysine 27, HeLa cells were treated with 
5-µM or 1 µM GSK343, which was added to the cell culture medium for 3 or 6 
days. Cells treated with equal volumes of DMSO were included as negative 
controls. To inhibit pre-mRNA splicing, cells were treated with 100 nM PlaB in the 
cell culture medium for 5 h. Cells treated with an equal volume of ethanol were 
included as a negative control. RNA Pol II was inhibited by culturing cells for 5 h 
in medium supplemented with 50 µg/ml  α-amanitin. 
 
2.4 RNA purification 
RNA was prepared from HeLa cells using the RNeasy Mini Kit (Qiagen, 
Germany) according to the manufacturers instructions. For DNA digestion, 2 µL 
of RQ1 DNAse, and 10 µL RQ1 10x buffer were added to each sample, and H2O 
was added to a total volume of 100 µL. The samples were kept at a reaction 
temperature of 37°C for 30 min. Subsequently the RNA was purified with RNeasy 
Mini Kit again according to the manufacturers instructions. The RNA was eluted 
in 30 µl RNase free H2O supplemented with 1 µl RiboLock. The concentration of 
each sample was determined with the NanoDrop. RNA integrity was tested on a 
2% E-gel (Thermo Fisher Scientific, USA).  
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2.5 Northern blotting 
15 µg total or nuclear RNA were resolved by 1.1 % agarose, 2% formaldehyde-
MOPS gel electrophoresis and blotted onto a Hybond-N+ nylon membrane over 
night with 20X SSC. The membrane was washed in 2X SSC, baked at 120°C for 
20 min and hybridized with DIG-labeled probes at 42°C in DIG Easy Hyb solution 
(TeloTAGGG Telomere Length Assay, Roche, Switzerland) over night according 
to the manufacturer’s instructions. The membrane was then washed twice in 2X 
SSC-0.1% SDS for 5 min at room temperature and twice with 0.5X SSC-0.1% 
SDS for 20 min at 65°C. The TeloTAGGG Telomere Length Assay (Roche) was 
used for detection according to the manufacturer’s instructions: the membrane 
was rinsed in 1X washing buffer and incubated in blocking solution for 30 min at 
room temperature and another 30 min in anti-DIG-AP working solution. The 
membrane was then washed twice with washing buffer for 15 min at room 
temperature. Before detection the membrane was briefly incubated with detection 
buffer. Approximately 1.5 ml substrate solution were then added to the 
membrane and the signal was allowed to develop for at least 5 min. Blots were 
developed on Chemi Doc Gel documentation system. 
 
2.6 Quantitative real-time PCR 
First-strand cDNA was transcribed from 1 µg RNA using 50 ng random hexamer 
primers (Thermo Fisher Scientific, USA), 1 mM dNTPs and 10 U/µl SuperScript III 
reverse transcriptase according to the manufacturers instructions. Finally, 0.5 U 
RNase H were added to digest the residual RNA fragments for 20 min. Controls 
without reverse transcriptase (-RT) were included and analyzed in parallel to 
exclude contamination with genomic DNA. qRT-PCR was conducted with a Light 
Cycler 480 SybrGreen I Master mix and 0.5 µM of transcript specific primers in a 
StepOne Plus RT-PCR system. For quantification, a standard curve was 
measured that ranged from 0.6 ng/µl to 180 ng/µl cDNA. At least three replicates 
of each of three biologically independent samples were used. Normalization was 
done with ACTB as an internal control. The following amplification programs were 
40 Materials and Methods 
 
 
applied: 95°C for 10 min followed by 40 cycles at 95 °C (10 sec), 60 °C (10 sec) 
and 72 °C (10 sec). Acquisition of the melt curves and 2% agarose gel runs were 
conducted for detection of contaminations.  
 
2.7 Ethynyl uridine labeling of RNA 
To label RNAs with ethynyl uridine in, cells were incubated with 1 mM 5-ethynyl 
uridine (EU) over night, fixed with 4% paraformaldehyde/PBS and EU-labeled 
transcripts were detected using Alexa Fluor 488 azide using the Click-it RNA 
imaging Kit (Thermo Fisher Scientific, USA) according to the manufacturers 
instructions. 
 
2.8 RNA fluorescence in situ hybridization 
For RNA-FISH cells were grown on coverslips and permeabilized in CSK buffer 
containing 10 mM vanadyl ribonucleoside complex (VRC, New England Biolabs, 
Germany) or 50 µg/ml RNase A. Cells were subsequently fixed with 4% 
paraformaldehyde/PBS, dehydrated by sequential washes with ethanol (70%, 
85%, and 100%) and air-dried. For MS2 stem loop RNA detection 50ng 
5’-Atto-565 labeled antisense probe per slide were mixed with 10 µg salmon 
sperm DNA and 5 µl formamide. The mixture was heated to 37°C for 10 min and 
74°C for 7 min before 5 µl hybridization buffer and 10mM VRC and 50 µg/ml 
RNase A were added. For detection of endogenous sequences 5 µl of 
digoxigenin (DIG)-labeled probe (final concentration 50 ng/µl in 50% Formamide, 
2x SSC + 10% Dextrane) per slide were used. In both cases the RNA was 
hybridized overnight in hybridization buffer at 37°C. The next day slides were 
washed twice with 2X SSC, 50% formamide at room-temperature for 15 min, 
once with 0.2X SSC, 0.1% Tween at 40°C for 10 min and once with 2X SSC at 
room temperature for 5 min. When using ATTO labeled probes the slides were 
washed again in PBS, incubated with 1x DAPI solution and mounted on 
microscope slides (Menzel-Gläser, Germany) with Mowiol. When using DIG 
Materials and Methods 41 
 
 
labeled probes the slides were subjected to immunofluorescence directed against 
DIG as described in section 2.15 of the materials and methods. 
 
2.9 RNA in vitro transcription 
DNA templates for in vitro transcription were amplified using cDNA from HeLa 
cells or g-blocks, and specific primers with T7 promoter sequences. In vitro 
transcription was performed using the RNA polymerase T7 High Yield RNA 
Synthesis Kit according to the manufacturer’s instructions. Briefly, 1X reaction 
buffer, 2  µl T7 Polymerase, ATP, GTP, CTP and UTP at a final concentration of 
10 mM and 1 µg template DNA were mixed and incubated at 37°C for 2 h. The 
RNA was purified using the RNeasy Mini kit (Qiagen) and its integrity was tested 
on a 2% E-gel (Thermo Fisher Scientific, USA). For the production of 
fluorescently labeled or biotinylated transcripts, UTP-fluorescein (fluorescein-12-
UTP, Thermo Fisher Scientific, USA) and UTP-biotin (biotin-16-UTP, Epicentre, 
Great Britain), respectively, were used and mixed with unlabeled UTP at a ratio 
of 1:1.  
 
2.10 Rescue experiment 
HeLa cells grown on 18 mm cover slips were washed in PBS and permeabilized 
for 30 sec in 0.035% Triton X-100/PBS (v/v), washed in PBS and incubated for 5 
min in 3 mg/ml RNase A/PBS. Cells were then washed in PBS and incubated 
with cell culture medium containing 30 µl RiboLock to inhibit residual RNase A. 
For testing various RNAs, cells were incubated with the RNA of interest for 
15 min after addition of 16.7 ng/µl RNA. Cells were then fixed with 4% PFA, the 
nuclei were counterstained with DAPI and the slides mounted with Mowiol.  
 
2.11 Nucleoli preparation 
Nucleoli were prepared as described by (Busch et al, 1963; Sullivan et al, 2001). 
HeLa cells were harvested by trypsinization, washed twice with ice-cold PBS and 
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resuspended in buffer A. After 5 min incubation on ice the cell suspension was 
dounced 10 to 15 times in a pre-cooled dounce tissue homogenizer. The 
homogenized cells were centrifuged at 218 g for 5 min, taken up in 3ml 0.35 M 
sucrose/0.5 mM MgCl2 and sonicated until there were no intact cells or nuclei in 
the suspension as observed by checking using a phase contrast microscope. The 
sonicated sample was layered over 3 ml of a 0.88mM sucrose/0.5 mM MgCl2 
cushion and centrifuged at 3000g for 10 min at 4°C. The nucleoli were then 
contained in the pellet and further processed for RNA extraction.  
 
2.12 Nuclear extract preparation 
Cells were washed with PBS once, harvested by scraping in PBS and pelletized. 
2-3 volumes cell lysis buffer were added and the cells were kept on ice for 10 min. 
To obtain the nuclear pellets the cells were centrifuged at 4 °C and 5000 rpm for 
5 min. The nuclei pellet was resuspended in 3-4 volumes of nuclei lysis buffer, 
and incubated for 30 min at 4 °C on a rotor. The supernatant containing the 
nuclear protein extract, was transferred in a fresh tube after centrifugation at 
13000 rpm for 10 min at 4 °C. The NaCl concentration of the nuclear lysate was 
adjusted to 200 mM with the nuclei lysis buffer without NaCl. The protein 
concentration of the extract was determined with the Pierce BCA Protein Assay 
Kit (Thermo Fisher Scientific, USA) according to the manufacturers instructions 
and using the NanoDrop.  
 
2.13 In Vitro methylation assay 
To investigate the activity of EZH2 in vitro the EZH2 Assay Kit (BPS Bioscience, 
USA) was used according to the manufacturer’s instructions. Briefly, the 
microwells were rehydrated by adding TBST buffer to every well and incubating 
at room temperature for 15 min. The EZH2 complex was diluted in 1X HMT assay 
buffer at 10 ng/µl. The EZH2 complex, 400 µM S-adenosylmethionine and the 
RNA or protein lysate of interest were added to the wells in duplicates in a total 
volume of 50 µl and incubated at room temperature for 1 h. Instead of the 
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reaction buffer supplied in the kit, the reaction was carried out in a custom-made 
4X methylation buffer (Cifuentes-Rojas et al, 2014). The wells were then washed 
three times with TBST buffer. Next, 100 µl of blocking buffer was added to every 
well and incubated on a rotating platform for 10 min. The wells were incubated 
with the primary antibody, α-H3K27me3, diluted 1:100 in blocking buffer, for 1 h 
at room temperature with slow shaking. Before addition of the secondary 
antibody the wells were washed again three times in TBST buffer and again 
incubated in blocking buffer as described above. The secondary, HRP-coupled 
antibody was diluted 1:1000 in blocking buffer and incubated on the wells at room 
temperature with slow shaking for 30 min. Finally the wells were washed again 
with TBST and 50 µl HRP chemiluminescent substrate A and 50 µl 
chemiluminescent substrate B were added to the wells. The luminescence was 
read out immediately with the plate reader Infinite® M200 (Tecan Austria GmbH, 
AT). The integration time was 1000 ms. The EZH2 activity in the samples (%) 
was calculated via the ratio of the sample luminescence (L) to the value of the 
positive control (posCtrl), after subtraction of the blank values.  
 
EZH2 activity [%]= 
Lsample-Lblank
LposCtrl.-Lblank
 x 100% 
 
2.14 RNA affinity purification 
RNA affinity purification was performed as described previously (Caudron-Herger 
et al, 2015). Briefly, cell nuclei were isolated from HeLa S3 to prepare a nuclear 
extract using nuclear lysis buffer (see section 2.12, materials and methods). 5 µg 
of biotinylated RNA transcripts were incubated with 50 µl of pre-washed 
streptavidin-coated magnetic beads (Thermo Fisher Scientific, USA) at room 
temperature in 100 mM NaCl solution for 30 min. Beads were washed in washing 
buffer and incubated for 3 h in 70 µg nuclear extract in a total volume of 100 µl. 
After 3 steps of washing in nuclear lysis buffer, the beads were resuspended in 
50 µl of this buffer and bound proteins were eluted by adding 30 µg of RNase A 
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at 4°C for 30 min. Beads were retrieved on a magnet and the protein solution was 
further proceeded for western blot analysis or mass spectrometry. 
 
2.15 Immunofluorescence 
For immunofluorescent stainings, cells were grown on glass coverslips and fixed 
with 4 % paraformaldehyde/PBS. They were permeabilized for 5 min in ice-cold 
0.5% Triton X-100/PBS (v/v), washed three times in PBS and blocked with 10 % 
goat serum/PBS at room temperature for 30 min. Primary antibodies specific to 
the protein of interest were diluted in the blocking solution as indicated in Table 5 
and incubated on the slides for at least 1 h at room temperature. To remove 
excessive primary antibody, cells were washed three times with 
0.002%NP40/PBS (v/v). Appropriate secondary antibodies conjugated with 
fluorescent dyes (Table 6) were also diluted in the blocking solution and 
incubated on the slides at room temperature for 30 min. The slides were again 
washed three times in PBS, incubated with 1x DAPI solution in PBS and mounted 
on microscope slides (Menzel-Gläser, Germany) with Mowiol.   
 
2.16 Western blotting 
Protein lysates were prepared by lysing cells in RIPA buffer, unless indicated 
otherwise. Protein concentrations of lysates were measure with the Pierce BCA 
Protein assay kit (Thermo Fisher Scientific, USA) according to the manufacturers 
instructions and using the NanoDrop. Lysates were taken up in 1X Laemmli 
buffer and incubated at 95°C for 5 min for denaturation and loaded onto precast-
stain-free gels (Mini-PROTEAN® TGX Stain-Free™ Precast Gels, 4-20%). After 
electrophoretic protein separation, the proteins were transferred to a 
nitrocellulose (Whatman, UK) or PVDC (BioRad, USA) membrane using semi-dry 
blotting. The membranes were blocked with 5% milk powder (Roth, Germany) in 
TBS at room temperature for 1 h and were incubated in primary and secondary 
antibodies either at 4°C overnight or at room temperature for 1 h (Table 5, Table 
6). Antibody incubation was followed by three washing steps with TBS 
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supplemented with 0.05% Tween 20 (v/v). HRP-linked secondary antibodies 
were detected using a chemiluminescent ECL reagent (BioRad, Germany) and 
the Chemi Doc Gel documentation system (BioRad, Germany) was used for 
detection. 
 
2.17 Acid extraction of histones 
To extract soluble proteins approximately 106 cells were pelleted and washed 
once with PBS. The pellet was then dissolved in 0.25 M HCl (100 µl/106 cells) 
and homogenized. The suspension was rotated over night at 4°C. After 
centrifugation for 5 min at 208000xg and 4°C the supernatant was collected. The 
remaining pellet was suspended again in half the volume of 0.25 M HCl 
(50 µl/106 cells) to ensure complete extraction of the soluble proteins. After a 
second centrifugation step for 5 min at 208000xg and 4°C the supernatants were 
combined. To precipitate histones TCA was added to a final concentration of 33% 
(v/v) and the mixture was incubated on ice for 30 min. After centrifugation for 
20 min at 4°C the pellet was washed twice with TBME/EtOH (1:1). The pellet was 
then air-dried, dissolved in water and processed for western blotting. (Shechter et 
al, 2007; Villar-Garea et al, 2008) 
 
2.18 Mass spectrometry 
Mass spectrometry was carried out at the Mass Spectrometry Core Facility of the 
ZMBH (Zentrum für Molekulare Biologie der Universität Heidelberg). Proteins 
eluted from the RNA affinity purification were shortly run into a Mini-PROTEAN® 
TGX™ Precast Gels (4-20%) and stained by colloidal Coomassie blue. For each 
sample, the entire lane was cut into two gel slices. After in-gel digestion with 
trypsin the samples were subjected to mass spectrometry and analyzed with the 
Scaffold Proteome Software. The gene ontology (GO) term analysis proteins 
identified by mass spectrometry was carried out using the DAVID tool (Database 
for Annotation, Visualization, and Integrated Discovery) (Dennis et al, 2003). 
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2.19 ChIP-seq 
Chromatin immunoprecipitation 
1x106 to 1x107 Cells were collected by trypsinization, washed once with PBS and 
fixed with 8 ml PBS/formaldehyde (1%, (v/v)) at room temperature for 10 min. 
The reaction was stopped with 1 ml 1M Glycin for 5 min. The pellet was then 
washed three times with cold PBS and stored until further processing at -80°C. 
Cells were then resuspended in 0,9 ml MNase buffer including protease inhibitor 
and 80U MNase were added for 15 min at 37°C while shaking the cells. Then, 
100 µl 10x covaris sonication buffer were added, the mixture was incubated on 
ice for 5 min and all samples were sonicated with Covaris with the following 
settings: Burst 200, Cycle 20%, Intensity 8, 20 min. The chromatin was then 
pelletized at 14800 rpm, 4°C for 10 min and the supernatant was taken for further 
processing. The chromatin concentration was determined with the Qubit 
fluorometer and for each immunoprecipitation 4.4 µg HeLa chromatin was used 
and supplemented with 10% (440 ng) chromatin derived from mouse embryonic 
stem cells. The supernatants were the pre-cleared by incubation with Protein G 
beads for 30 min at 4°C on a rotating platform. The beads were pelleted, 10% of 
the supernatant taken as input and the rest distributed for immunoprecipitation 
with antibodies against H3K27me3, H3 and normal rabbit IgG. Antibody-
chromatin complexes were allowed to form for 2 h at 4°C on a rotating platform. 
25 µl Protein G beads (NEB CHIP-Grade, binding capacity 0.4 µg/µl) were pre-
equilibrated with Covaris sonication buffer twice for 10 min and incubated with the 
antibody-chromatin complexes at 4°C over night. The beads were then washed 
with Covaris buffer, high-salt buffer, Li-buffer and twice with TE buffer, each for 5 
min. Final elution was done with 250 µl elution buffer twice for 15 min at 37°C. To 
reverse-crosslink samples 0.5 µl RNase A (10 mg/ml) were added to the elution 
buffer and incubated for 1 h at 37°C. Then 20 µl 5M NaCl and 2 µl Proteinase K 
(20 mg/ml) were added and incubated over night at 65°C. The next day 1 volume 
of isopropanol (500 µl), 1/10 ammoniumacetat (50 µl) and 1,5 µl glycoblue 
(Ambion, USA) were added and incubated for 60 min at 20°C. The precipitation 
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was centrifuged at 14800 rpm, 4°C for 30min. The pellet was washed once with 
75% ethanol, dried and dissolved in 20 µl H2O.  
 
Library preparation for sequencing 
Immunoprecipitated DNA from incubations with antibodies against H3K27me3, 
H3 and normal rabbit IgG were cloned into a multiplexed library using the 
NEBNext Ultra DNA Library Prep Kit (Illumina, USA) exactly according to the 
manufacturers instructions. All GSK343 treated samples and DMSO treated 
samples from two replicates were pooled together, respectively. Peak size and 
quality of the libraries were checked on a Tape station. Each pool was 
sequenced on 3 lanes as 50-bp reads on the Illumina HiSeq 2000 platform 
sequencer (Genomics & Proteomics Core Facility, DKFZ).  
 
Analysis of ChIP-seq data 
The quality of the raw sequence data from H3K27me3 ChIPs and the 
corresponding controls was monitored using FastQC (Andrews, 2010). 
Sequences were mapped to the human and mouse genomes using bowtie 
(Langmead et al, 2009) allowing for 2 mismatches with the following options: 
human: bowtie -t --chunkmbs 256 --best --strata -v 2 -m 1 -e 70 --seed 12345678 
hs37d5; mouse: bowtie -t --chunkmbs 256 --best --strata -v 2 -m 1 -e 70 --seed 
12345678 mm9. The ambiguity of reads mapping to both the human and the 
mouse genome was checked by applying BEDtools (intersectBed, options: -f 1 -r 
-v) (Quinlan & Hall, 2010). All reads in the H3K27me3 sample were normalized 
by subtraction of a weighted control IP signal obtained from the IgG control and 
enrichment over the background signal (input) (Molitor et al, 2015). To check for 
the quality of the replicates pseudo-autocorrelations were calculated using multi-
scale correlation evaluation (MCORE) (Molitor et al, 2015). Peaks of H3K27me3 
enrichment were called using Sicer (Zang et al, 2009) with the following options: 
1 200 75 0.7 600 1e-03. Overlapping peaks in the DMSO and GSK343 treated 
samples were identified using the intersectBed tool (options: -f 5e-8). The 
48 Materials and Methods 
 
 
position of Sicer-identified peaks relative to annotated genes, introns, exons, 
5’-UTRs and 3’-UTRs was classified using intersecBed (options: -f 5e-8) with 
RefSeq annotations as the reference (Pruitt et al, 2014). Traces of the control 
and ChIP samples were visualized with the Integrative Genomics Viewer (IGV) 
(Robinson et al, 2011). 
 
2.20 Fluorescence-activated cell sorting 
Cells were washed once with PBS, trypsinized and counted. The same number of 
cells were pelletized and resuspended in 1 ml cold PBS. 3 ml cold ethanol was 
added dropwise to each cell suspension under constant mixing. To pelletize, the 
suspensions were centrifuged for 5 min, 400 x g. The pellets were resuspended 
in 200 µL cold PBS, 0.25 % Triton X-100 (v/v), and incubated on ice for 5 min. 
After washing the pellets three times with 1 % BSA/PBS solution 100 µL of 
α-H3K27me3-antibody (Table 5) were added, and incubated over night at 4 °C on 
a rotor. After washing the cells again three times with 1 % BSA in PBS, they were 
incubated with the secondary antibody (α-rabbit-Alexa633, Table 6) for 2 h at 
4 °C on a rotor in the dark. The cells were washed again three times and 
resuspended in 200 µL of 1 % BSA/PBS. To singularize the cells, they were 
filtered before FACS analysis. The FACS analysis was performed with the 
FACSCanto II, measuring at least 10000 cells of each sample. 
 
2.21 Microinjection  
For microinjection of living cells, HeLa were grown in Nunc Lab-Tek chamber 
slides. Microinjection was performed with a computer-assisted system (AIS2, 
CellBiology Trading). Injections of approximately 50 fl of volumes were performed 
using a needle with a tip-diameter of ca. 300 nm, 150 hPA pressure and 0.5 sec 
injection time. For 10 µl injection mix, 2 µl propidium iodide (PI, 1 mg/ml) were 
mixed with 1 µg of RNA in PBS or 1 µg of fluorescein labeled RNA in PBS was 
used directly. Following microinjection, cells were cultured under standard 
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conditions for 15 min and prepared for confocal microscopy image acquisition by 
fixation and staining as indicated. 
 
2.22 Fluorescence microscopy 
Confocal imaging was done with a Leica TCS SP5 confocal laser scanning 
microscope (CLSM) equipped with a HCX PL APO lambda blue 63x/1.4 NA oil 
immersion objective (Leica Microsystems CMS GmbH, Mannheim, Germany). A 
near UV diode, diode-pumped solid-state, argon and helium-neon lasers were 
used for DAPI (λ = 405 nm), Alexa 488 or GFP (λ = 488 nm), Alexa 568 (λ = 561 
nm) or Atto-565 and Alexa 633 (λ = 633 nm) excitation. For multi-color analysis 
sequential image acquisition was applied. The emission detection ranges were 
adjusted to minimize crosstalk between the different channels. The detection 
pinhole had a diameter corresponding to one airy disk.  
 
2.23 Image analysis 
ImageJ (Schneider et al, 2012) was used for the analysis of microscopy pictures. 
For analysis of the size of particles images were segmented via thresholding and 
the function “Analyze Particles” was used to automatically measure the size of 
lacO arrays. To measure the enrichment of protein factors at the lacO arrays the 
fluorescent signal of the MS2-GFP-LacI protein was used to identify the position 
of the arrays. The mean intensity values of the immunofluorescent staining 
against protein of interest were then measured and the enrichment over the 
background signal in the nucleus of the same cell was calculated. In both cases 
only cells that showed a positive signal for the MS2-stem loops RNA-FISH at the 
arrays were taken into consideration.  
Protein levels (and H3K27me3 levels) on western blots were analyzed by 
selecting the respective lanes on the western blot and displaying the 
corresponding intensity histograms of the lanes. The area under the peak was 
calculated and the ratio to the loading control determined.  
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Results 
1 Methods to detect and characterize nuclear RNAs were 
established 
Over the last years, accumulating evidence showed that RNA is a crucial factor in 
shaping the genome and its nuclear environment. In a report by Caudron-Herger 
and colleagues, it was demonstrated that digestion of single-stranded RNAs by 
RNase A induces a distinct micrometer scale chromatin aggregation of 
decondensed chromatin regions (Caudron-Herger et al, 2011). After purification 
of an RNA fraction that allows rescuing this aggregation, the associated 
transcripts were found to be enriched in long 3’-UTR sequences. It is proposed 
that they play a role in organizing transcriptionally active chromatin. Similarly, it 
has been observed that depletion of RNA Pol II transcripts from the nucleus 
results in the dissolution of nucleoli into so-called “necklace” structures (Granick, 
1975; Haaf & Ward, 1996). Motivated by these findings, the goal of this thesis 
was to shed light on the role of long single-stranded RNAs in chromatin 
organization.  
In order to do so, it was essential to establish methods to visualize the RNAs of 
interest in the cell and to investigate their functions. Building on previously 
described techniques, two methods were advanced here to achieve these goals: 
First, microinjection of fluorescently labeled RNA was applied to monitor 
subcellular localization of RNAs and to explore their functions on the time-scale 
of minutes after microinjection. Second, a system involving the MS2 coat protein 
and MS2 stem loop-tagged transcripts was established. It was used to investigate 
the influence of specific RNAs on the chromatin when they are immobilized at a 
specific locus. Using these methods, particular focus was laid on the chromatin 
organizing function of 3’-UTR sequences with respect to regulating the 
expression of transcripts variants at their locus. Furthermore, also intronic, RNA 
Pol II derived transcripts that were suggested to play a role in nuclear 
organization were examined in more detail. The latter were primarily addressed in 
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the first part of this work, where the main focus was on establishing the methods 
to detect and characterized nuclear RNAs. 
 
1.1 Microinjection of RNA allows the investigation of their cellular 
localization and their chromatin organizing function 
First, microinjection of RNAs directly into the nuclei of living cells was chosen as 
a method to observe transcripts independently of a foreign sequence attached to 
it. For all microinjection experiments shown here a computer assisted 
microinjection system was used resulting in the efficient treatment of a high 
number of cells as needed to perform statistical analyses of the observed 
phenotype (Figure 6).  
 
In vitro transcribed, microinjected RNAs show different subcellular 
localization 
It was tested whether microinjection can be used to investigate the subcellular 
localization of various RNAs and how different RNAs behave when microinjected 
directly into the nuclei of living cells. To this end, specific transcripts derived from 
selected 3’-UTRs were produced in vitro in the presence of fluorescein-labeled 
UTP and microinjected directly into the nuclei of HeLa cells. Assuming an 
injection volume of approximately 50 fl, every cell received a total amount of 
approximately 50 fg RNA. The cells were then incubated for 15 minutes before 
fixation to allow the microinjected RNAs to relocalize from the point of injection to 
their final position according to their physiological properties. Figure 8 shows that 
different RNAs behaved differently: Figure 8A depicts RNAs that were retained 
within the nucleus. In the bottom panel, it is also noted that the microinjected 
RNA did not leave the cell of interest to enter a neighboring cell. Only the cell that 
was injected showed the fluorescent signal emitted from the fluorescein-labeled 
transcript. Figure 8B displays examples of RNAs that were also found outside the 
nucleus. In the top panel, a cell is depicted where the transcript distributed evenly 
over the whole cell including nucleus and cytoplasm. The bottom panel illustrates 
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an RNA that left the nucleus to completely redistribute to the cytoplasm even 
when microinjected into the nucleus. In conclusion, RNAs of various nature with 
putatively different physiological roles also behaved differently when 
microinjected into the nuclei of living cells. It is observed that they redistributed 
distinctly on the minutes time-scale. Microinjection is therefore a suitable tool to 
investigate whether an RNA transcript preferentially resides in the nucleus or 
distributes to the cytoplasm in the living cell. 
 
Figure 8: Microinjection as a tool to investigate subcellular localization of RNAs. RNA 
transcripts were produced in vitro in the presence of fluorescein-labeled UTP and microinjected 
into the nuclei of living cells. The RNAs were allowed to redistribute over the subcellular 
compartments for 15 minutes. Cells were fixed for image acquisition and counterstained with 
DAPI. (A) Confocal laser scanning microscopy (CLSM) images of microinjected, nuclear retained 
3’-UTRs of CDV3 (top panel) and EIF2S3 (bottom panel) are shown. (B) CLSM images of the 
microinjected anti-sense 3’-UTRs of STARD7 (top panel) and FADS (bottom panel) are shown as 
examples of RNAs that left the nucleus to partly or fully redistribute to the cytoplasm. Green: 
fluorescein-labeled RNA, blue: DAPI, scale bars: 10 µm. 
 
A pool of purified RNAs can perform its physiological function after 
microinjection 
The next step was to test whether microinjected RNAs can still perform their 
physiological function. HeLa cells were treated with the RNA Pol II inhibitor 
α-amanitin for five hours. As demonstrated previously by Haaf and colleagues, 
this caused the loss of nucleolar structure, an increase in the number of nucleolar 
domains and a decrease in their size (Haaf & Ward, 1996) (Figure 9A). To test 
whether purified nucleolar RNA can rescue the disrupted phenotype upon 
microinjection, nucleolar RNA was extracted from HeLa cells. Propidium iodide 
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(PI) was added to the microinjection mix in order to be able to identify the 
microinjected cells. PI binds nucleic acids (Suzuki et al, 1997) and was therefore 
a well-suited fluorescent agent to mark the cells. Α-amanitin-treated HeLa cells 
were microinjected with the RNA/PI mixture and the RNAs were allowed to 
redistribute and to perform their activity for 30 minutes before cells were fixed. 
The number and size of nucleolar domains per cell – visualized by 
immunostaining of the nucleolar protein nucleophosmin (NPM) – was taken as a 
measure for the extent to which the RNA pool was able to trigger nucleolar 
reassembly. As depicted in the exemplary CLSM images in Figure 9A, 
microinjection of RNA from purified nucleoli led to a decrease in the number of 
nucleolar bodies. This correlated with an increase in their size. A quantitative 
analysis of the images (Figure 9B) indicated that indeed only the nucleolar RNA 
fraction but not the buffer or the total RNA of the cells could trigger nucleolar 
reassembly. 
 
Figure 9: Microinjection of purified nucleolar RNA into the nuclei of living cells. HeLa 
cells were treated with α-amanitin for 5 hours and then microinjected with buffer, total RNA or 
the purified nucleolar RNA fraction. After fixation nucleolar domains were visualized by 
immunofluorescence of NPM. (A) CLSM images of an untreated cell injected with PI 
containing buffer only (top panel) and α-amanitin-treated cells microinjected with either buffer 
only (middle panel) or the nucleolar RNA fraction (bottom panel). Red: PI, green: NPM, scale 
bars: 10 µm. (B) The graph represents the average number of nucleolar domains (+/- 95% 
confidence interval (CI)) based on the analysis of 90, 87, 80 and 86 cells, respectively. 
**p<0.01 (Student’s t-test). Adapted from Caudron-Herger et al, 2015. 
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First, this indicates that the nucleolar RNA fraction contained RNA transcripts that 
counteracted the α-amanitin-induced segregation of nucleolar regions. Second, 
this experiment demonstrates that the microinjected nucleolar RNA pool was 
active in the cell and could perform its functions. Finally, it shows that 
microinjection is a powerful technique to differentiate the physiological roles of 
different RNA pools in the nucleus.  
 
Single in vitro transcribed RNAs can perform their function after 
microinjection 
The previous section suggested that a whole RNA pool purified from the 
nucleolus can perform its nucleolus-assembling function after microinjection into 
α-amanitin-treated cells. It was therefore hypothesized that single transcripts that 
are highly enriched in this RNA fraction could also be able to show this 
phenotype after microinjection. The most enriched transcripts found in the 
nucleolar RNA fraction were RNA Pol II-transcribed repetitive intronic Alu 
elements, termed aluRNAs (Caudron-Herger et al, 2015). Therefore, a prototypic 
aluRNA was produced in vitro, mixed with PI and microinjected into HeLa cells 
that had been treated with α-amanitin for 5 hours. Again, the number of nucleolar 
domains per cell was taken as a measure for the extent, to which the aluRNA 
was able to trigger nucleolar reassembly. Nucleolar domains were identified by PI 
staining. As depicted in Figure 10A, microinjection of in vitro transcribed aluRNAs 
triggered reassembly of nucleolar particles as manifested by a decrease in the 
number of nucleolar domains. As controls, the reverse sequence of the prototypic 
aluRNA and an RNA originating from another frequent repetitive element, the L1 
repeat, were used. Notably, the forward aluRNA was most efficient in rescuing 
the nucleolar dispersion in a quantitative comparison to the reverse aluRNA, the 
L1-repeat RNA transcript, or the buffer only Figure 10B). As described above for 
the whole pool of nucleolar RNA, this shows that also single in vitro transcribed 
RNAs can perform their functions when microinjected into living cells. In 
conclusion, microinjection is a well-suited technique to investigate the cellular 
localizations and functions of single RNA transcripts as well as RNA pools.  
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Figure 10: Microinjection of an in vitro-transcribed prototypic aluRNA into the nuclei of 
living cells. HeLa cells were treated with α-amanitin for 5 hours and microinjected with forward 
aluRNA, reverse aluRNA and L1-repeat RNA or buffer only. Nucleoli were visualized by their 
enrichment in PI. (A) CLSM images of an α-amanitin-treated cell microinjected with buffer only 
(top) or the forward aluRNA transcript (bottom). Scale bars: 10 µm. (B) The graph represents 
average number of nucleolar domains (+/- 95% CI) base on the analysis of 90, 87, 86, 83 and 86 
cells, respectively. **p < 0.01 (Student’s t-test). Adapted from Caudron-Herger et al, 2015. 
 
1.2 Specific RNAs immobilized at a lacO array in living cells can act 
as chromatin modifiers 
In order to assess more than the global effect of RNA on nuclear structure, it is 
also very informative to quantify the effects of a specific RNA at a defined 
genomic locus. Amongst others, the following features can be investigated with a 
model system such as the lacO arrays that were used here: recruitment of 
putative protein interaction partners, the impact on epigenetic chromatin 
modifications such as posttranslational modifications of histones, the effect on 
chromatin compaction, or the localization of the genomic locus in respect to other 
nuclear sub-compartments. Here, I established an experimental system to 
immobilize RNAs at a specific genomic locus. It made use of two highly affine 
and highly specific nucleic acid-protein interactions: First, mammalian cells that 
have stable genomic integrations of an array of the bacterial lacO sequence, 
which are bound by the LacI repressor protein, were employed (Belmont & 
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Straight, 1998; Jegou et al, 2009; Robinett et al, 1996) (Figure 7A). Second, the 
RNAs of interest were tagged with the bacteriophage MS2 stem loop sequence, 
which is recognized and bound by the MS2 coat protein (Johansson et al, 1998; 
Shevtsov & Dundr, 2011). The two were combined by transfecting a plasmid 
encoding the MS2-tagged RNA and a fusion protein of MS2 and LacI into cells 
with stably integrated lacO arrays. The localization of the lacO array within the 
nucleus could be visualized by introducing a fluorescent protein, e.g. GFP, to the 
fusion construct of MS2 and LacI. To ensure efficient recruitment, plasmids 
encoding for 18 sequential MS2 stem loops were used. Taken together, this 
provided a toolkit that could be used to immobilize any RNA at a specific, known 
chromatin locus and to evaluate its activity at this locus. Methods to detect the 
RNA enriched at the array and to visualize potential protein interaction partners 
are described in the following (Figure 7B). 
Various cell lines containing stable lacO integrations are available, in which the 
arrays are integrated at different locations in the genome. Here, two human cell 
lines were selected, called EC4 and F4IIB8, both of which are derived from the 
human osteosarcoma cell line U2OS (Jegou et al, 2009). Additionally, a Chinese 
hamster ovary (CHO) cell line, called AO3, was used (Luijsterburg et al, 2012; 
Tumbar et al, 1999). All three cell lines have a single integration of multiple 
copies of the lacO repeat.  
 
Ethynyl-uridine incorporation or RNA-FISH can be used to visualize RNA 
enrichment at lacO arrays in the MS2-LacI-mediated recruitment system 
The first step of establishing the MS2/LacI-mediated recruitment system was to 
find suited methods to detect the enrichment of RNA at the arrays. There are 
several methods to do so, two of which will be described in the following. First, 
RNA enrichment at the array was visualized by using ethynyl-uridine (EU), which 
is incubated with the cells before fixation so that RNA Pol II incorporates it into 
freshly made RNA. The EU containing RNA transcripts were then made visible by 
attaching a fluorophore to the EU using an azide-alkyne cycloaddition reaction, 
called “click” chemistry (Liang & Astruc, 2011). EC4 cells were transfected with 
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the MS2-GFP-LacI fusion protein and a plasmid encoding for an MS2 stem loop-
tagged RNA oligonucleotide of 60 nucleotides in length. 6 hours after transfection 
EU was added to the medium of the transfected cells and allowed to be 
incorporated into RNAs overnight. Figure 11A shows a cell, in which a clear 
enrichment of the EU signal could be seen at the arrays, visualized by the GFP-
tagged LacI protein. In this experimental setup EU is incorporated into all newly 
synthesized RNAs, not just the MS2-tagged RNAs. Nonetheless, the enrichment 
of the RNA at the array was strong enough to identify the array via its EU signal 
in comparison to the nuclear background signal. It is therefore concluded that EU 
incorporation and labeling by “click” chemistry is a suited method to assess 
whether RNA is enriched at the lacO array when recruiting it there via the 
MS2/LacI-mediated recruitment system. 
 
   
Figure 11: Visualization of MS2 stem loop-tagged RNA recruited to lacO arrays with a 
fusion protein of MS2-GFP-LacI. Cells were transfected with the MS2-GFP-LacI fusion protein 
and a plasmid encoding for an MS2 stem loop-tagged RNA oligonucleotide of 60 nucleotides. 
(A) EC4 cells were treated with EU overnight and EU was marked with a fluorophore using “click” 
chemistry after fixation. (B) AO3 cells were fixed 24 hours after transfection and RNA-FISH with 
an ATTO-565-labeled probe directed against the MS2 stem loop sequence was performed. 
RNase A-treated cells were included in order to rule out unspecific binding of the RNA probe to 
DNA sequences. Insets show enlargements of the lacO arrays. Red: RNA, green: MS2-GFP-LacI, 
blue: DAPI, scale bars: 10 µm.  
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The second method involves RNA fluorescence in situ hybridization (RNA-FISH) 
with specific probes directed against the MS2 stem loop sequence (schematically 
depicted in Figure 7B). AO3 cells were transfected with the MS2-GFP-LacI fusion 
protein and the same plasmid encoding for a short MS2 stem loop-tagged RNA 
as above. Cells were fixed 24 hours after transfection and an RNA-FISH with a 
fluorescently labeled probe directed against the MS2 stem loop sequence was 
performed (Goodier et al, 2010). To ensure that the sequence detected by the 
RNA-FISH is in fact the RNA sequence and not the DNA sequence of the 
plasmid, an RNase A-treated control was included in the analysis. Since 
RNase A cleaves all single stranded RNAs including the MS2 stem loop-tagged 
RNA no RNA-FISH signal was expected after RNase A treatment. As depicted in 
Figure 11B, an enrichment of the RNA-FISH signal that co-localizes with the 
MS2-GPF-LacI fusion protein could be seen (Figure 11B, upper panel), whereas 
no RNA-FISH signal was detected at the array after RNase A treatment (Figure 
11B, bottom panel). Due to the high affinity of the MS2 stem loops to the MS2 
coat protein immobilized at the array, most of the MS2-tagged RNA was 
expected to be found at the array whereas very little should be distributed over 
the nucleus. Indeed, the background signal was very low. It is therefore reasoned 
that RNA-FISH directed against the MS2 stem loop sequence is a well-suited 
method to detect enrichment of the MS2 stem loop-tagged RNA at genomic lacO 
sequences. From both the RNA detection by EU and by RNA-FISH it can 
furthermore be concluded that the lacO system works well to locally tether and 
enrich an RNA of interest at the lacO arrays.  
 
Immobilized RNAs at the lacO arrays recruit protein interaction partners 
The next step was to investigate whether the RNA of interest is able to recruit its 
known protein interaction partners and to perform its function. As before, the cell 
lines that have stable lacO array integrations and the MS2-GFP-LacI fusion 
protein were used. As shown above aluRNA is a nucleolar enriched RNA that 
could rescue the nucleolar dispersion induced by RNA Pol II inhibition. Given that 
aluRNA has been shown to play a role in nucleolar structure, it was hypothesized 
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that it could also interact with prominent nucleolar proteins such as the nucleolin 
(NCL). Here, it was therefore tested whether aluRNA interacts with NCL in the 
living cell. F4BII8 cells were transfected with MS2-GFP-LacI and the MS2 stem 
loop-tagged aluRNA. 24 hours after transfection cells were fixed and an 
immunostaining directed against NCL was performed. Figure 12 shows that MS2-
aluRNA induced recruitment of NCL to the lacO array. This observation suggests 
that indeed aluRNA interacts with the nucleolar protein NCL to play a role in 
nucleolar organization. Furthermore, this shows that the MS2/LacI-mediated 
recruitment system can be used to study RNA – protein interactions in living cells.  
 
 
Immobilized RNAs at the lacO array influence nuclear localization of the 
arrays 
Next, it was investigated whether the RNAs also perform their function in terms of 
influencing the sub-nuclear localization of the arrays depending on which RNA is 
tethered to the array. In this experiment, it was therefore analyzed whether 
tethering aluRNA to the arrays also has an influence on the localization of the 
arrays within the nucleus. It was previously shown that aluRNAs are nucleolar 
localized RNAs and that they interact with NCL. Hypothetically, aluRNA could 
therefore be able to recruit the lacO arrays to the nucleoli driven by their own and 
Figure 12: Ectopically expressed and lacO array-immobilized MS2-aluRNA recruited the 
nucleolar protein NCL. F4IIB8 cells were transfected with forward MS2-aluRNA and 
MS2-GPF-LacI (shown in green) and an immunostaining against NCL (shown in red) was 
performed. Localization of MS2-GPF-LacI and NCL are shown and the arrow indicates the lacO 
array, which is associated with a nucleolar domain. Green: LacI-GFP-MS2, red: NCL, scale bar: 
10 µm. Adapted from Caudron-Herger et al, 2015. 
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their protein interaction partner’s affinity for the nucleolus. To test whether 
tethering the aluRNAs to the lacO arrays is a suited system to investigate this, 
F4IIB8 cells were again transfected with MS2-aluRNA and MS2-GFP-LacI. As 
controls, the MS2 stem loops alone, the two separate arms of the Alu sequence 
(left, L and right, R) and a selected set of further MS2-tagged RNAs of various 
lengths were included in the analysis. Using an immunostaining of NPM the 
nucleolar localization of the lacO arrays with respect to the nucleolus was 
analyzed quantitatively. Figure 13A displays an exemplary CLSM image of a cell 
where a lacO array was located in close proximity to a nucleolus. A quantitative 
analysis of the percentage of arrays that show nucleolar localization after MS2-
aluRNA recruitment is depicted (Figure 13B). It is noted that both the full-length 
aluRNA and its right arm fragment aluRNAR significantly increased the number of 
lacO arrays localizing in the nucleoli.  
 
 
Figure 13: Ectopically expressed and lacO array-immobilized MS2-aluRNA caused 
nucleolar localization of the lacO arrays. F4IIB8 cells were transfected with the MS2 
loops-containing aluRNA, its left arm (L), or right arm (R), and the MS2-GFP-LacI fusion 
protein. The MS2 stem loops only, MS2-tagged 3’-UTRs of CDV3, STARD7 and CORO1C 
served as controls. An immostaining against NPM was performed. (A) Exemplary CLSM 
image after recruitment of MS2-aluRNA showing the array in proximity of a nucleolus. Green: 
MS2-GFP-LacI, red: NPM, scale bar: 10 µm. (B) Plot of the percentage of nucleolar 
localization as evaluated by the average number of lacO arrays detected in nucleoli. n>100, 
*p<0.05 (Student’s t-test), (+/- 95% CI). Adapted from Caudron-Herger et al, 2015. 
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This suggests that aluRNA not only interacts with NCL as shown above but also 
targets genomic loci to the nucleoli. This also demonstrates that the experimental 
model system used here allows for investigation of the localization of the arrays 
in dependence of the recruited RNA. These results reinforces that the MS2/LacI-
mediated recruitment system is well-suited to evaluate the physiological 
behaviors of immobilized RNAs at the chromatin.  
 
The above sections describe the methodologies of microinjection and MS2/LacI-
mediated recruitment to chromatin in the context of the interplay of the nucleolus 
with aluRNA. In the following parts of this thesis these two methods were used to 
characterize the role of 3’-UTRs in chromatin organization. Microinjection was 
employed to determine the sub-cellular localization of putative chromatin-
organizing 3’-UTR candidates. The recruitment of RNAs to the lacO arrays was 
used to investigate the effect of specific 3’-UTR sequences on the local chromatin 
at the array: their effect on chromatin compaction, histone modifications and 
recruitment of chromatin modifying enzymes was examined.  
 
2 3’-UTRs have chromatin organizing function 
3’-UTRs are known for their roles in regulating mRNA stability and protein 
translation (Matoulkova et al, 2012). A number of publications have suggested 
additional functions of 3’-UTRs. For example, specific 3’-UTRs have been 
reported to exist independently of the protein coding sequence of the 
corresponding mRNA transcripts (Furuno et al, 2006). Moreover, 3’-UTR 
transcripts can be found in the nucleus independently of the protein coding part of 
the mRNA (Mercer et al, 2011). Also, it has been reported that digestion of single 
stranded RNAs in the nuclei of mammalian cells causes a distinct micrometer 
scale chromatin aggregation of decondensed regions (Caudron-Herger et al, 
2011). It is suggested that a homogeneous chromatin distribution can be restored 
by a soluble nuclear RNA fraction that is enriched in long 3’-UTR transcripts, 
referred to as the F2 fraction. It is proposed that these RNAs could act as 
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architectural genome organizing factors. Based on these observations, there is 
evidence that 3’-UTRs play an important role in nuclear architecture and 
chromatin organization. The goal of the following sections was to identify 
particularly interesting 3’-UTR sequences with a chromatin organizing function. 
To do so, the most enriched 3’-UTRs from the above named F2 RNA fraction 
were investigated. First, they were tested for their potential to rescue 
RNase A-induced chromatin compaction. Second, their sub-cellular localization 
was investigated to find out whether these RNAs can be found in the nucleus as 
expected from an RNA with chromatin organizing function. Third, using the above 
described and tested MS2/LacI-mediated recruitment system, the effect of these 
3’-UTR sequences, when immobilized at a specific chromatin locus, was 
examined. Combining the results of these three experiments provided criteria for 
selecting a particularly interesting 3’-UTR candidate, the 3’-UTR of CDV3 
(carnitine deficiency-associated gene expressed in ventricle 3) that was then 
further investigated with respect to its chromatin organizing function.  
 
2.1 Specific long 3’-UTR sequences can rescue chromatin 
aggregation induced by RNase A treatment 
In the rescue experiments described by Caudron-Herger and colleagues 
(Caudron-Herger et al, 2011), HeLa cells were permeabilized and treated with 
RNase A. The RNase A was then washed away and inhibited by specific 
RNase A inhibitors. Different RNAs were then added to test their propensity to 
rescue the initial chromatin distribution. The RNase A-induced changes of 
chromatin organization and their rescue could be visualized by observing 
changes in the distribution of the DAPI fluorescent signal (Figure 14). 
It was tested whether specific 3’-UTRs that where highly enriched in the F2 
fraction could rescue RNase A-treated chromatin. For this experiment, the 
transcripts were produced in vitro and tested in the rescue experiment as 
described Figure 14. 
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Figure 14: Principle of the rescue experiment. Left panel: DAPI stained control and RNase A-
treated cells and intensity profiles along the indicated lines show the more heterogeneous 
chromatin distribution after RNase A digestion in comparison to the control cell. Right panel: After 
RNase A treatment, RNase inhibitor and 5 µg of the RNA of interest were added and incubated 
for 15 minutes to assess the putative potential of the RNA to rescue the initial and more 
homogenous chromatin distribution. Adapted from Caudron-Herger et al, 2011. 
 
The phenotype of the chromatin was evaluated by visual inspection of CLSM 
images of at least 100 cells per RNA transcript. The percentage of cells with 
rescued chromatin was calculated and compared to control cells. As controls, 
RNAs with similar sizes derived from the intergenic spacer of the rRNA genes 
were selected. These transcripts were not enriched in the F2 fraction. 3’-UTR 
transcripts were considered to have rescuing capacity if more than 50% of the 
cells showed a homogeneous chromatin distribution after rescue. They were 
considered to have no effect if less than 35% of the cells had homogeneous 
chromatin. Figure 15A depicts representative CLSM images of five 3’-UTRs that 
were able to fully reverse the chromatin phenotype after RNase A treatment. 
Furthermore, five transcripts that partly rescued this phenotype and four 
transcripts – including the negative controls – that showed no homogeneous 
chromatin distribution are displayed. A quantification of these results is given in 
Figure 15B.  
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Figure 15: The 3’-UTRs of the SSR3, CDV3, SURF3, STARD7 and CORO1C transcripts 
rescued chromatin aggregation induced by RNase A treatment. (A) Representative CLSM 
images of DAPI stained nuclei that were permeabilized, treated with RNase A, and treated with 
RNase inhibitor and the respective in vitro-transcribed 3’-UTR of the gene indicated above the 
images. RNA sequences derived from the intergenic spacer of the rRNA genes were used as 
controls. They were not enriched in the RNA pool that can rescue RNase A-treated chromatin. 
The nuclei were counterstained with DAPI. (B) Percentage of cells, in which addition of the 
indicated RNA rescued the initial homogeneous chromatin distribution after RNase A treatment. 
n>100.  
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The 3’-UTRs of the SSR3 (signal sequence receptor, gamma), CDV3 (carnitine 
deficiency-associated gene expressed in ventricle 3), SURF4 (surface 4 integral 
membrane protein), STARD7 (star-related lipid transfer (START) domain 
containing 7) and CORO1C (coronin, actin binding protein, 1C) transcripts were 
able to rescue the homogeneous chromatin distribution. This suggests that within 
the F2 fraction, there are specific long 3’-UTR sequences that can reverse the 
RNase A-induced chromatin aggregation, when used in the rescue assay as 
single in vitro transcribed transcripts. The 3’-UTRs of the EIF4B (eukaryotic 
translation initiation factor 4B), FADS1 (fatty acid desaturase 1), DDX21 (DEAD 
(Asp-Glu-Ala-Asp) box helicase 21), EIF2S3 (eukaryotic translation initiation 
factor 2, subunit 3 gamma), PTTG1IP (pituitary tumor-transforming 1 interacting 
protein) and FAM83A (family with sequence similarity 83, member A) transcripts 
proved little or no rescuing capacity. Therefore, clearly, not all 3’-UTR sequences 
that were enriched in the F2 RNA fraction had the same potential to rescue 
RNase A-treated chromatin. 
 
2.2 Fluorescently labeled 3’-UTR transcripts, which remain in the 
nucleus after microinjection, are selected 
In the following, it was investigated, whether the 3’-UTRs that could rescue 
RNase A-treated chromatin had nuclear localization. Only those were more likely 
to have an in vivo nuclear function such as chromatin organization. The 3’-UTR 
sequences that were tested in the rescue experiment above were therefore 
produced in vitro with fluorescein-labeled UTP and microinjected into the nuclei of 
HeLa cells as described in section 1.1 of the results. The RNAs were allowed to 
distribute over the cells within 15 minutes and cells were fixed and counterstained 
with DAPI for inspection by confocal microscopy. As illustrated in Figure 16, a 
number of the putative chromatin organizing 3’-UTRs resided in the nucleus 
(Figure 16A). In contrast, others distributed over the whole cell, i.e. nucleus and 
cytoplasm (Figure 16B), or even left the nucleus entirely and were exclusively 
localized in the cytoplasm (Figure 16C).  
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Figure 16: Fluorescently labeled 3’-UTRs of the SSR3, CDV3, STAR7 and CORO1C 
transcripts remained in the nucleus after microinjection. HeLa cells were microinjected with 
the in vitro transcribed and fluorescently labeled 3’-UTR sequences of the indicated RNAs. The 
transcripts were allowed to redistribute within 15 minutes before cells were fixed and 
counterstained with DAPI. Representative CLSM images are depicted. (A) Nuclear retained 3’-
UTR sequences, (B) 3’-UTR sequences that distribute over nucleus and cytoplasm, (C) 3’-UTR 
sequences that are exclusively found in the cytoplasm after microinjection into the nucleus. 
Green: RNA, blue: DAPI, scale bars: 10 µm.  
 
Four of the five RNAs that performed well in the rescue experiment described 
above (Figure 15) were also RNAs that reside in the nucleus after microinjection: 
the 3’-UTRs of SSR3, CDV3, STARD7 and CORO1C. SURF4-3’-UTR was the 
only exception and was exclusively found in the cytoplasm after microinjection 
into the nucleus. Additionally, EIF2S3-3’-UTR, a 3’-UTR that was not able to fully 
rescue RNase A-treated chromatin, was also found to remain in the nucleus after 
microinjection. All other 3’-UTR transcripts that demonstrated no or only limited 
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rescuing capacity showed distribution over the entire cell or even completely 
redistributed into the cytoplasm. In summary, this procedure further restricted the 
selection of 3’-UTRs sequences that are considered as relevant transcripts with 
chromatin organizing function. Only 3’-UTRs that had the capacity to rescue 
RNase A-induced chromatin perturbation and that showed nuclear localization 
after microinjection into the nucleus were further considered in the following 
analyses. This included the 3’-UTRs of SSR3, CDV3, STARD7 and CORO1C. 
 
2.3 The 3’-UTR of CDV3 induces changes in chromatin compaction 
at the lacO array 
Next, the chromatin organizing function of the SSR3-, CDV3-, STARD7- and 
CORO1C-3’-UTRs was examined in more detail. The MS2/LacI-mediated 
recruitment system described in section 1.2 of the results was applied, since it is 
a well-suited assay to examine the behavior of RNAs at the chromatin. Based on 
the above observations, it was hypothesized that immobilization and local 
enrichment of the chromatin organizing 3’-UTRs at a genomic locus would affect 
the chromatin compaction at the array.  
AO3 cells containing a stable insertion of the bacterial lacO repeat sequence 
were transfected with a fusion protein of MS2-GFP-LacI and the RNA of interest 
tagged with 18 MS2 stem loop sequences. AO3 cells were chose for this 
experiment for two reasons: On the one hand, the usual compact state of their 
arrays allows for observation of decondensation of the chromatin at the array as 
demonstrated by Luijsterburg and colleagues (Luijsterburg et al, 2012). On the 
other hand, their arrays per se are relatively loose so that also potential 
condensation could be observed. To detect RNA enrichment at the array, 
RNA-FISH with fluorescently labeled probes directed against the MS2 stem loop 
sequence was performed. The size of the arrays served as an indicator for the 
degree of chromatin compaction. It was calculated after segmentation via 
thresholding and by applying the function “Analyze Particles” in ImageJ 
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(Schneider et al, 2012). Cells transfected with no RNA or with the MS2 stem 
loops sequence only were used as controls.  
Figure 17A shows representative CLSM images of cells that were transfected 
with no RNA, the MS2 stem loops and the MS2-tagged 3’-UTR of CDV3. The 
corresponding samples treated with RNase A (bottom panel) are also depicted 
demonstrating that the RNA-FISH only specifically hybridized to the MS2 RNA 
and not the plasmid DNA. By visual inspection, it became clear that recruitment 
of the 3’-UTR of CDV3 decreased the size of the array. Recruiting just the MS2 
loops did not affect the size of the array. This observation was substantiated by a 
quantitative analysis of the size of the arrays as displayed in Figure 17B. Only the 
3’-UTR of CDV3 but not those of SSR3, STARD7 or CORO1C was able to 
significantly influence the degree of compaction of the lacO array.  
 
Figure 17: The 3’-UTR of CDV3 compacted chromatin when immobilized at the lacO arrays. 
AO3 cells containing a stable insertion of the bacterial lacO repeat sequence were transfected 
with a fusion protein of MS2-GFP-LacI and the RNA of interest tagged with the MS2 stem loop 
sequences. The MS2 loops were detected by RNA-FISH and nuclei counterstained with DAPI. 
(A) CLSM images of cells transfected with no RNA, the MS2 stem loops only or the 3’-UTR of 
CDV3 tagged with the MS2 stem loops. Each RNA was transfected twice and one sample of each 
was treated with RNase A (lower two panels). Insets show enlargements of the lacO arrays. Red: 
RNA-FISH, green: MS2-GFP-LacI, blue: DAPI, scale bar: 10 µm. (B) Quantitative analysis of the 
size of the lacO array depending on the RNA recruited to it. The median, the upper and lower 
quartiles and the 95% confidence intervals are shown. n>50, *p<0.05 (Wilcoxon test).  
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Thus, only the 3’-UTR of the CDV3 gene fulfilled three criteria that make it a 
particularly interesting 3’-UTR with chromatin organizing function: i) the transcript 
can rescue RNase A-treated chromatin as an in vitro transcribed RNA, ii) it 
resides within the nucleus after being microinjected directly into the nuclei of 
HeLa cells and iii) it compacts chromatin when immobilized at the lacO array, that 
is stably integrated into the chromatin of AO3 cells. Combining the results of 
these three experiments provided me with criteria for selecting the 3’-UTR of 
CDV3 for further analyses on the mechanism by which it influences chromatin 
and on its endogenous role in chromatin organization. 
 
2.4 CDV3 is a nuclear and cytoplasmic RNA with several splice 
variants 
CDV3 codes for a protein that is up-regulated in the ventricles of mice with 
carnitine-deficient juvenile visceral steatosis, a condition, in which mice suffer 
from fatty liver, hyperammonemia, hypoglycemia and growth retardation 
(Fukumaru et al, 2002). Earlier reports had already identified the human homolog 
of CDV3 as being upregulated in HER-2/NEU over expressing breast tumors (Oh 
et al, 1999) and as a potential carrier of a small nucleotide polymorphism (SNP) 
that might affect colorectal cancer risk (Abuli et al, 2011). Intriguingly, one study 
suggests that the 3’-UTR of CDV3 is expressed separately from the associated 
protein-coding sequence, to which it is normally linked, in human and mice 
(Mercer et al, 2011). All of these previous reports agree that CDV3 has two splice 
variants both, of which are expressed as detected by northern blotting and by 
using anti-sera raised against the protein. Although it carries a nuclear 
localization signal, the protein is found mainly in the cytoplasm (Tsuchiya et al, 
2003). From genome-wide sequencing studies it is now known that there are at 
least three splicing forms of the CDV3 transcript, one of which has an alternative 
transcription start site. The other two differ in their last exon with the CDV3a 
transcript carrying a longer 3’-UTR and the CDV3b transcript an alternative exon 
with a shorter 3’-UTR (Figure 18A). Since this thesis focuses on putative 
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chromatin organizing signals in the 3’-UTR of the RNA only the latter two splicing 
variants will be considered in the following and referred to as CDV3a and CDV3b. 
For convenience the 3’-UTR of CDV3a will in the following be called “CU-RNA”, 
for CDV3-3’-UTR-RNA. The following experiments aimed at a closer 
characterization of the CDV3 transcripts with special focus on their 3’-UTRs. 
 
Figure 18: The CDV3 transcript is a nuclear and cytoplasmic RNA with two transcript 
variants that differ in their last exon and the length of their 3’-UTR. (A) Schematic illustration 
of the 3’ end of the genomic sequence of CDV3 and two of its splice variants that differ in the last 
exon (exon 5) and in the length of their 3’-UTRs. The blue exon represents their last common 
exon (exon 4). Red indicates the last exon including the 3’-UTR of both transcripts. The dotted 
grey line in between represents intronic sequences that are spliced out from the pre-mRNA. 
(B) Northern blot of total RNA extracts with DIG-labeled probes directed against β-actin (ACTB) 
and both splicing forms of CDV3. The expected sizes of the bands and the exposure time of the 
blot are indicated. The lower panel shows an image of the agarose gel used for blotting 
demonstrating the integrity of ribosomal RNA in the samples. (C) Same as (B) comparing equal 
amounts of total and nuclear RNA. (D) RNA-FISH of CDV3 RNA in HeLa cells. Specific DIG-
labeled probes targeting both splicing forms of CDV3 were used and visualized with an 
immunostaining against DIG. Nuclei were counterstained with DAPI. Untreated and RNase A-
treated cells are shown. Green: CDV3 RNA, blue: DAPI, scale bar: 10 µm. (E) Agarose gel of 
strand specific RT-PCRs of the 3’-UTR of CDV3.  
 
First, a northern blot of the transcript was performed using total RNA extract from 
HeLa cells. A combination of three DIG-labeled probes that could bind in the 
3’-UTRs of all splicing forms of the CDV3 transcripts revealed two strong and one 
weak band, presumably corresponding to the three splicing variants (Figure 18B). 
The two stronger bands could also be observed in a nuclear RNA extract as 
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depicted in Figure 18C. Northern blot analysis, revealed no obvious difference in 
expression of these two RNAs when comparing equal amounts of total RNA with 
nuclear RNA. Additionally, the endogenous RNA was detected by RNA-FISH with 
the same DIG-labeled probes used for northern blotting. As illustrated in Figure 
18D, the endogenous RNA could be found in the nucleus as well as in the 
cytoplasm. Finally, it was tested whether there was significant anti-sense 
transcription happening within CU-RNA. Strand specific RT-PCR revealed that 
the majority of the transcript is made in the sense direction and only a 
neglectable amount of PCR product was observed in the anti-sense direction 
(Figure 18E). From this set of experiments it can be summarized that CDV3 is 
expressed in 3 splicing forms, the pool of which can be detected in the nucleus 
and in the cytoplasm and that the majority of its 3’-UTR is produced in the sense 
direction with respect to the gene.  
 
3 CU-RNA recruits EZH2 and induces H3K27me3 when tethered 
to lacO arrays 
As described in section 2.3 of the results, it was observed that CU-RNA can 
induce compaction of the chromatin at the lacO arrays, a feature that was distinct 
for CU-RNA and not measured for any of the other RNAs tested. Presumably, 
CU-RNA functions together with chromatin modifying proteins, which are either 
recruited to the arrays by the RNA, or which need CU-RNA to properly perform 
their chromatin modifying function. The following sections focus on changes of 
the chromatin on the level of posttranslational histone modifications enforced by 
the presence of CU-RNA. Additionally, it was investigated which protein 
interaction partner is recruited to the array by CU-RNA to perform the RNA-
mediated chromatin changes.  
 
3.1 CU-RNA induces H3K27me3 at the lacO arrays  
Chromatin compaction is generally associated with heterochromatin (Fraser & 
Bickmore, 2007). Because CU-RNA induced chromatin compaction when 
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recruited to the lacO arrays, the next step was to investigate the presence of the 
typical heterochromatic marks, H3K9me3 and H3K27me3. To do so, AO3 cells 
were transfected with the MS2-GFP-LacI fusion protein and the MS2 stem loop-
tagged CU-RNA. Cells transfected with the MS2 loops alone and the 
SSR3-3’-UTR, which does not induce chromatin compaction, were included as 
controls. The RNA enrichment at the array was detected by RNA-FISH directed 
against the MS2 stem loops. H3K9me3 and H3K27me3 were visualized by 
immunofluorescent stainings. H3K9me3 was not found at the arrays (Figure 19).  
 
Figure 19: CU-RNA did not promote H3K9me3 when immobilized at the lacO array. AO3 
cells containing a stable insertion of the bacterial lacO repeat sequence were transfected with the 
MS2-GFP-LacI fusion protein and the MS2 stem loop-tagged CU-RNA. The MS2 loops were 
detected by RNA-FISH and H3K9me3 by immunostaining. Nuclei were counterstained with DAPI. 
A representative CLSM image is shown. Insets show enlargements of the lacO arrays. Grey: 
H3K9me3, red: RNA-FISH, green: MS2-LacI-GFP, blue: DAPI, scale bar: 10 µm. 
 
However, as depicted in Figure 20A, CU-RNA led to an enrichment of H3K27me3 
at the array. To quantify this finding, the fold enrichment of H3K27me3 at the 
arrays was determined. This was achieved by comparing the fluorescent signal 
intensity of the H3K27me3 immunofluorescence at the array to the surrounding 
background levels in the nucleus. Additionally, the RepA RNA, a 420 nucleotides 
long transcript that originates from the first exon of the XIST RNA, was included 
into the analysis as a positive control. It is proposed to be important for 
H3K27me3 deposition in X inactivation (Zhao et al, 2008). Interestingly, the 
H3K27me3-promoting activity was not observed to the same extend for all RNAs 
tested. As depicted in Figure 20B RepA RNA induced H3K27me3 as expected, 
albeit not as efficiently as CU-RNA. The 3’-UTR of the SSR3 gene also showed 
H3K27me3 enrichment but the enrichment was lower in comparison to CU-RNA.  
 
Results 73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: CU-RNA promoted H3K27me3 when immobilized at the lacO array. AO3 cells 
containing a stable insertion of the bacterial lacO repeat sequence were transfected with the 
MS2-GFP-LacI fusion protein and the RNA of interest tagged with the MS2 stem loop sequences. 
The MS2 loops were detected by RNA-FISH and H3K27me3 by immunostaining. Nuclei were 
counterstained with DAPI. (A) CLSM images of cells transfected with no RNA, the MS2 stem 
loops only or CU-RNA tagged with the MS2 stem loops. Each RNA was transfected twice and one 
sample of each was treated with RNase A (lower panel). Insets show enlargements of the lacO 
arrays. Grey: H3K27me3, red: RNA-FISH, green: MS2-LacI-GFP, blue: DAPI, scale bar: 10 µm. 
(B) Quantitative analysis of the enrichment of H3K27me3 at the array as compared to the 
background, based on the fluorescent intensity of the H3K27me3 signal. n>30, *p<0.05 (Wilcoxon 
test). (C) Percentage of cells that show a two-fold enrichment of H3K27me3.  
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The MS2 stem loops alone were not able to induce any H3K27me3 enrichment in 
comparison to the basal level of H3K27me3 at the arrays. These differences 
became even more obvious when comparing the percentage of cells that had a 
two-fold enrichment in H3K27me3 (Figure 20C). Thus, of the RNAs tested, 
CU-RNA recruitment to the lacO array promoted the highest enrichment of 
H3K27me3, but also RepA could efficiently induce H3K27me3. Therefore, it is 
concluded that the H3K27me3-promoting activity represents a characteristic 
feature of CU-RNA that is not shared by another 3’-UTR, as for example 
SSR3-3’-UTR. It points towards a difference in the RNAs tested that potentially 
could explain the differences observed with respect to chromatin compaction. 
 
3.2 RNAs immobilized at the lacO array recruit EZH2 with low 
specificity 
H3K27me3 is set by EZH2, which is part of the PRC2 complex. Having observed 
H3K27me3-induction at the arrays after recruitment of CU-RNA, the next step 
was to investigate the presence of EZH2. To do so, the same experimental setup 
and controls as described above were used with an immunostaining directed 
against EZH2. As illustrated in Figure 21A, CU-RNA induced the recruitment of 
EZH2 to the lacO array when immobilized there. Figure 21A and Figure 21B 
show that not only CU-RNA but all other RNAs, including the MS2 stem loops 
alone, recruited EZH2 to the arrays. All RNAs that were analyzed here led to a 
significant enrichment of EZH2 at the arrays in comparison to the basal level of 
EZH2 found at the arrays when no RNA was tethered there. Setting a threshold of 
1.4 and calculating the percentage of cells that show an enrichment of EZH2 at 
the arrays above this threshold further supported this observation (Figure 21C). 
From the set of transcripts investigated here, it is thus concluded that the 
interaction of EZH2 with the RNAs tested seemed to be rather unspecific. The 
mere recruitment of EZH2 to the array could consequently not explain why 
CU-RNA also induced H3K27me3 while other RNAs did not. Instead there must 
be additional factors that determined when H3K27me3 was set. 
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Figure 21: CU-RNA recruited EZH2 when immobilized at the lacO array. AO3 cells containing 
a stable insertion of the bacterial lacO repeat sequence were transfected with the MS2-GFP-LacI 
fusion protein and the RNA of interest tagged with the MS2 stem loop sequences. The MS2 loops 
were detected by RNA-FISH and EZH2 by immunostaining. Nuclei were counterstained with DAPI. 
(A) CLSM images of cells transfected with no RNA, the MS2 stem loops only or CU-RNA tagged 
with the MS2 stem loops. Each RNA was transfected twice and one sample of each was treated 
with RNase A (lower panel). Insets show enlargements of the lacO arrays. Grey: EZH2, red: RNA-
FISH, green: MS2-LacI-GFP, blue: DAPI, scale bar: 10 µm. (B) Quantitative analysis of the 
enrichment of EZH2 at the array as compared to the background, based on the fluorescent 
intensity of the EZH2 signal. n>30, *p<0.05 (Wilcoxon test). (C) Percentage of cells that show an 
enrichment of EZH2 above a threshold of 1.4.  
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3.3 CU-RNA contains a 250 nucleotide long functional element, T0, 
that is needed for H3K27me3 deposition 
Of all RNAs tested the 3097 nucleotides long CU-RNA was the transcript that 
most significantly led to an enrichment of the H3K27me3 mark at the arrays. The 
next goal was to narrow down its H3K27me3-promoting activity to a shorter 
functional sequence. The full length CU-RNA was thus systematically fragmented 
into smaller transcripts that were cloned together with the MS2 stem loop tag. 
Their EZH2-recruiting and H3K27me3-inducing capacities were then tested with 
the MS2/LacI-mediated recruitment system as described above. Each sequence 
element that still carried the EZH2-recruiting and H3K27me3-promoting capacity 
was in the next step cut down to even smaller fragments. Figure 22 depicts the 
fragments of CU-RNA that were tested for their activity in this deletion study.  
 
Figure 22: Fragments of CU-RNA that were used in the deletion study. Each fragment was 
cloned together with the MS2 stem loops sequence and tested for EZH2 recruitment and 
H3K27me3 induction in the MS2/LacI-mediated recruitment system.  
 
Figure 23 depicts the results of the recruitment assays using H3K27me3 
enrichment as the readout. A 250 nucleotides long transcript was identified that 
induced H3K27me3 as efficiently as the full length CU-RNA. In the following this 
sequence element will be referred to as “CU-RNA-T0”. All other fragments 
derived from CU-RNA were less efficient than the full length CU-RNA itself. 
Tethering of smaller fragments derived from CU-RNA-T0 did not lead to 
H3K27me3 enrichment at the array, suggesting that CU-RNA-T0 is the minimal 
element that is necessary for CU-RNA to induce H3K27me3.  
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Figure 23: The CU-RNA-T0 fragment recruits H3K27me3 to the lacO array as efficiently as 
full length CU-RNA. AO3 cells containing a stable insertion of the bacterial lacO repeat 
sequence were transfected with the MS2-GFP-LacI fusion protein and the RNA of interest tagged 
with the MS2 stem loop sequences. The MS2 loops were detected by RNA-FISH and H3K27me3 
by immunostaining. (A) Quantitative analysis of the enrichment of H3K27me3 at the array as 
compared to the background, based on the fluorescent intensity of the H3K27me3 signal. The 
propensity of each fragment to recruit H3K27me3 was compared to that of the full length CU-RNA. 
n>30, *p<0.05 (Wilcoxon test). (B) Percentage of cells that show a two-fold enrichment of 
H3K27me3.  
 
The experiment was repeated testing for EZH2 enrichment at the array 
depending on the CU-RNA fragment that is tethered. It can be seen that all RNAs 
had the ability to recruit EZH2 to the array (Figure 24). Although some had a 
lower efficiency than the full length CU-RNA or even than the MS2 stem loops 
alone they still led to an enrichment of EZH2 that is twice as high as the basal 
level of EZH2 at the array without tethering any RNA.  
Figure 24: A deletion study of CU-RNA revealed that all fragments derived from CU-RNA 
recruit EZH2 to the lacO array. AO3 cells containing a stable insertion of the bacterial lacO 
repeat sequence were transfected with the MS2-GFP-LacI fusion protein and the RNA of 
interest tagged with the MS2 stem loop sequences. The MS2 loops were detected by RNA-
FISH and EZH2 by immunostaining. (A) Quantitative analysis of the enrichment of EZH2 at the 
array as compared to the background, based on the fluorescent intensity of the EZH2 signal. 
The propensity of each fragment to recruit EZH2 was compared to that of the full length 
CU-RNA. n>30, *p<0.05 (Wilcoxon test). (B) Percentage of cells that show an enrichment of 
EZH2 above a threshold of 1.4. 
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3.4 CU-RNA-ΔT0, a transcript variant lacking the full length T0 
element, cannot induce H3K27me3 deposition 
In the next step, CU-RNA-T0 was investigated with respect to its position within 
the CDV3a transcript and the alternative splicing form CDV3b. It is noted that T0 
is not fully represented in the splice form CDV3b, because the sequence overlaps 
with the alternative splice site of exon 5b (Figure 25). To investigate the role of 
CU-RNA-T0 as part of the CDV3a transcript in relation to the CDV3b transcript, a 
second RNA fragment originating from the CDV3b was designed. In this fragment 
the first 80 nucleotides of the 250 bases long CU-RNA-T0 were replace by the 
corresponding sequence from CDV3b. This fragment was termed CU-RNA-ΔT0, 
as depicted in Figure 25.  
 
 
Figure 25: Schematic illustration of the position of CU-RNA-T0 and CU-RNA-ΔT0 with 
respect to CDV3a and CDV3b. Genomic CDV3 (top panel) and the two transcript variants in 
their unspliced and spliced forms (bottom panels) indicating the positions of CU-RNA-T0 (T0), 
CU-RNA-T2 (T2) and CU-RNA-ΔT0 (ΔT0) are depicted (not drawn to scale). CU-RNA-ΔT0 shares 
the 3’ part with CU-RNA-T0, the part of the sequence that is present in both the CDV3a and 
CDV3b transcripts. The first 80 nucleotides of the CU-RNA-T0 are not present in the CDV3b 
transcript. They are replaced with the corresponding sequence from the CDV3b transcript to form 
the CU-RNA-ΔT0 fragment.  
 
In the following, CU-RNA-ΔT0 was investigated with respect to its H3K27me3-
promoting activity and its EZH2-recruiting ability. To this end, CU-RNA-ΔT0 was 
recruited to and tethered at the stably integrated lacO arrays in AO3 cells. The 
enrichment of H3K27me3 and EZH2 was investigated as described above 
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(sections 3.1 and 3.2 of the results). Figure 26A and Figure 26B suggest that the 
efficiency of CU-RNA-ΔT0 to promote H3K27me3 at the array was significantly 
lower compared to CU-RNA-T0. From Figure 26C and Figure 26D it can be 
concluded that CU-RNA-ΔT0 recruited EZH2 to the arrays at least as efficiently 
as CU-RNA-T0. Therefore, the H3K27me3-promoting capacity of CU-RNA-T0 is 
indeed highly specific and can be abolished by exchanging the first 80 
nucleotides as shown by recruiting CU-RNA-ΔT0.  
 
Figure 26: CU-RNA-ΔT0 recruits EZH2 but fails to induce H3K27me3. AO3 cells containing a 
stable insertion of the bacterial lacO repeat sequence were transfected with the MS2-GFP-LacI 
fusion protein and the RNA of interest tagged with the MS2 stem loop sequences. The MS2 loops 
were detected by RNA-FISH and H3K27me3 (A and B) and EZH2 (C and D) by immunostaining. 
(A) Quantitative analysis of the enrichment of H3K27me3 at the array as compared to the 
background, based on the fluorescent intensity of the H3K27me3 signal. n>30, *p<0.05 (Wilcoxon 
test) (B) Percentage of cells that show a two-fold enrichment of H3K27me3. (C) Same as in (A) 
with an immunostaining against EZH2. (D) Same as in (B) with an immunostaining against EZH2. 
A threshold of 1.4 was used. 
 
3.5 RNA transcripts have a non-specific inhibitory effect on EZH2 
activity in vitro  
It was observed that EZH2 was catalytically active and methylated H3K27 in the 
MS2/LacI recruitment assay, only when in complex with certain RNAs such as 
CU-RNA-T0. Therefore, an in vitro methylation assay was used to measure the 
activity of EZH2 in the presence of different RNA transcripts. The assay 
comprises of the purified enzyme in complex with its physiological interaction 
partners EED, SUZ12, RBAP48 and AEBP2 (Margueron & Reinberg, 2011). 
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Immobilized histone H3 peptide substrate was incubated with the 5-component 
enzyme complex and S-adenosyl methionine (SAM) as a methyl donor. The 
amount of H3K27me3 as detected by a horseradish peroxidase (HRP)-coupled 
antibody was used as an indication for EZH2 activity (Figure 27A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: CU-RNA-T0 has an inhibitory effect on EZH2 activity in an in vitro methylation 
assay. (A) Principle of the EZH2 in vitro methylation assay. EZH2 in complex with EED, SUZ12, 
RBAP48 and AEBP2, the methyl donor S-adenosylmethionine (SAM) and the RNAs of interest 
were added to immobilized H3 peptide substrate. The amount of H3K27me3 was detected with a 
specific antibody directed against H3K27me3 and a secondary antibody coupled to HRP. The 
amount of emitted chemiluminescence was used as a measure for the amount of H3K27me3 in 
the sample. (B) 10 nM of the EZH2 enzyme complex were incubated with the indicated amounts 
of CU-RNA-T0, CU-RNA-ΔT0, CU-RNA-T2 and RepA RNA. The activity of EZH2 is plotted as the 
percentage of the total EZH2 activity achieved when no RNA is added to the reaction. (C) The 
indicated amounts of nuclear lysate extracted from AO3 cells were incubated with 10 nM of 
CU-RNA-T0 in the EZH2 in vitro methylation assay. The activity of EZH2 is plotted as the 
percentage of the total EZH2 activity achieved when no lysate and no RNA were added to the 
reaction. SAH: S-adenosyl-homocysteine. 
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CU-RNA-T0 was added to the reaction in approximately equimolar concentration 
to the EHZ2 complex. Additionally, a ten times lower concentration of 
CU-RNA-T0 was tested. As negative controls, CU-RNA-ΔT0 and CU-RNA-T2 
fragments were included as transcripts of similar length that did not harbor the 
H3K27me3-promoting activity. The earlier mentioned RepA transcript was 
chosen as the positive control. This RNA has been described to inhibit EZH2 
catalytic activity in an in vitro methylation assay using EZH2 in a 4-component 
complex with EED, SUZ12 and RBAP48 (Cifuentes-Rojas et al, 2014). Figure 
27B shows that when EZH2 and CU-RNA-T0 were present at approximately 
equimolar concentrations (10 nM), EZH2 activity was abolished to less than 10 %. 
This was the case with all three RNAs tested. Adding 1 nM of any RNA to the 
reaction, thus only a tenth of the amount of EZH2, left EZH2 almost fully active. 
Unlike the initial hypothesis that CU-RNA-T0 could have a positive effect on the 
activity of EZH2, it is concluded that in the in vitro assay CU-RNA-T0 negatively 
influences EZH2 H3K27 methylation ability. This setting also confirmed previous 
results that RepA inhibited EZH2 activity.  
Based on these data, it was proposed that there must be other factors to explain 
the differential H3K27me3-promoting capacity of CU-RNA-T0 that was observed 
in the experiments using the MS2/LacI model system. Therefore, it was then 
tested whether a nuclear lysate extracted from AO3 cells could rescue the 
inhibitory effect of CU-RNA-T0 on EZH2 in the in vitro methylation assay. 
Hypothetically, the factors, that together with CU-RNA-T0 enhance the 
H3K27me3-activity of EZH2, should be present in this lysate and should be able 
to also perform this function in vitro. The lysate was added to the methylation 
reaction in increasing concentrations as depicted in Figure 27C. For comparison, 
the lysate was loaded twice, once in combination with CU-RNA-T0 and once 
without (Figure 27C). The nuclear lysate alone had only limited effect on the 
activity of EZH2 up to a protein concentration of 9.2 ng/ml. However, at a 
concentration of 46 ng/ml the lysate alone almost fully inhibited EZH2 catalytic 
activity. Adding 10 nM CU-RNA-T0 to the reaction in combination with the lower 
lysate concentrations inhibited EZH2 activity to the same extend as observed 
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without the nuclear extract (Figure 27B). At the highest lysate concentration, that 
itself already had an inhibitory effect, CU-RNA-T0 reduced EZH2 activity even 
further to less than 1%. The AO3 nuclear lysate thus did not rescue the EZH2 
inhibitory effect of CU-RNA-T0. The factor that can rescue EZH2 activity in the 
living cells at the lacO arrays was thus either not present in the lysate or only 
inactive in the chromatin-independent context. Thus, this factor remains to be 
determined.  
 
3.6 The inhibitory effect of RNAs on EZH2 activity might be rescued 
by JARID2 
It is proposed that the PCR2 accessory factor JARID2 relieves EZH2 repression 
by RNA, boosting its methylation rate in an RNA and dose dependent manner 
(Cifuentes-Rojas et al, 2014). Here, it is therefore tested whether JARID2 could 
be the factor that differentiates CU-RNA-T0 from other RNAs that bind EZH2 but 
do not promote H3K27me3. To this end, the following experiments were 
conducted: First, RNA affinity purification using immobilized biotinylated 
CU-RNA-T0 in combination with western blotting was used to test for the specific 
interaction of CU-RNA-T0 with JARID2. Second, the MS2/LacI-mediated 
recruitment system was used to investigate whether JARID2 is also recruited to 
the arrays by CU-RNA-T0 in the living cell.  
 
JARID2 interacts with CU-RNA-T0 
To investigate the differential interaction of CU-RNA-T0 and CU-RNA-ΔT0 with 
JARID2, RNA affinity purification was performed: The biotinylated RNAs were 
immobilized on streptavidin coated magnetic beads. These were incubated with 
nuclear protein lysate extracted from HeLa S3 cells. Specifically bound proteins 
were eluted with RNase A and processed for western blotting (Figure 28A). As 
controls, the proteins bound to the beads alone, a control RNA of similar size 
(aluRNAR), CU-RNA-T2 and RepA were included. Moreover, as a proof of 
principle, EZH2 binding was monitored by western blotting, as it was previously 
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shown to bind all RNAs tested with similar affinity. As depicted in Figure 28B, 
both CU-RNA-T0, CU-RNA-ΔT0, CU-RNA-T2 and RepA pulled down EZH2 while 
the beads alone and the control RNA showed no EZH2 enrichment. Despite the 
low contrast, the western blot against JARID2 showed that CU-RNA-T0, 
CU-RNA-ΔT0, CU-RNA-T2 and RepA bound JARID2 (Figure 28C) while the 
beads alone and the control RNA did not. The blot also displayed that 
CU-RNA-T0 and RepA bound slightly more JARID2 than CU-RNA-ΔT0 and 
CU-RNA-T2. This suggests that the affinity of CU-RNA-T0 and RepA for JARID2 
is higher than that of the other RNAs tested. Therefore, JARID2 could be the 
factor distinguishing CU-RNA-T0 from CU-RNA-ΔT0 and CU-RNA-T2.  
 
 
 
Figure 28: CU-RNA-T0, CU-RNA-ΔT0, CU-RNA-T2 and RepA pulled down EZH2 and JARID2 
in an in vitro binding assay. (A) Schematic representation of the RNA affinity purification 
workflow. The RNAs of interest were in vitro transcribed with biotinylated UTP and immobilized on 
streptavidin-coated magnetic beads. Nuclear protein lysate was incubated with the RNAs, 
unbound proteins were washed off and proteins that specifically bound to the RNAs were eluted 
with RNase A. The identity of these proteins could be analyzed by western blot or mass 
spectrometry. (B) Western blot of EZH2 showing its enrichment through CU-RNA-T0, 
CU-RNA-ΔT0, CU-RNA-T2 and RepA using RNA affinity purification. (C) Same as (B) with an 
antibody against JARID2 (Abcam antibody). The blot was cut to show only the RNAs of interest 
here. All fragments shown were treated equally and not processed differently. 
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JARID2 recruitment to the lacO arrays by CU-RNA fragments 
To investigate whether JARID2 is also recruited to the arrays by CU-RNA-T0 in 
the living cell, the MS2/LacI-mediated recruitment system was used. AO3 cells 
were transfected with the MS2-GFP-LacI fusion protein and the MS2 stem loop-
tagged CU-RNA-T0 and CU-RNA-ΔT0. CU-RNA-T2 and the MS2 stem loops 
were used as negative controls, while RepA served as a positive control. RNA at 
the lacO arrays was detected by RNA-FISH. Two different antibodies were used 
to investigate differential enrichment of JARID2 at the arrays. The enrichment of 
JARID2 was calculated as the ratio of the intensity of the fluorescent signal at the 
array against the background levels in the nucleus. Figure 29A and Figure 29C 
depict the enrichment analysis of this experiment. From the analysis using the 
Abcam antibody (Figure 29A) it could be concluded that all RNAs tested including 
the MS2 stem loops slightly enriched JARID2 at the arrays. The variations in 
enrichment were subtle. Furthermore, tethering the positive control, RepA RNA, 
which was shown to interact with JARID2 (Cifuentes-Rojas et al, 2014), did not 
increase JARID2 enrichment as compared to its basal level at the array. Another 
antibody was tested in the same experimental setup and lead to inconsistent 
results with respect to the RNA dependent enrichment of JARID2 at the arrays 
(Figure 29C). Here, the MS2 stem loops, CU-RNA-T0, CU-RNA-T2 and RepA 
showed a slight enrichment of JARID2. However, tethering full-length CU-RNA 
did not change JARID2 levels.  
Having observed the inconsistency of the data retrieved from the recruitment 
assay above, the quality of both antibodies was assessed in a western blot 
analysis with nuclear protein extract of HeLa cells. The Abcam antibody (Figure 
29B) showed a single band that could potentially represent the 138 kDa large 
JARID2, although the band ran slightly higher than expected. The Novusbio 
antibody (Figure 29D) however, gave rise to a multitude of bands of various sizes. 
Although the expected band at approximately 138 kDa was also faintly visible, 
this demonstrated low specificity of the antibody and made it useless for 
immunofluorescent analyses. The Novusbio antibody was therefore not used in 
subsequent experiments. The Abcam antibody was apparently showing enough 
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specificity, but there is no guaranty that it is suited for immunofluorescence. From 
this experimental setup JARID2 could not be proven to be the factor that 
differentiated CU-RNA-T0 from other RNAs that bind EZH2.  
  
Figure 29: CU-RNA-T0 dependent JARID2 enrichment at the lacO arrays. (A) and (C) AO3 
cells containing a stable insertion of the bacterial lacO repeat sequence were transfected with the 
MS2-GFP-LacI fusion protein and the RNA of interest tagged with the MS2 stem loop sequences. 
The MS2 loops were detected by RNA-FISH and JARID2 by immunostaining using an Abcam 
antibody (A) or a Novusbio antibody (C). A quantitative analysis of the enrichment of JARID2 at 
the array as compared to the background, based on fluorescent intensity of the JARID2 signal is 
shown. (B) and (D) Western blot analysis of the two antibodies used to detect enrichment of 
JARID2 at the lacO arrays using nuclear protein lysate of HeLa cells.  
 
4 Splicing of the CDV3 transcript variants is dependent on 
H3K27me3 
It has been shown that the H3K27me3-promoting capacity of CU-RNA-T0 is 
highly specific to its 250 nucleotide sequence. Exchanging the first 80 nucleotides 
of the 5’ sequence, giving rise to CU-RNA-ΔT0, led to almost complete depletion 
of the H3K27me3-promoting activity in the MS2/LacI-mediated recruitment 
system. Given that these two variants of CU-RNA originate from the endogenous, 
different splice variants of the CDV3 transcript, I hypothesized that the 
H3K27me3-promoting ability of CU-RNA-T0 is intrinsically linked to the regulation 
of alternative splicing resulting in CDV3a or CDV3b. In support of this possibility, 
it has been postulated by other groups that indeed the local level of H3K27me3 
can influence alternative splicing (Gonzalez et al, 2015; Luco et al, 2010). To test 
whether H3K27me3 levels may influence CDV3 splicing, EZH2 was inhibited by 
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the small molecule inhibitor GSK343 and the levels of the CDV3 transcripts were 
measured by qRT-PCR.  
 
4.1 H3K27me3 levels at the CDV3 locus determine the ratio of the 
CDV3a and CDV3b splice variants 
To be able to measure the expression levels of CDV3a and CDV3b, with regards 
to the H3K27me3 levels, two conditions had to be satisfied: First, it was required 
to show that the inhibition of EZH2 by the small molecule inhibitor GSK343 
effectively inhibits EZH2 and leads to reduction in H3K27me3 globally and at the 
CDV3 locus. Second, CDV3a and CDV3b specific primer pairs had to be 
designed, which are able to differentially detect the expression levels of the two 
splice variants.  
 
GSK343 globally reduces H3K27me3 levels  
From what is known to date, EZH2 is the only methyltransferase that 
trimethylates H3K27. Therefore, a knockdown or inhibition of EZH2 should be 
sufficient to globally alter the levels of H3K27me3. The specific small molecule 
inhibitor GSK343 has been shown to be a highly potent, selective and cell-active 
inhibitor of EZH2 (Verma et al, 2012). To test the inhibitor, HeLa cells were 
treated with two concentrations of GSK343, 1 µM and 5 µM, or the corresponding 
volume of the solvent, DMSO, as a control, for three days. The global levels of 
H3K27me3 were measured by FACS analysis and western blotting. Figure 30A 
depicts the levels of H3K27me3 in DMSO-treated HeLa cells in comparison to 
HeLa cells that have been treated with the EZH2 inhibitor for three days as 
determined by FACS analysis. It was observed that with both concentrations, the 
level of H3K27me3 was reduced to the intensity of the background signal, which 
was determined by measuring the signal intensity of cells that were not incubated 
with the H3K27me3 primary antibody. The same result was obtained by 
measuring the amount of H3K27me3 in DMSO- and GSK343-treated (5 µM) 
HeLa cells by western blotting of histone extractions (Figure 30B). A reduction to 
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only 13% of H3K27me3 can be observed suggesting that GSK343 is a potent 
inhibitor of the enzymatic activity of EZH2.  
 
Figure 30: Treatment with the EZH2-small molecule inhibitor GSK343 globally reduced the 
H3K27me3 levels. (A) HeLa cells were treated with 1 µM and 5 µM GSK343 or the equivalent 
volume of DMSO for 72 hours. H3K27me3 was stained with a specific antibody and FACS 
analysis was applied to measure the H3K27me3 levels of the cells. A sample that was not 
incubated with the primary antibody against H3K27me3 served as the background control. The 
histogram shows the intensity of the H3K27me3-staining in each of the samples. (B) HeLa cells 
were treated with 5 µM GSK343 or the corresponding volume of DMSO. The histones were 
extracted and subjected to western blot analysis using specific antibodies against H3K27me3 and 
histone H3. The H3K27me3 levels were quantified and are displayed as the ratio of histone H3 in 
each sample.  
 
GSK343 treatment leads to a genome-wide redistribution of H3K27me3 and 
reduces H3K27me3 at the CDV3 locus 
To examine the influence of EZH2 inhibition by GSK343 on a genome-wide scale, 
H3K27me3 specific chromatin immunoprecipitation and sequencing (ChIP-seq) of 
cells that were treated with 5 µM GSK343 for six days was performed in two 
replicates. The input chromatin, an immunoglobulin G (IgG) control, and a ChIP 
against histone H3 were included as controls. Furthermore, a spike-in control was 
included by adding 10% of chromatin from untreated mouse embryonic stem cells 
to all samples (Bonhoure et al, 2014). The number of total reads yielded in each 
reaction is shown in Appendix 1. The reads were mapped to the human and 
mouse genomes using bowtie (Langmead et al, 2009), allowing for two 
mismatches. Ambiguous reads mapping to both the human and mouse genome 
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were removed from the analysis. Figure 31A depicts the distribution of reads 
mapping to human and mouse. 59% to 77% of all reads could be assigned to the 
human genome, whereas 5% to 22% mapped to the mouse genome. 16% to 
18% of all reads could not be mapped to either of the genomes. In the H3 ChIP, 
IgG control, input, and untreated H3K27me3 samples, the percentage of reads 
mapping to the mouse genome was expected to be approximately 10% 
corresponding to the amount of mouse chromatin that was spiked in. With 5% to 
22% the variability of the amount of reads mapping to the mouse genome in 
those samples was thus higher than expected. Figure 30 shows that GSK343 
treatment reduced the global level of H3K27me3. It was therefore expected that 
in the GSK343-treated samples more reads would align with the mouse genome, 
since in relation less human material should be pulled down in the H3K27me3 
ChIP. This trend could, however, not be observed here. 
First, to compare the two replicates of the ChIP-seq experiment, all H3K27me3 
ChIP data sets were normalized to obtain comparable read occupancy profiles. 
This was done by subtracting the weighted control IP (IgG) and calculating the 
enrichment of the signal over the input sample. Next, a correlation function of the 
two DMSO- and GSK343-treated samples respectively was calculated using 
multi-scale correlation evaluation (MCORE) (Molitor et al, 2015). To do so, the 
normalized read occupancy profiles from each H3K27me3-IP were shifted with 
respected to each other along the genomic coordinates. The Pearson correlation 
coefficient for each shifting distance along the human chromosome 3, the 
chromosome CDV3 is located on, was calculated and plotted in Figure 31B. The 
positive correlation of the co-localization of signal in the two replicates indicates 
co-occurrence at the given shift distance. The amplitude of the correlation 
function is a measure for the abundance of H3K27me3 domains. The correlation 
amplitude was higher for the two DMSO-treated samples (0.028) than for the 
GSK343 replicates (0.008) reflecting a higher signal to noise ratio in the DMSO- 
than in the GSK343-treated cells. It can therefore be concluded that under 
GSK343 treatment, the localization of H3K27me3 over the genome redistributes, 
resulting in less well-defined H3K27me3 domains. 
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Figure 31: Inhibition of the enzymatic activity of EZH2 by GSK343 redistributes H3K27me3 
genome wide and reduces H3K27me3 at the CDV3 locus. HeLa cells were treated with 5 µM 
GSK343 for six days and ChIP-seq was performed against H3K27me3. H3, IgG, and input 
chromatin were included as controls. A spike-in control consisting of 10% chromatin from 
untreated mouse embryonic stem cells was added to each sample. (A) Distribution of reads 
mapped to the human and mouse genomes. Both replicates (1 and 2) of DMSO- and GSK343-
treated samples are shown for the H3K27me3 and H3 ChIPs, IgG control, and input. (B) MCORE 
Pearson correlation functions of the DMSO- and GSK343-treated replicates on the human 
chromosome 3, where CDV3 is located (Molitor et al, 2015). (C) H3K27me3 peaks called with 
Sicer in replicate 1 of the DMSO- and GSK343-treated samples. The numbers of differentially 
identified and overlapping peaks are indicated. (D) Percentage of Sicer peaks overlapping with 
genes, promoters, exons, introns, 5’-UTRs, and 3’-UTRs in replicate 1 of both the DMSO- and 
GSK343-treated cells. The ratio of the percentages in the control and treated cells is indicated. 
(E) Interactive genome viewer (IGV) trace of the read distribution in CU-RNA. The left panel 
depicts replicate 1 of the DMSO-treated sample and the right panel replicate 1 of the GSK343-
treated sample. Raw read distributions of the input, IgG control, and H3K27me3 samples are 
shown in black. The normalized H3K27me3 occupancy is depicted in blue for the DMSO-treated 
cells and in red for the GSK343-treated cells. All traces are scaled equally.  
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To identify regions that are enriched in H3K27me3, peaks were called using Sicer 
(Zang et al, 2009). No peaks could be called for the second replicates of both the 
DMSO- and GSK343-treated samples with the parameters used (window size: 
200 and gap size: 600). This indicates a poor enrichment of the H3K27me3-IP 
over the background signal and low quality of the data. The second replicate was 
therefore not used for further analyses. For the first replicate, a total of 3524 
peaks could be called in the DMSO-treated sample and 1893 in the GSK343-
treated sample. 821 of the peaks overlapped whereas the others were unique to 
either of the samples (Figure 31C). First, the fact that a large proportion of peaks 
did not overlap indicates a redistribution of H3K27me3 over the genome after 
GSK343 treatment. This confirms the findings from the MCORE analysis (Figure 
31B). Second, the fact that less peaks could be called in the GSK343-treated 
sample, shows a reduction in the enrichment of H3K27me3 at certain domains, 
as expected after GSK343 treatment. Subsequently, all peaks were assigned to 
genomic regions of coding genes. It was found that in the DMSO-treated sample 
the majority of peaks (93%) overlapped with genes, while this fraction was only 
57% in the GSK343-treated sample. The most profound differences in overlaps 
between the treated and untreated samples were found in promoters and 5’-
UTRs (3.6 and 3.7 times more in the DMSO sample). Furthermore, also 
significantly more peaks were found in 3’-UTRs in DMSO-treated cells (2.6 times 
more). This analysis implies that many H3K27me3 domains in annotated genes 
were affected by the GSK343 treatment and reinforces the fact that H3K27me3 is 
redistributed by inhibition of EZH2.  
Lastly, the level of H3K27me3 at the CU-RNA locus was examined. From the raw 
read occupancy profiles but even more clearly from the MCORE normalized 
occupancies (Figure 31E, row 4) it could be deduced that there was an 
enrichment of H3K27me3 at the start of the alternative exon of CDV3 (exon 5b) in 
DMSO-treated cells (Figure 31E, left panel, blue trace). This enrichment 
disappeared entirely after GSK343 treatment (Figure 31E, right panel, red trace). 
This indicates a strong reduction of H3K27me3 by GSK343 treatment at the 
CU-RNA locus. This occurs specifically at the site where CDV3 can be 
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alternatively spliced. At the same time, more H3K27me3 was found in the 
upstream intron and the 3’-UTR after GSK343 treatment suggesting that 
H3K27me3 is very specifically altered at the alternatively spliced exon and its 
surrounding. In conclusion, GSK343 is thus a potent inhibitor of EZH2 leading to 
a global reduction and redistribution of H3K27me3 over the genome, reduction of 
H3K27me3 in annotated genes, and a local reduction of H3K27me3 at the 
CU-RNA locus, at the start of the alternative exon of CDV3. 
 
Transcript levels of alternative CU-RNA variants can be quantified by 
real-time PCR 
In order to measure whether the local level of H3K27me3 at the CDV3 locus has 
an effect on the ratio between the two CDV3 transcript variants, the first step was 
to set up an assay to stably detect each of the variants. Quantitative reverse-
transcriptase PCR (qRT-PCR) was ran with primers pairs that specifically 
detected only one of the two splicing forms (Figure 32).  
 
Figure 32: Detection of the the two splicing forms of the CDV3 gene via qRT-PCR 
analysis. Pimers 1 and 2 were used to specifically detect a 196 nucleotide long PCR product 
amplified from the CDV3a transcript. Primers 1 and 3 were used to specifically amplify a 163 
nucleotide PCR product amplified from the CDV3b transcript. Theoretically, the primer pair 1 
and 3 could also amplify an 897 nucleotide product from the CDV3a transcript. However, the 
time given for the polymerase to elongate the products was short enough to not allow for the 
amplification of the longer transcript. 
 
92 Results 
 
 
As depicted in Figure 32 the CDV3a transcript was detected by a forward primer 
in exon 4 and a reverse primer in its 3’-UTR giving rise to a PCR product of 196 
nucleotides. This set of primers could exclusively detect CDV3a and not CDV3b 
because the hybridization site of the reverse primer is spliced out of CDV3b and 
is not present in the mature transcript. For detection of CDV3b the same forward 
primer was used and a reverse primer positioned in exon 5b amplifying a PCR 
product of 163 nucleotides. Theoretically, this primer could also bind the CDV3a 
transcript and amplify a second product of 897 nucleotides. However, the 
elongation time for the polymerase to produce this PCR product was set short 
enough to allow only for the amplification of the shorter transcript.  
To test for the specificity of the primers, synthetic PCR templates corresponding 
to either of the two splice variants were used in combination with each of the 
primer pairs. Figure 33A shows that only primer pair 1 and 2 led to a PCR 
product with CDV3a as a template and conversely only primer pair 1 and 3 
produced a PCR product from CDV3b as the template. Furthermore, the melting 
curves of both PCR products using total HeLa cDNA as the template were 
measured to demonstrate that only one PCR product is amplified. The melting 
curve was obtained by measuring the fluorescence signal of the double-strand 
DNA (dsDNA) dye in dependence of increasing temperatures. This resulted in 
decreasing fluorescence due to dissociation of the dsDNA binding dye when the 
DNA became single stranded. The change in slope of this decrease was plotted 
and depicted in Figure 33B for CDV3a and Figure 33C for CDV3b. Both curves 
showed a single peak indicating that only one PCR product was present. Lastly, 
as a proof of principle that the levels of CDV3a and CDV3b can be distinguished 
by qRT-PCR, HeLa cells were treated with PlaB, an inhibitor of splicing. PlaB 
treatment should leave the transcripts unspliced as precursor mRNA. Due to the 
fact that the primers should not be able to detect unspliced pre-mRNA, a 
difference in expression of both transcript variants should be visible. qRT-PCR for 
β-actin (ACTB) and both transcripts was performed. In the case of ACTB, less 
PCR product was expected because one of its primers binds at an exon-exon 
junction that is not present in the unspliced transcript. Figure 33D shows that 
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indeed the amount of ACTB RNA was reduced to one third. The primer pairs for 
CDV3a and CDV3b theoretically could still produce a PCR product on the pre-
mRNA of CDV3 and CDV3a, however they would be too long to be elongated in 
the chosen PCR program. Thus, no CDV3 PCR product was expected in the 
PlaB-treated samples. The expression levels of CDV3a (Figure 33E), CDV3b 
(Figure 33F) and the ratio of the expression level of the two in respect to each 
other (Figure 33G) are plotted. Both the levels of CDV3a and CDV3b mRNA 
decreased after PlaB treatment in comparison to cells that had been treated with 
the solvent control. As expected, the RNA extract from PlaB-treated HeLa cells 
contained significantly less CDV3a and CDV3b mRNA than that from untreated 
cells. Moreover, the ratio between the two splice variants remained unchanged 
after PlaB treatment demonstrating that both transcript variants were equally 
affected. In summary, a qRT-PCR-based assay with specific primer pairs that can 
distinctly measure the endogenous abundance of each of the two splicing 
variants of CDV3 was established.  
 
Figure 33: Establishment of a qRT-PCR-based assay to specifically detect the CDV3a and 
CDV3b splice variants. (A) Synthetic PCR templates were used to demonstrated that with the 
primer pairs used and the chosen PCR program only primers 1 and 2 can detect CDV3a and 
primers 1 and 3 CDV3b (see Figure 32 for the position of the primers). (B) and (C) Melting curves 
for the CDV3a and the CDV3b PCR product. (D) - (G) HeLa cells were treated with the splicing 
inhibitor PlaB or the solvent control ethanol (EtOH). (D) Expression levels of ACTB are depicted, 
normalized to the solvent-treated cells. (E) and (F) Plots showing the relative levels of CDV3a and 
CDV3b RNA normalized to ACTB mRNA and the solvent-treated cells. (G) The ratio of the two 
transcript variants is plotted. n=3, *p<0.05 (Student’s t-test).  
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EZH2 inhibition changes the ratio between the CDV3 transcript variants 
The above-established qRT-PCR assay was applied to measure whether the 
local level of H3K27me3 at the CDV3 locus had an effect on the ratio between 
the CDV3a and CDV3b transcript variants. To this end, HeLa cells were treated 
with 5 µM GSK343 to reduce the levels of H3K27me3 (Figure 30 and Figure 31). 
CDV3a and CDV3b levels and the ratio of the two splice variants were 
determined by qRT-PCR after three and six days of treatment. As plotted in 
Figure 34A and Figure 34C, the levels of ACTB remained unchanged by the 
inhibitor treatment so that it could be used for normalization of the CDV3a and 
CDV3b expression levels. Figure 34B shows that CDV3a expression increased 
after three days of EZH2 inhibition, while CDV3b expression remained 
unchanged (Figure 34C). The ratio of CDV3b over CDV3a expression decreased 
after GSK343 treatment as depicted in Figure 34D.  
 
 
Figure 34: EZH2 inhibition changed the CDV3a and CDV3b ratio. HeLa cells were treated 
with 5 µM of the EZH2 inhibitor GSK343 for three and six days. (A) qRT-PCR of ACTB after 
inhibitor treatment for three days. (B) – (D) qRT-PCR of the two splice variants CDV3a and 
CDV3b was performed after three days. The relative mRNA levels of CDV3a (B) and CDV3b (C) 
normalized to ACTB mRNA and the ratio of CDV3b over CDV3a (D) are shown. (E) – (H) Same 
as (A) – (D) after six days of inhibitor treatment. n=5, *p<0.05 (Student’s t-test). 
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The same trend was observed after 6 days of EZH2 inhibition (in Figure 34E - 
Figure 34H). Here, the increase in expression level of CDV3a was even more 
pronounced, whereas CDV3b expression remained unaffected. The ratio of the 
two splice variants was thus significantly influenced by the inhibition of EZH2, 
supporting the hypothesis that the local H3K27me3 level indeed affects the 
expression ratio of the two CDV3 splicing forms.  
 
4.2 CU-RNA-T0 is enriched in splicing and H3K27me3 promoting 
factors 
Next, the aim was to differentially identify proteins that bind CU-RNA-T0 and 
CU-RNA-ΔT0 to gain insight into the mechanism that connects alternative 
splicing of the CDV3 transcripts to the H3K27me3-promoting activity of 
CU-RNA-T0. To this end, RNA affinity purification of both RNAs was carried out 
as described in Figure 28 and the protein interaction partners were compared. An 
RNA of similar size (aluRNAR), CU-RNA-T2 and RepA were included as controls. 
As depicted in Figure 35A, CU-RNA-T0, CU-RNA-ΔT0, CU-RNA-T2 and RepA 
pulled down more protein than the control RNA and the beads. Moreover, the 
patterns of bands that were enriched with CU-RNA-T0, CU-RNA-ΔT0, 
CU-RNA-T2 and RepA differed for all four RNAs. This suggests that the RNAs 
pulled down diverse proteins with various affinities and thus had distinct protein 
interaction partners. The entire lanes were subjected to mass spectrometry. For 
analysis of the mass spectrometry data, stringent parameters with regards to 
protein and peptide probabilities were applied. Only proteins, for which at least 
two peptides were identified with high confidence, were taken into consideration. 
Many proteins that were identified were known RBPs, demonstrating the 
specificity of the assay. While EZH2 and JARID2 were earlier found to bind 
CU-RNA-T0 as detected by western blotting (Figure 28), they could not be 
identified in the mass spectrometry data using these criteria. It remains unclear 
how the discrepancies between mass spectrometry and western blotting arise. 
However, explanations could be found in the high binding specificity of the 
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antibodies used for western blotting and the high abundance of proteins in the 
pull-down samples. 
 
Figure 35: RNA affinity purification of CU-RNA-T0 and CU-RNA-ΔT0 enriched proteins that 
are involved in RNA metabolism, splicing, processing, stabilization and posttranscriptional 
regulation of gene expression. RNA affinity purification and mass spectrometry was carried out 
as described in Figure 28. (A) Proteins that were retrieved in the indicated samples by RNA 
affinity purification were separated by gradient SDS-PAGE. The entire lanes were subjected to 
mass spectrometry. (B) Venn diagram depicting the overlap and unique proteins that were pulled 
down by CU-RNA-T0 and CU-RNA-ΔT0. (C) GO term analysis of the CU-RNA-T0/ΔT0 interacting 
proteins. The five GO terms identified with the lowest p-values (7x10-66 – 7x10-35) are depicted. 
The sizes of the circles are assiged according to the p-values. Most of the proteins interacting 
with CU-RNA-T0 could be assigned to play a role in RNA metabolism, splicing, processing, 
stabilization and postranscriptional regulation of gene expression.  
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Figure 35B gives an overview over all proteins that were pulled down by 
CU-RNA-T0 as compared to CU-RNA-ΔT0. The majority of proteins was pulled 
down by both transcripts and only a minority was uniquely pulled down by either 
of the two transcripts. A gene ontology (GO) term analysis of the common 
CU-RNA-T0/ΔT0 proteome was performed based on biological processes. Figure 
35C shows the five most relevant GO terms. This analysis revealed that 
CU-RNA-T0 and CU-RNA-ΔT0 were primarily bound by proteins that play a role 
in RNA metabolism, splicing, processing, and stabilization and in 
posttranscriptional regulation of gene expression (for a complete list of all 
proteins identified by mass spectrometry please refer to Appendix 2). Also 
proteins, which bound uniquely to CU-RNA-T0, could be assigned to functions in 
RNA processing, metabolism or splicing. The proteins that were uniquely found to 
bind CU-RNA-ΔT0 enriched for the GO terms RNA metabolism and gene 
expression but also other very diverse other biological processes. Most of these 
proteins were, however, only identified with very low peptide count so that it 
remains to be determined whether they have functions that are necessary to 
distinguish CU-RNA-ΔT0 from CU-RNA-T0 in terms of the H3K27me3-promoting 
capacity.  
To gain insight into the mechanism that might be involved in linking alternative 
splicing at the CDV3 locus to the H3K27me3 inducing-capacity of CU-RNA-T0, all 
proteins that were enriched at CU-RNA-T0 in comparison to CU-RNA-ΔT0 with a 
factor of at least 1.3 were investigated more closely (Table 15). In combination 
with a literature research, the following proteins from this list were considered to 
be of particular interest fort this thesis: PTBP1, U2AF2 and HNRNPK. The 
splicing regulator PTBP1 (polypyrimidine tract binding protein 1) has been 
described to play a role in linking alternative splicing to chromatin via a protein-
protein interaction with MRG15 (mortality factor 4 like 1), a reader of H3K36me3 
(Gonzalez et al, 2015; Luco et al, 2010). U2AF2 (U2 small nuclear RNA auxiliary 
factor 2), also a regulator of splicing, has not directly been linked to chromatin 
modifications at the locus of the transcript that is to be spliced. However, it is 
interesting in this context because it plays a role in defining the functional 3’ 
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splice site of introns and is an opponent of HNRNPC (heterogeneous nuclear 
ribonucleoprotein C) by competing for the same binding sites on the pre-mRNA 
(Zarnack et al, 2013). HNRNPC interestingly was found to bind CU-RNA-ΔT0 
(see Appendix 2). Thus, the interplay between U2AF2 and HNRNPC might play a 
role in defining whether the pre-mRNA is spliced in favor of CDV3a or CDV3b. 
The nuclear matrix protein HNRNPK (heterogeneous nuclear ribonucleoprotein 
K) was found to bind the XIST RNA and has been described to play a role in the 
specific XIST-mediated recruitment of repressive chromatin marks such as 
H3K27me3 (Chu et al, 2015; Minajigi et al, 2015). It is therefore interesting in this 
context because it might play a role in H3K27me3 transmission mediated by 
CU-RNA-T0 at the CDV3 locus. Furthermore, HNRNPK has been described to 
interact with PTBP1 (King et al, 2014), potentially linking the splicing reaction 
directed by PTBP1 to H3K27me3-induction by CU-RNA-T0. Incidentally, it is also 
interesting that DDX17 (DEAD (Asp-Glu-Ala-Asp) box helicase 17) only binds to 
CU-RNA-T0. While it has been described to act as a transcriptional co-activator 
(Rossow & Janknecht, 2003) it can also, in some contexts, act as a 
transcriptional repressor by interaction with HDAC1 (histone deacetylase 1) 
(Wilson et al, 2004). By interacting with CU-RNA-T0 it could therefore link 
deacetylation of H3K27 by HDAC1 to its methylation by EZH2 (Reynolds et al, 
2011).  
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Table 15: RNA affinity purification of CU-RNA-T0 enriched proteins that are involved in 
splicing regulation and H3K27me3 induction in comparison to CU-RNA-ΔT0. RNA affinity 
purification was carried out as described in Figure 28. The table shows the peptide counts and all 
proteins that were at least 1.3 fold enriched at CU-RNA-T0 in comparison to CU-RNA-ΔT0. For a 
complete list of proteins that were identified by RNA affinity purification and mass spectrometry of 
CU-RNA-T0 and CU RNA-ΔT0 and the controls please refer to Appendix 2. *Proteins of particular 
interest for which the CU-RNA-T0 binding capacity was confirmed by western blotting (Figure 36). 
protein T0 ΔT0 T0/ΔT0 
TIA1 7 0 > 7 
DDX17 6 0 > 6 
U2AF2* 28 6 4,7 
PSPC1 6 2 3,0 
AQR 3 1 3,0 
DRG1 6 2 3,0 
SND1 58 21 2,8 
SF01 5 2 2,5 
FUBP1 85 42 2,0 
GRSF1 2 1 2,0 
DDX1 2 0 > 2 
RS5 4 2 2,0 
RL22 4 2 2,0 
IF2B3 13 7 1,9 
HNRNPF 20 11 1,8 
PTBP1* 43 24 1,8 
TADBP 14 8 1,8 
FUBP2 61 35 1,7 
PUF60 5 3 1,7 
HNRNH1 28 17 1,6 
SMD3 11 7 1,6 
G3BP1 35 23 1,5 
IF2B1 12 8 1,5 
RBM14 3 2 1,5 
HNRNH2 19 13 1,5 
SNRPA 16 11 1,5 
TIAR 13 9 1,4 
U2AF1 7 5 1,4 
RENT1 4 3 1,3 
KHDR1 12 9 1,3 
EWS 4 3 1,3 
NONO 84 65 1,3 
HNRNPK* 57 45 1,3 
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The interactions of PTBP1, U2AF2, HNRNPC, and HNRNPK with CU-RNA-T0 
and CU-RNA-ΔT0, respectively, were validated by western blotting as depicted in 
Figure 36A and Figure 36B. Both the beads alone and the control RNA interacted 
with the tested proteins to a much lesser extent than CU-RNA-T0, CU-RNA-ΔT0, 
CU-RNA-T2 and RepA suggesting that the observed interactions are specific to 
the RNAs tested. Moreover, the western blot against the histone H3 loading 
control showed that none of the RNAs, nor the beads, interacted with histone H3. 
PTBP1 was pulled down by RepA and CU-RNA-T2 most strongly, but importantly 
CU-RNA-T0 pulled down more PTBP1 than CU-RNA-ΔT0 confirming the data 
obtained by mass spectrometry. U2AF2 showed a similar pattern. HNRNPC, the 
U2AF2 opponent, was pulled down approximately equally strongly by 
CU-RNA-T0, CU-RNA-ΔT0, CU-RNA-T2 and RepA whereas the mass 
spectrometry data suggested that it was enriched at CU-RNA-ΔT0 in comparison 
to CU-RNA-T0. It is noted however, that the peptide count for HNRNPC is very 
low in the mass spectrometry data so that no real quantitative statement can be 
made. HNRNPK is pulled down most strongly by the RepA RNA and in 
agreement with the mass spectrometry data shows a slightly stronger binding to 
CU-RNA-T0 than CU-RNA-ΔT0. Finally, the western blot against EZH2 is 
depicted again for comparison. It shows that EZH2 bound all RNAs except the 
control RNA, although it could not be detected by mass spectrometry.  
 
Figure 36: RNA affinity purification of CU-RNA-T0 confirmed PTBP1, U2AF2 and HNRNPK 
as its protein interaction partners. RNA affinity purification was carried out as described in 
Figure 28. (A) and (B) Proteins that were identified by mass spectrometry and were found to be 
of particular interest for this thesis were validated by western blot analysis. The same sample was 
equally distributed over two blots and antibodies against the indicated proteins were incubated 
with either one of the two blots. The EZH2 blot is the same shown in Figure 28.  
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Combining the mass spectrometry data with the western blot validations gives a 
comprehensive overview, over which proteins bind CU-RNA-T0 and 
CU-RNA-ΔT0, respectively. In summary, both RNAs bound to proteins, which are 
important for the processing and splicing of RNA. Additionally, CU-RNA-T0 
bound HNRNPK, which has been described to play a role in RNA-mediated 
H3K27me3. This gives insight into the putative protein players that regulates 
alternative splicing of the CDV3 transcript variants in dependence of the local 
level of H3K27me3, which in turn is presumably regulated by CU-RNA-T0 itself.  
 
4.3 Knock-down of HNRNPK and MRG15 changes the ratio between 
the CDV3 transcript variants 
To investigate the role of HNRNPK and MRG15 in the regulation of alternative 
splicing of the CDV3 transcript variants, an siRNA-mediated knockdown of the 
two proteins was performed and the levels of CDV3a and CDV3b were measured 
by qRT-PCR as described in section 4.1 of the results (Figure 32). As determined 
by western blotting HNRNPK was knocked down to 1% of the protein level in 
comparison to the non-target control siRNA (Figure 37A). After HNRNPK 
knockdown the level of CDV3a did not change significantly, whereas the relative 
abundance of CDV3b decreased to 86% of the level in the control siRNA treated 
sample (Figure 37B and Figure 37C). The ratio of the two transcript variants – 
CDV3b over CDV3a – was therefore also decreased (Figure 37D). The fact that 
the ratio of the two transcript variants changes indicates that indeed HNRNPK is 
involved in the regulation of alternative splicing of the CDV3 transcripts. 
Furthermore, these results suggest that HNRNPK might be involved in the 
regulation of the local H3K27me3 levels as proposed since its knockdown shows 
a similar effect as inhibiting the setting of H3K27me3. 
The same experiment was repeated with a knockdown against MRG15. A 
knockdown to 37% of the protein level in comparison to the non-target control 
siRNA could be observed (Figure 37E). Furthermore the MRG15 knockdown 
increased the relative abundance of both the CDV3a and CDV3b transcript 
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variants significantly (Figure 37F and Figure 37G). Due to the fact, that the 
increase in the CDV3a variant was moderately higher compared to the CDV3b 
isoform, a small change in in the ratio of CDV3b over CDV3a was observed 
(Figure 37H). This suggests that also MRG15 influences the alternative splicing 
regulation of CDV3. 
 
 
Concluding the results from the knockdown experiments, the mass spectrometry 
data and their western blot validations an alternative splicing regulatory 
mechanism of the CDV3 transcript variants is proposed: It involves the specific 
binding of HNRNPK to CU-RNA-T0 which might be a regulatory factor for the 
local H3K27me3 level. Furthermore, the chromatin reader MRG15 as the 
connecting factor between the chromatin and the splicing machinery seems to be 
involved. Thereby, the CDV3 transcript could regulate its own alternative splicing, 
Figure 37: Knockdowns of HNRNPK and MRG15 changed the ratio between expression of 
the two transcript variants CDV3a and CDV3b. HeLa cells were transfected with an siRNA 
against HNRNPK, MRG15, or a non-target control siRNA. Cells were harvested after 72h. 
(A)  and (E) The efficiency of the knockdown was determined by western blotting. The protein 
levels were quantified and the amounts of HNRNPK or MRG15 relative to histone H3 are 
depicted. (B) – (D) qRT-PCR of CDV3a and CDV3b was performed. Plotted are the relative 
expression levels of CDV3a (B) and CDV3b (C) normalized to ACTB mRNA expression and the 
ratio of CDV3b expression over CDV3a expression (D). (F) – (H) Same as (B) – (D) with a 
knockdown of MRG15. n=3, *p<0.05 (Student’s t-test). 
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presumably through a sequence element in its own 3’-UTR via an H3K27me3-
mediated mechanism. 
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Discussion 
3’-UTRs are well-known for their roles in regulating mRNA stability and protein 
translation. However, several reports point to additional nuclear activities of 
3’-UTRs (Caudron-Herger et al, 2011; Mercer et al, 2011). Therefore, it was 
investigated in this thesis whether and how 3’-UTRs are linked to chromatin 
modifications. Towards this goal, methods for the detection and functional 
characterization of nuclear RNAs were established. These included 
microinjection of in vitro-transcribed RNAs and RNA pools purified from distinct 
cellular compartments. Moreover, specific RNAs were tethered to lacO arrays 
stably integrated in the chromatin using an MS2-LacI-mediated recruitment 
system to investigate their effect on chromatin. The advantages and limitations of 
these methods are discussed in section 1. In the second part of this thesis, these 
methods were used for the detailed analysis of a number of specific 3’-UTR 
sequences and in particular the 3’-UTR sequence originating from the CDV3 
gene, called CU-RNA. A mechanism was proposed, in which CU-RNA induces 
H3K27me3 of its own locus and thereby establishes a feedback loop regulating 
its own nuclear processing. The experiments leading to this model are discussed 
in sections 2, 3, and 4. Finally, all experiments from this thesis are integrated with 
previously published observations in section 5 to present a comprehensive model 
of how the 3’-UTR-mediated H3K27me3 modification is connected to splicing and 
thereby might regulate 3’-UTR dependent cellular stability of the CDV3 transcript. 
A perspective outlook is given in section 6, on how this mechanism might control 
nuclear RNA processing and mRNA stability, including the implications this might 
have for biomedical applications.  
 
1 Microinjection and chromatin recruitment of RNAs were 
established as methods to investigate nuclear RNAs  
Two microscopy-based methods were established in order to detect and 
functionally characterize nuclear RNAs. Generally, this has the advantage that 
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cells are studied at the single-cell level as opposed to population averaging done 
with biochemical and deep sequencing-based methods. The two techniques 
discussed here involve microinjection as a tool to monitor the subcellular 
localization of RNAs and to link this to their function. The second technique 
applies a model system that can be used to immobilize a transcript of interest at a 
specific genomic locus and to examine its effect on the local chromatin 
environment. The following sections discuss the advantages and challenges of 
these methods. In addition, the techniques used to visualize the RNAs in each 
case are put into perspective.  
 
1.1 Microinjection as a tool to dissect the structural and functional 
roles of nuclear RNAs 
In the first set of experiments, microinjection was established as a tool to 
investigate the subcellular localization of RNAs. It could be shown that RNAs of 
different origin and sequence behave differently after microinjection into the 
nucleus (Figure 8): Some transcripts remained in the nucleus whereas others 
distributed over both the nucleus and the cytoplasm, or were entirely found 
outside of the nucleus. To validate that the localizations observed by 
microinjection also represent the natural physiological distribution of the RNAs, 
methods to label the endogenous transcript, such as RNA-FISH, are informative. 
For CU-RNA an RNA-FISH against the endogenous transcript was also 
performed (Figure 18). Comparing its distribution after microinjection (Figure 16) 
to the RNA-FISH revealed that in both cases the RNA is found in the nucleus. 
RNA-FISH also gave a signal in the cytoplasm. This discrepancy is, however, not 
surprising given that RNA-FISH also stains the full-length CDV3 mRNA, which 
can of course also be found in the cytoplasm as functional mRNA. In summary, it 
is concluded that microinjection is a powerful technique to analyze the subcellular 
localization of RNAs in living cells as also other groups have demonstrated 
previously (Ainger et al, 1993; Sato et al, 2015; Theurkauf & Hazelrigg, 1998; 
Wilkie & Davis, 2001; Yuan & Sun, 2009).  
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Additionally, it was investigated whether microinjected RNAs can perform their 
function. As a proof of principle, it could be shown that microinjection of the 
nucleolar RNA fraction counteracted the α-amanitin-mediated segregation of 
nucleolar domains (Figure 9). This provided a quantifiable measure for the extent, 
to which microinjected RNAs perform their function. Moreover, a single in vitro-
transcribed prototypic aluRNA transcript, which was enriched in the nucleolar 
RNA fraction, was able to significantly promote nucleolar reassembly after 
microinjection (Figure 10). Biologically, these observations are very interesting as 
they give a strong indication that RNA influences nuclear and nucleolar structure 
as recently also indicated by other publications (Bergmann & Spector, 2014). 
Although transcripts originating from the intergenic spacer of rDNA have been 
implicated in the nucleolar stress response (Audas et al, 2012; Jacob et al, 2012; 
Jacob et al, 2013), these observations, for the first time, provide insight into the 
identity of regulatory nucleolar transcripts that are needed for maintenance of 
nucleolar structure. Furthermore, these finding collectively show that various 
RNAs behave differently after microinjection into the nucleus and that they have a 
structural influence on the nucleus, suggesting that they also perform their 
functions after microinjection. Microinjection was therefore used to study the 
subcellular localization of specific 3’-UTRs and to determine, which ones have 
putative functions in nuclear organization (Figure 16).  
 
1.2 The MS2/LacI-mediated recruitment system as a tool to study 
RNA-protein interactions and their effect on chromatin in single cells 
In this thesis, the focus was directed on exploiting the MS2/LacI system for 
studying the effect of RNA immobilized at chromatin. To test whether this system 
is suited for this purpose, two readouts were investigated in more detail. First, it 
was tested whether lacO-immobilized RNA can recruit protein interaction partners. 
Again as a proof of principle, it could be shown that recruitment of the aluRNA, 
the RNA that also rescued α-amanitin-induced nucleolar segregation, to the lacO 
array led to enrichment of nucleolin at the array (Figure 12). This finding 
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supported previous observations that aluRNA bound nucleolin in an in vitro 
binding assay (Caudron-Herger et al, 2015) and provided evidence that this 
interaction also exists in the living cell. Moreover, also nucleophosmin, another 
nucleolar protein, was shown to interact with aluRNA tethered at the array (Figure 
13). This suggests that aluRNA exerts its nucleolar maintaining activity by 
interacting with nucleolar proteins similar to the previously reported interaction of 
rRNA with nucleolin (Tajrishi et al, 2011). Of note, these interactions might also 
partly explain the enrichment of aluRNA in the nucleus after microinjection 
(Figure 9 and Figure 10). As also previously demonstrated by other groups 
(Shevtsov & Dundr, 2011), chromatin-tethered RNA can thus interact with and 
recruit its protein interaction partners. This demonstrates the well-suited 
application of the LacI/MS2-mediated recruitment system to study RNA-protein 
interactions in the nucleus in the living cell.  
Second, it was investigated whether lacO-tethered RNA could also affect nuclear 
localization of the arrays. As depicted in Figure 13, arrays enriched in aluRNA 
showed an increased localization within or in proximity to the nucleoli supporting 
the model of aluRNA-promoted nucleolar assembly. The MS2/LacI-mediated 
recruitment system has thereby been demonstrated to be a valuable system to 
study the contribution of RNA to chromatin organization. Since the lacO 
sequence is part of the E.coli lac operon, it offers a unique, well-defined binding 
site after incorporation into the genome of mammalian cells. However, a potential 
disadvantage might be that the array consists of repetitive DNA sequences, 
which might not properly mimic the mammalian chromatin at coding regions. To 
address this issue, one could make use of TALENs- (Miyanari et al, 2013) or 
CRISPER/Cas-mediated tagging of chromatin (Chen et al, 2013). Nevertheless, 
both systems would also require the choice of a specific sequence in the 
chromatin, which might still introduce bias into the observations.  
In addition, the MS2 stem loop sequences and the binding of the MS2 coat 
protein might present a rather artificial tethering of the RNA. Alternative methods 
for tagging the RNA could be used as described in other publications (Baron-
Benhamou et al, 2004; Coller & Wickens, 2002; Daigle & Ellenberg, 2007; De 
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Gregorio et al, 1999; Keryer-Bibens et al, 2008; Lim et al, 2001; Wakiyama et al, 
2012) (see section 4.3, introduction). Nonetheless, all of these systems would 
also include tagging of the RNA with a foreign sequence and binding to a specific 
protein, and thus present no effective improvement of this point.  
This study shows that the MS2/LacI model system used in this thesis is well-
suited to investigate the involvement of RNA in chromatin organization in the 
living cell. Therefore, it was used to study RNA-dependent chromatin compaction, 
changes in histone methylation levels at the arrays and the RNA-dependent 
recruitment of EZH2 to the arrays. 
 
1.3 Labeling and visualizing ectopic RNAs  
Visualizing microinjected RNAs in living cells 
When investigating nuclear RNAs using microscopy-based methods such as 
microinjection or immobilization at chromatin, it is also essential to be able to 
make them visible. In the case of microinjection, two RNA labeling methods were 
chosen that bypass labeling of microinjected RNA with ectopic sequences such 
as aptamers or hybridization: First, in vitro-transcribed, fluorescein-labeled RNAs 
were microinjected to test for their cellular localization (Figure 8 and Figure 16). 
In some microinjected cells, clusters of the fluorescein signal were detected in the 
nucleus (for example Figure 8A, upper panel or Figure 16A, third panel). It 
remains to be determined whether these foci represent enrichments of the 
microinjected RNAs due to the transcripts physiological properties and their 
function in the nucleus. Alternatively, these could be artifacts caused either by 
aggregation of the fluorescein itself or too high concentrations of the 
microinjected RNAs. Additional experiments, e.g. co-staining for proteins that are 
known to be found in distinct foci in the nucleus, would be required to deepen this 
question. Generally, fluorescein did, however, allow for distinct localization of the 
RNAs of interest, making it a suitable compound to label microinjected RNAs. 
In a second set of experiments, the microinjected RNAs were labeled by mixing 
with nucleic acid-binding PI. From Figure 9 and Figure 10 it can be seen that PI 
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labeled preferentially RNA, as the cellular compartments that are most enriched 
in RNA, namely the cytoplasm and the nucleoli, are stained most intensively. 
Furthermore, the nucleoli were also stained with high intensity due to the fact that 
nucleolar RNA and aluRNA were microinjected that relocalized to the nucleoli 
after being injected. The fact that aluRNA is an RNA that enriches in the 
nucleolus was supported by the MS2/LacI-mediated recruitment studies (see 
above in section 1.2, discussion).  
 
Visualizing ectopic RNAs tethered at the lacO array 
In the process of establishing the MS2/LacI-mediated recruitment system, an 
appropriate method for labeling the RNA at the array had to be developed. In 
contrast to the microinjection experiments, however, the staining of RNA was 
conducted after fixation of the cells. Labeling the RNA enriched at the array 
proved to be essential in all experiments conducted with this system to ensure 
that not only the MS2-GFP-LacI fusion protein but also the RNA of interest was 
enriched. Two ways of visualizing the RNA were tested: First, EU incorporation 
and fluorescent labeling by “click” chemistry was applied. Second, a fluorescently 
labeled probe was hybridized to the MS2 stem loops sequence (Goodier et al, 
2010) that is part of the RNA transcript. Enrichment of RNA at the arrays could be 
successfully detected with both methods (Figure 11). Both techniques have their 
advantages and disadvantages: While incorporation of EU is experimentally easy 
to handle and can be readily combined with immunofluorescence, it is less 
specific than directly detecting the MS2 stem loops-tagged RNA. In principle, the 
EU is incorporated into all newly synthesized transcripts in the cell. Thus, 
although unlikely, the signal from the EU-labeled RNA at the array might not 
originate solely from the MS2 stem loop-tagged RNA. In contrast, detecting the 
MS2 stem loops tagged-RNA with RNA-FISH shows the presence of a specific 
transcript. This technique, however, requires more caution in the experimental 
handling. Due to incubation with formamide-containing buffers, this method is not 
compatible with every antibody used in subsequent immunofluorescent stainings. 
Additionally, controls that have been treated with RNase A have to be included to 
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ensure that the probe only hybridized to the RNA and not the plasmid DNA. To 
be even more specific in the RNA detection, one could also make use of RNA-
FISH probes directly against the RNA of interest. However, using probes against 
the MS2 stem loops makes the system more versatile by being able to use the 
same probes for all RNAs of interest. Finally, since every RNA is tagged with 
more than one MS2 stem loop, the fluorescent signal is amplified accordingly by 
the hybridization of several probes per transcript. Therefore, using RNA-FISH 
with probes directed against the MS2 stem loops was the method applied in the 
course of this thesis. 
 
2 Nuclear 3’-UTRs rescue aggregation of decondensed 
chromatin and compact chromatin when tethered to a specific 
locus 
In order to dissect the mechanism, by which 3’-UTRs modify chromatin, selected 
3’-UTR sequences were investigated. One of them, the CU-RNA, was classified 
as particularly interesting according to the following criteria: (i) the in vitro-
transcribed RNA was able to rescue the chromatin aggregation induced by 
RNase A treatment, (ii) it remained in the nucleus after microinjection, (iii) its 
corresponding endogenous sequence was present in the nucleus as detected by 
northern blotting of RNA from purified nuclei and RNA-FISH, and (iv) it induced 
chromatin compaction at the lacO arrays. These findings are discussed and put 
into perspective in the following sections.  
 
2.1 Role of nuclear 3’-UTRs in rescuing the RNase A-induced 
aggregation of decondensed chromatin regions 
It was reported that digestion of nuclear single-stranded RNAs causes distinct 
micrometer scale chromatin aggregation of decondensed chromatin regions 
(Caudron-Herger et al, 2011). The RNase A-induced chromatin compaction could 
be rescued by a soluble nuclear RNA fraction that is enriched in long 3’-UTR 
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transcripts, called the F2 fraction. In this thesis, it was observed that also single 
transcripts that were highly enriched in this RNA fraction were able to rescue the 
RNase A-induced chromatin aggregation (Figure 15). This activity was specific 
for transcripts such as the 3’-UTRs of SSR3, CDV3, SURF4, STARD7, and 
CORO1C and could not be observed to the same extend for all other 3’-UTRs 
and non-3’-UTR transcripts tested.  
It is interesting that single in vitro-produced transcripts from the F2 fraction could 
rescue the effect of the RNase A treatment. This points to a very strong 
chromatin rescuing phenotype of the 3’-UTRs tested here. Observations made in 
the microinjection experiments supported this possibility: With the exception of 
SURF4, all RNAs that rescued RNase A-induced chromatin compaction were 
also found to reside in the nucleus after their microinjection (Figure 16). This 
suggests that they have a role in the nucleus. It is, however, noted that the 
concentration of RNA that is added is likely to be above the physiological 
concentration. Assuming that several of the RNAs present in the F2 fraction 
share a common mechanism of action, the fact that only a single type of 
transcripts is added could therefore be compensated by the concentration used in 
this experimental setup.  
While the rescue experiment points to a structural role of these specific 3’-UTR in 
chromatin organization, their mechanism of action remains unclear. In the first 
place, it cannot be fully explained why RNase A treatment of mammalian 
interphase nuclei induces such vast rearrangements of the chromatin structure. 
Since RNA has long been known to be a major component of chromatin, it seems 
logical that removing the RNA will affect chromatin organization (Huang & Bonner, 
1965; Paul & Duerksen, 1975; Pederson & Bhorjee, 1979). As listed by Caudron-
Herger et al. (Caudron-Herger et al, 2011), there are a number of perturbations of 
cellular function that lead to a similar chromatin phenotype: for example treatment 
of cells with the RNA Pol II inhibitor α-amanitin (Caudron-Herger et al, 2011) or 
an increased degree of histone acetylation (Görisch et al, 2005; Lleres et al, 
2009; Toth et al, 2004) also results in chromatin rearrangements as observed 
after RNase A treatment. Perturbation of histone acetylation and the involved 
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enzymes might be regulated by nuclear RNAs, for example by signals found in 
3’-UTRs. In fact, mRNAs bind many more proteins than the originally known RNA 
processing factors. They contain many protein interaction motifs encoded in their 
sequence or secondary structure (Baltz et al, 2012; Castello et al, 2012; 
Karapetyan et al, 2013; Mignone et al, 2002). The interaction of the 3’-UTRs with 
chromatin modifying proteins might explain the changes in chromatin morphology 
observed here. Thus, one possibility is that the chromatin topology is influenced 
by the 3’-UTRs via regulations of the histone modification state as suggested by 
Caudron-Herger et al. (Caudron-Herger et al, 2011). Alternatively, the 3’-UTRs 
could perform their function indirectly by acting as decoys for proteins that 
otherwise would induce chromatin compaction. Their digestion by RNase A would 
therefore cause chromatin aggregation. 
In view of the follow-up experiments in this thesis that showed EZH2 binding to 
the 3’-UTRs (Figure 21), the PRC2 complex is a potential candidate for such an 
RNA-dependent chromatin-organizing complex. The polycomb complexes have 
been described to be able to compact chromatin (Engreitz et al, 2013; Francis et 
al, 2004; Margueron et al, 2008; Naughton et al, 2010; Rego et al, 2008) and to 
bind RNA (Brockdorff, 2013). Furthermore, it has been shown that transcriptional 
inhibition in mouse embryonic stem cells is sufficient to induce genome-wide 
PRC2 recruitment to its target genes (Riising et al, 2014). In this publication, it is 
suggested that the transcriptional state governs PRC2 binding. Thus, although it 
has not been confirmed so far and would need further experimental validation, in 
the unperturbed state, the 3’-UTRs would keep the RPC2 complexes away from 
the chromatin, disabling them to compact the chromatin. When cells are treated 
with RNase A the polycomb complexes would no longer be kept in solution by the 
RNAs and would be recruited to the chromatin leading to a global compaction 
phenotype. A similar mechanism has previously been suggested by other groups 
(Davidovich et al, 2014; Davidovich et al, 2013; Kaneko et al, 2013). Furthermore, 
analogous mechanisms could be envisioned for RNA-binding chromatin 
modifying complexes other than the polycomb complexes, although direct 
experimental evidence is lacking.  
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2.2 Chromatin compaction and H3K27me3 induction by CU-RNA at 
the lacO arrays 
From the microinjection and rescue experiments, a number of specific 3’-UTRs 
were identified as particularly interesting nuclear 3’-UTRs with chromatin 
organizing function. However, only CU-RNA, the 3’-UTR of the CDV3 transcript, 
showed an effect on chromatin compaction when recruited to the lacO arrays 
(Figure 17). It is intriguing that recruitment of a specific RNA can be the trigger for 
such a drastic rearrangement of chromatin. Classically, chromatin compaction is 
associated with the formation of heterochromatin (Trojer & Reinberg, 2007). The 
H3K9me3 mark, which is enriched at silenced genes and is a mark of constitutive 
heterochromatin, (Lehnertz et al, 2003; Muller-Ott et al, 2014) could not be found 
at the arrays after CU-RNA recruitment (Figure 19). However, the H3K27me3 
mark was found specifically after CU-RNA recruitment (Figure 20) as 
schematically depicted in Figure 38.  
 
It has been reported that repressive histone marks such as H3K27me3 alone are 
not necessarily sufficient for chromatin compaction in heterochromatin formation 
(Chandra et al, 2012). Thus, other factors in addition to the CU-RNA-promoted 
H3K27me3 at the array could be important to induce chromatin compaction. In 
the case of X chromosome inactivation for example, it is still under debate 
Figure 38: Chromatin states of the lacO array with recruitment of different RNAs. 
(A) Tethering of an “inactive” RNA recruits EZH2 but cannot promote H3K27me3 and leaves the 
chromatin decondensed. (B) Tethering of an active RNA, such as CU-RNA, recruits EZH2, 
promotes H3K27me3 and leads to chromatin condensation. 
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whether PRC2 recruitment and H3K27me3 are the cause or consequence of 
chromatin compaction. A number of additional factors such as histone H2A 
monoubiquitination, the heterochromatin protein 1-binding protein HBiX1 and the 
structural maintenance of chromosomes hinge domain–containing protein 1 
(SMCHD1) have been suggested to be essential for organization of the compact 
Xi structure (Kalb et al, 2014; Nozawa et al, 2013). Nonetheless, there seems to 
be a link between PRC2, H3K27me3 and the compaction of the X chromosome 
as it is proposed that both the PRC2 complex and SMCHD1-HBiX1 are needed 
for compaction of Xi. Furthermore, the polycomb complexes themselves have 
been described to be able to compact chromatin (Francis et al, 2004; Margueron 
et al, 2008; Naughton et al, 2010; Rego et al, 2008). Thus, although no direct 
connection between EZH2 and chromatin compaction has been found so far, the 
presence of the enzyme at the arrays after CU-RNA recruitment was tested here 
and confirmed (Figure 21). In conclusion, H3K27me3 together with EZH2 and 
potentially further – yet to be discovered – factors might explain the CU-RNA-
mediated chromatin compaction of the lacO arrays through a mechanism that 
seems to resemble compaction of the inactive X chromosome.  
 
3 EZH2 binds RNA unspecifically and exerts its histone 
methylation activity only upon interaction with CU-RNA-T0 
By systematically studying fragments derived from the CU-RNA, different 
activities were assigned: the RNAs were either only able to recruit EZH2 to the 
lacO array or to recruit EZH2 and additionally induce the H3K27me3 modification. 
The binding of the CU-RNA to EZH2 and its influence on the catalytic activity are 
discussed here.  
 
3.1 CU-RNA contains a 250 nucleotide long functional element, T0, 
that is needed for its H3K27me3 inducing activity 
After the 3 kb long CU-RNA had been identified as an RNA that not only recruited 
EZH2 to the lacO arrays but also promoted H3K27me3, it was cut down to its 
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minimal functional element that still performs this function, the CU-RNA-T0. 
Testing CU-RNA-ΔT0, the CU-RNA-T0-corresponding sequence originating from 
a CDV3 alternative transcript variant, CDV3b, showed that replacing the first 80 
nucleotides of the 5’ end fully abolished the H3K27me3-promoting activity. 
Furthermore, it could be demonstrated that recruiting solely these 80 nucleotides, 
or further smaller fragments from the CU-RNA-T0 was not sufficient to induce 
H3K27me3 at the lacO array. Therefore, the 80 nucleotides at the 5’ end and an 
additional substantial part of the CU-RNA-T0 are essential to perform the 
H3K27me3 function (Figure 23 and Figure 26).  
Advantages of having identified this 250 nucleotide long transcript from the 3 kb 
CU-RNA are the following: First, cutting down the long CU-RNA automatically 
generated CU-RNA-T2 as a negative control that in subsequent experiments 
could be used as a non-H3K27me3-promoting transcript that has the same length 
as CU-RNA-T0. Second, the smaller fragment is easier to manipulate in terms of 
its experimental handling. Third, RNA affinity experiments become much more 
specific to the function that is actually ascribed to the CU-RNA-T0 transcript in 
comparison to doing the pull-down with the whole CU-RNA transcript. Fourth, the 
binding of RNA to the PCR2 complex has been suggested to be a function of the 
size of the RNA of interest (Davidovich et al, 2013). According to this publication, 
CU-RNA-T0 is roughly in the proposed size range were maximal binding of RNA 
to PRC2 is observed but where increasing its length would probably not increase 
its affinity. In summary, a minimal functional sequence element of the CU-RNA 
was successfully identified that could be further investigated to reveal the 
mechanisms by which it operates.  
 
3.2 RNA binding to the PRC2 complex is not specific 
Interestingly, all RNAs investigated in the LacI/MS2-mediated chromatin 
recruitment system, even the MS2 stem loops alone, and also the 80-nucleotide 
short transcripts derived from the CU-RNA-T0 (CU-RNA-S1, CU-RNA-S2 and 
CU-RNA-S3) could enrich EZH2 (Figure 22, Figure 24, Figure 26). The positive 
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control, RepA was also found to recruit EZH2 to the arrays (Zhao et al, 2008). 
With this assay, it remains unclear whether EZH2 is the component of the PRC2 
complex that promotes the interaction with the RNAs. Alternatively, the 
interaction could also be mediated by one of the other PRC2 components that 
have RNA-binding capacities (Cifuentes-Rojas et al, 2014). Nonetheless, this 
finding was in agreement with the promiscuous binding of RNA to the PRC2 
complex observed both in vitro (Davidovich et al, 2013) and in vivo as suggested 
by a number of publications (Guil et al, 2012; Kaneko et al, 2014b; Kaneko et al, 
2013; Kanhere et al, 2010; Karapetyan et al, 2013; Khalil et al, 2009; Zhao et al, 
2010). While RNA binding to the PRC2 complex has been suggested to be rather 
promiscuous, it has been stated that its interactions with RNA are still specific 
(Davidovich et al, 2015). Having this controversy in mind, the binding specificity of 
RNA to PRC2 and EZH2 in particular remains to be dissected in detail. As far as 
the MS2/LacI-mediated recruitment assays conducted here in the living cell can 
reveal, there seem to be only subtle differences in the binding affinity of EZH2, 
directly or indirectly, to the tested RNAs.  
 
3.3 RNA affects the catalytic activity of EZH2 
While all RNAs tested in this work could recruit EZH2 to the lacO arrays, only 
certain transcripts could also induce H3K27me3, suggesting that the RNAs differ 
in their effect on the catalytic activity of EZH2. Besides its H3K27me3-promoting 
activity, CU-RNA was also the only 3’-UTR that also induced chromatin 
compaction at the arrays as discussed in section 2.2. The influence of RNA on 
EZH2 catalytic activity both in vitro and in vivo is only partly understood. This 
thesis supports previous findings showing in an in vitro methylation assay that the 
EZH2 catalytic activity is inhibited by any RNA transcript at approximately 
equimolar concentrations (Figure 27) (Cifuentes-Rojas et al, 2014; Davidovich et 
al, 2013). In contrast, it is observed for the first time using the MS2/LacI-mediated 
recruitment system that there are differences in the capacity of different RNAs to 
promote H3K27me3 in living cells (Figure 20 and Figure 23). It can be argued 
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that the lacO array does not represent a natural mammalian chromatin 
environment and that the endogenous H3K27me3-promoting capacity of 
CU-RNA might be different. Nevertheless, it was shown that with this system 
tethering of the positive control RepA, an essential factor for H3K27me3 in X 
chromosome inactivation (Zhao et al, 2008), also triggers the H3K27me3 
modification. This suggests that the MS2/LacI-mediated recruitment assay is a 
valid system to study the effect of specific RNAs on the posttranslational histone 
modification H3K27me3. It is remarkable that the capacity of CU-RNA and 
CU-RNA-T0 to promote H3K27me3 at the array is even higher than that of the 
positive control RepA.  
To explain the inconsistencies between the in vitro methylation assay and the 
observations made in living cells, there must be additional factors in the cell that 
rescue the inhibitory effect of RNA on EZH2 activity. Figure 39 illustrates a model 
to explain the discrepancies between the RNAs that induce H3K27me3 at the 
lacO array and those that do not promote H3K27me3. For many RNAs, binding to 
EZH2 inhibits its catalytic activity (Figure 39A) so that no H3K27me3 is set at the 
array, even though the PCR2 complex is present. In case of specific “active 
RNAs” (Figure 39B), it is suggested that additional factors are recruited that 
activate the PCR2 complex so that H3K27 is trimethylated. In this model it is 
assumed that EZH2 is not recruited alone but in a multi-protein complex with the 
other core components of PRC2. Strictly speaking, this has not been shown in 
this study, since only the presence of EZH2 at the array but not that of the other 
PRC2 components was tested. It is also possible that with “inactive RNAs” just 
EZH2 and not the whole PRC2 complex is recruited to the array, which might 
explain why in the one case EZH2 is catalytically active and in other cases not. 
Noteworthy, adding nuclear lysate to the in vitro methylation assay conducted in 
this study did not rescue the enzymatic activity of EZH2. Although it was 
reasoned that the lysate should in principle contain the factors distinguishing the 
activities of various RNAs, it appears that an in vivo environment as in the cells is 
needed for certain RNAs to rescue EZH2 catalytic activity.  
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In vitro studies suggest for example that SUZ12 and EED are mandatory for the 
enzymatically active complex (Cao & Zhang, 2004; Cloos et al, 2008; Margueron 
& Reinberg, 2011; Pasini et al, 2010). SUZ12 is a particularly interesting 
candidate because it has been shown to also bind RNA with high affinity 
(Cifuentes-Rojas et al, 2014). A recent study applied quantitative mass 
spectrometry to determine the stoichiometry of the PRC2 complex. They could 
show that the PRC2 complex contains at least a monomer of each EZH2, EED 
and SUZ12 and additional interactors, suggesting that in vivo EZH2 is always in 
complex with the whole PRC2 (Smits et al, 2013). This would suggest that 
SUZ12 is present in the inactive state. On the contrary, for binding of the HOTAIR 
RNA to PRC2 it was found in vitro that only the EZH2-EED heterodimer is 
necessary (Wu et al, 2013). Thus, it remains to be determined whether all of the 
PRC2 core components that make the complex catalytically active are recruited 
to the array with the RNAs that are investigated here.  
Figure 39: Schematic illustration of the discrepancy between RNAs that do not lead to 
H3K27me3 and those that promote H3K27me3 at the lacO arrays. (A) RNA is recruited to the 
array via the MS2-GFP-LacI fusion protein and EZH2 is recruited via its interaction with the RNA. 
For some inactive RNAs this interaction inhibits the catalytic activity of EZH2 and therefore 
H3K27 is not methylated. (B) In the case of “active RNAs”, an additional factor, here called “X”, 
is recruited to the array, which activates the PCR2 complex to set H3K27me3 at the lacO array. 
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Assuming that in all cases RNAs recruit the whole PRC2 core complex to the 
arrays, it is also conceivable that accessory factors distinguish inactive from 
active PRC2 when certain RNAs are bound. In the recent years, the polycomb-
like proteins PCL1 and PCL2 (Cao et al, 2008; Casanova et al, 2011; Sarma et al, 
2008), and ATRX (Sarma et al, 2014) have been demonstrated to have a 
stimulating activity on PCR2 activity. Additionally, two studies investigating the 
XIST proteome identified the nuclear matrix protein HNRNPK by mass 
spectrometry (Chu et al, 2015; Minajigi et al, 2015). They demonstrated that it 
has a crucial function in the accumulation of H3K27me3 on the Xi, which could 
also point to its involvement in setting the H3K27me3 mark. Interestingly, 
HNRNPK was found to be slightly enriched at CU-RNA-T0 in comparison to 
CU-RNA-ΔT0 as shown by mass spectrometry and western blot analysis (Table 
15, Figure 36 and Appendix 2) in this thesis. In the same mass spectrometry 
analysis, it was also shown that RepA is enriched in HNRNPK. While RepA 
served as a positive control and was thus expected to bind HNRNPK, the very 
strong enrichment observed with RepA cannot explain why the H3K27me3-
promoting capacity of CU-RNA-T0 is higher than that of RepA (Figure 20). It is 
noted, however, that the mass spectrometry as conducted here presents no 
quantitative measure for the amount of identified proteins. Large differences in 
the peptide counts of the same proteins point to a difference in the amount of the 
protein present in the sample. Yet, alternative methods would be superior for 
quantification purposes as discussed in more detail in section 4.3. Thus 
additional experiments are needed to compare the enrichment of HNRNPK at 
CU-RNA-T0, CU-RNA-ΔT0 and RepA.  
In a second experiment the functional impact of HNRNPK on CDV3 splicing was 
investigated. It was found that HNRNPK knockdown influences the expression 
level of the CU-RNA-ΔT0 containing CDV3b and thereby the ratio of the two 
CDV3 transcript isoforms (Figure 37). Thus, although the enrichment of HNRNPK 
at the CU-RNA-T0 was small, it could potentially be an important factor that 
distinguishes the H3K27me3-promoting capacity of the CU-RNA-T0 from that of 
CU-RNA-ΔT0 or CU-RNA-T2. This does not exclude that there are additional 
120 Discussion 
 
 
factors other than HNRNPK that enhance the catalytic activity of EZH2 at the 
array in combination with CU-RNA and CU-RNA-T0. 
Finally, although controversially discussed, the two nucleosome binding factors 
AEBP2 (Kim et al, 2009) and JARID2 (Lee et al, 2006; Li et al, 2010; Pasini et al, 
2010; Peng et al, 2009; Shen et al, 2009) both have been proposed to enhance 
the catalytic activity of the RPC2 complex on their own and also together in a 
synergistic manner (Cao & Zhang, 2004; Son et al, 2013). JARID2 represents a 
particularly interesting accessory factor in view of the above-described model 
(Figure 38) because it has been also shown to bind RNA (Cifuentes-Rojas et al, 
2014). In this thesis, it could not be ultimately determined whether JARID2 is the 
factor that differentiates CU-RNA-T0 from CU-RNA-ΔT0 and CU-RNA-T2. 
Nevertheless, there is evidence that JARID2 binds the CU-RNA-T0 in vitro, 
suggesting its involvement in the H3K27me3-promoting activity of the transcript. It 
will therefore be discussed in more detail in the following paragraph.  
 
3.4 JARID2 binds CU-RNA-T0 and might be a factor that rescues the 
inhibitory effect of RNA on EZH2  
The presence of JARID2 at the lacO arrays when recruiting CU-RNA-T0 and 
CU-RNA-ΔT0 was examined in search for a potential factor that could account for 
the difference in the H3K27me3-promoting capacities of the two RNAs. JARID2 
was considered a good candidate in this context because a previous publication 
suggested that JARID2 could rescue the inhibitory effect of RNA on EZH2 activity 
in an in vitro methylation assay (Cifuentes-Rojas et al, 2014). Here, two 
commercial antibodies against JARID2 were tested in the MS2/LacI-mediated 
recruitment system. With both antibodies no clear enrichment of JARID2 at the 
arrays could be observed with any of the RNAs (Figure 29). This was either 
linked to a technical detection problem due to a lack of quality of the antibodies or 
JARID2 is not or only very weakly enriched. On the one hand, it cannot be fully 
excluded that the immunofluorescent staining of JARID2 did not work perfectly. 
Since the Novusbio antibody shows a multitude of bands of different size in a 
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western blot of nuclear HeLa extract, this antibody was not suited for 
immunofluorescence in the first place. The Abcam antibody gave a single band of 
approximately the expected size in the western blot test. Nonetheless, RNA-FISH 
to detect the MS2 stem loop containing RNA transcript at the array in 
combination with the immunofluorescent staining against JARID2 might present 
technical issues. Paraformaldehyde fixation and stringent washing steps as 
required in the RNA-FISH protocol might reduce the affinity of the Abcam JARID2 
antibody for example due to changes in the epitope structure during fixation.  
On the other hand, the model by Cifuentes-Rojas and colleagues has not been 
supported by in vivo experiments. They propose that RNA is the factor that 
targets PRC2 to chromatin but inhibits its enzymatic activity until PRC2 
associates with JARID2 on chromatin. JARID2 thereby weakens PRC2’s binding 
to RNA. The only evidence from in vivo studies to support this view are findings 
from other laboratories, reporting that JARID2 enhances PRC2 recruitment to 
chromatin at the Xi (da Rocha et al, 2014; Kaneko et al, 2014a; Li et al, 2010). 
The tests conducted here are thus the first experimental approach to study the 
model proposed by Cifuentes-Rojas et al. in the living cell but did not provide 
clear results. Nevertheless, it could still be shown that CU-RNA-T0 binds JARID2 
in vitro in an RNA affinity purification pull-down experiment (Figure 28). Here, 
despite the lack of a good antibody and ambiguous data, the pull-down 
experiment indicated an increased affinity of CU-RNA-T0 for JARID2 in 
comparison to CU-RNA-ΔT0. Thus, although more detailed studies are needed, 
JARID2 is still a potentially interesting candidate to explain discrepancies 
between the H3K27me3-promoting activities of different RNAs.  
 
4 CU-RNA regulates its own alternative splicing via 
establishment of a splicing specific chromatin signature 
In search of the endogenous function of the H3K27me3-promoting activity of 
CU-RNA-T0, it was noted that it is located at the alternative last exon of the 
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CDV3 transcript. Therefore a connection between the H3K27me3-promoting 
activity and alternative splicing was investigated.  
 
4.1 EZH2 inhibition influences H3K27me3 distribution at the CDV3 
locus and genome wide 
By western blotting and FACS analysis it was found that inhibition of EZH2 with 
the small molecule inhibitor GSK343 reduced the level of H3K27me3 in HeLa 
cells (Figure 30). In addition, ChIP-seq experiments of GSK343-treated and 
control cells were performed to obtain insight into the genome-wide changes in 
H3K27me3 (Figure 31). Several points suggest that the quality of data was not 
ideal: First, the expected increase in reads mapping to the mouse genome after 
GSK343 treatment was not observed. It was expected that in the GSK343 treated 
samples a higher proportion of reads should map to the mouse genome than in 
the untreated samples because less human chromatin carrying H3K27me3 is 
provided to the antibody to bind its epitope. However, the expected increase in 
reads mapping to the mouse genome after GSK343 treatment was not observed. 
It remains elusive why this is the case since the GSK343 inhibitor has been 
shown to perform its function properly on a global level by FACS anaylsis and 
western blot (Figure 30). A potential explanation could be differences in the 
binding affinity of the H3K27me3 antibody under the experimental conditions 
used for ChIP-seq in comparison to FACS and western blotting. 
Second, the MCORE correlation functions of H3K27me3 usually have and 
amplitude of up 0.1 in ChIP-seq experiments of high quality (Molitor et al, 2015), 
while only 0.03 was reached here. This supports the notion that the enrichment of 
the H3K27me3 signal over background is relatively low in the present data set. 
Third, in one of the replicates no peaks could be called using the Sicer algorithm 
(Zang et al, 2009) again suggesting a low signal to background ratio.  
To be able to better quantify and calibrate the findings from the ChIP-seq 
analysis the so-called internal standard calibrated ChIP (ICeChIP) could be used 
in stead of the mouse chromatin spike-in (Grzybowski et al, 2015). This method 
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also employs chromatin spike-ins but uses nucleosomes that are reconstituted 
from recombinant and semisynthetic histones together with barcoded DNA. The 
authors claim that unlike spiking in chromatin from a different organism, this 
method could measure actual amounts of marks using very defined standards 
and thereby provide an even better means of data correction. Experimentally, 
ICeChIP is more laborious than spiking in chromatin from a different organism but 
might be worth the effort to obtain a quantitative overview over the differential 
H3K27me3 before and after GSK343 treatment.  
Nevertheless, the combined analyses using MCORE and SICER showed that 
GSK343 treatment leads to a genome-wide redistribution of H3K27me3 and a 
reduction of H3K27me3 in annotated genes. Moreover, comparing the traces at 
the CU-RNA in the DMSO- and GSK343-treated samples demonstrated a 
reduction of H3K27me3 at the start of the alternative last exon of CDV3b and a 
slight increase in H3K27me3 at the upstream intron and the 3’-UTR. The findings 
are substantial to support the hypothesis that splicing of the CDV3 alternative 
transcripts is dependent on the differential H3K27me3 at the locus. 
 
4.2 EZH2 inhibition influences the balance between CDV3a and its 
splice variant CDV3b  
Expression of the two splice variants of the CDV3 transcript, CDV3a and CDV3b, 
was dependent on the activity of EZH2 and the levels of H3K27me3 at the CDV3 
locus. Inhibition of the catalytic activity of EZH2 led to a decrease in the local 
level of H3K27me3 at the alternative exon of CDV3b (Figure 31). Additionally, 
qRT-PCR of the two transcript variants revealed that the CDV3b/CDV3a ratio 
decreased to almost 50% after EZH2 inhibition while they were expressed at 
equal levels in the unperturbed state (Figure 34). The involvement of H3K27me3 
in splicing decisions has been described in a number of studies. For example 
siRNAs targeted against an intronic sequence next to a fibronectin exon in 
human cells promote an AGO1-dependent local increase in the H3K27me3. This 
is suggested to slow down RNA Pol II and to cause the inclusion of an alternative 
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exon that is skipped in the unmethylated state (Alló et al, 2009). Similarly, 
H3K27me3 distribution on specific genes is associated with changes in 
alternative splicing in differentiating neurons (Schor et al, 2013). Many of the 
models propose a kinetic mechanism according to which the chromatin template 
modulates the rate of transcription, which in turn impacts splicing decisions (de la 
Mata et al, 2003; Shukla & Oberdoerffer, 2012). Here it is proposed that the 
methylation of H3K27 rather functions as a chromatin signal that is read out and 
affects the ensemble of proteins involved in splicing (see sections 4.3 and 5, 
discussion).  
 
4.3 HNRNPK, PTBP1, U2AF2 and HNRNPC link splicing of CDV3 to 
the local chromatin state 
Two observations have led to the conclusion that the CU-RNA-T0 and 
CU-RNA-ΔT0 have distinct activities. The first one is that only CU-RNA-T0, as 
part of the CDV3a transcript, can induce H3K27me3 at the lacO array when 
immobilized there. The second one is that EZH2 inhibition changes the ratio of 
the two transcript variants CDV3a and CDV3b. The latter suggests that different 
splicing regulators are recruited depending on the H3K27me3 state of the 
chromatin locus. Based on these two observations, it was speculated that 
CU-RNA-T0 and CU-RNA-ΔT0 interact with distinct protein partners that function 
together with the transcripts to perform their function. RNA affinity purification in 
combination with mass spectrometry was therefore carried out to map the 
CU-RNA-T0 and CU-RNA-ΔT0 protein interaction partners. The majority of 
proteins pulled down by either of the two and the control RNAs were RNA-binding 
proteins (Figure 35 and Appendix 2). This confirms that the affinity purification 
protocol specifically enriched for RNA-binding proteins at the different sequences. 
Furthermore, the fraction of proteins that bound CU-RNA-T0 and CU-RNA-ΔT0 
largely overlapped. Since both RNA fragments are derived from the 3’-UTR of 
CDV3 and are identical in 170 out of 250 nucleotides this is not surprising. 
Nevertheless, several proteins were identified that could be responsible for the 
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H3K27me3-promoting activity of CU-RNA-T0 and its involvement in regulating 
alternative splicing (Table 15 and Figure 36) and are discussed in the following.  
 
U2AF2 
One of the most enriched proteins at CU-RNA-T0 in comparison to CU-RNA-ΔT0 
was U2AF2, with an enrichment factor of 4.7 fold (Table 15). Binding to 
CU-RNA-T0 was confirmed by western blotting whereas no binding to the 
CU-RNA-ΔT0 was detected (Figure 36). Furthermore, both mass spectrometry 
and western blotting indicated that RepA binds U2AF2 even stronger than the 
CU-RNA-T0 (Appendix 2 and Figure 36). Whether this binding event also plays a 
functional role awaits further analysis. However, it needs to be considered that 
mass spectrometry is not quantitative per se due to varying detector response 
and differing ionization yields of the different substrates. To receive a quantitative 
readout that can be compared more closely to the western blot analysis (Figure 
36) SILAC (stable isotope labeling by amino acids in cell culture) could be carried 
out (Ong et al, 2002). This method uses the fact that peak ratios from isotopic 
analogs are very accurate because there are no chemical differences between 
different species. Furthermore, alternative RNA affinity purification methods could 
be applied. For example, streptavidin-binding RNA aptamers could be used that 
were suggested to perform even better than the use of biotin-labeled transcripts 
in terms of labeling efficiency and background reduction (Butter et al, 2009; 
Leppek & Stoecklin, 2014).  
Although it needs further confirmation, the differential binding to CU-RNA-T0 and 
CU-RNA-ΔT0 could be relevant for the regulation of the CDV3 splicing. U2AF2 
has been reported to have the capacity to define functional 3’ splice sites 
(Valcarcel et al, 1996; Zamore et al, 1992) in 88% of the human genome (Shao et 
al, 2014). The 5’ splice site in the CDV3a and CDV3b transcript are identical. 
Thus, the 3’ splice site sequence provides the essential region for differentiating 
between the two (Figure 25). Potentially, U2AF2 is the splicing regulator that is 
needed to allow assembly of the spliceosome complex at the proper site in line 
with previous findings on its function (Ruskin et al, 1988).  
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HNRNPC 
HNRNPC has been suggested to compete with U2AF2 binding to protect the 
transcriptome from the exonization of Alu elements (Zarnack et al, 2013). In the 
context of this thesis, HNRNPC is interesting because the mass spectrometry 
data suggest that it binds to CU-RNA-ΔT0 but not to CU-RNA-T0. Confirming 
previous observations, here this protein also interacted with the RepA transcript 
here (McHugh et al, 2015). However, the peptide counts with only 2 and 5 hits 
respectively, were rather low in both cases. This might explain why the differential 
enrichment of HNRNPC at the CU-RNA-ΔT0 could not be confirmed by western 
blot, where CU-RNA-T0, CU-RNA-ΔT0, CU-RNA-T2 and RepA demonstrated 
approximately equal binding affinities (Figure 36). Further quantitative analyses 
are needed as described above (see under U2AF2). Based on the reported 
involvement of HNRNPC in the intronization of certain sequences, it is 
nonetheless considered as potentially relevant in the regulation of CDV3 splicing.  
 
PTBP1 
Interestingly, also the well-studied splicing regulator PTBP1 was found highly 
enriched at the CU-RNA-T0 as demonstrated by both mass spectrometry and the 
western blot (Table 15 and Figure 36). Similarly to U2AF2, both data sets also 
suggest that RepA and CU-RNA-T2 bind this factor most strongly. As stated 
above, the functional relevance of these observations remains to be investigated 
in more detail and with more quantitative methods (see under U2AF2). 
Nevertheless, the differential binding of PTBP1 to CU-RNA-T0 in comparison to 
CU-RNA-ΔT0 is potentially relevant for the underlying splicing mechanism. There 
are several publications suggesting that PTBP1 regulates alternative RNA 
processing by different activities (Spellman & Smith, 2006). For example it binds 
to both exonic and intronic CU-rich regions to obstruct exon definition (Izquierdo 
et al, 2005), to obstruct intron definition (Chou et al, 2000; Sharma et al, 2005) or 
to prevent the transition from exon to intron definition (Sharma et al, 2008). These 
findings are substantiated on a genome wide level in a study by Xue and 
colleagues revealing a positional effect of PTBP1 on the regulation of splicing 
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(Xue et al, 2009). There are also reports that suggest competitive binding of 
U2AF2 and PTBP1 making it unlikely that they both bind CU-RNA-T0 
simultaneously to regulate splicing of the CDV3 pre-mRNA (Lin & Patton, 1995; 
Sauliere et al, 2006; Singh et al, 1995). However, given the apparently broad role 
of PTBP1 in splicing regulation, involvement of both PTBP1 and U2AF2 in the 
CDV3a splicing is conceivable. Shao and colleagues (Shao et al, 2014) suggest 
also that there is an additional role of U2AF2 when it binds in intronic regions 
where it interferes with recognition of the downstream 3’-UTR splice site. With 
respect to splicing regulation of the CDV3 transcript, it remains unclear how 
exactly the inclusion of the CU-RNA-T0 containing exon is controlled by U2AF2 
and PTBP1 and where exactly in the transcript they bind. However, based on the 
current knowledge about the many mechanistic roles of the two proteins it 
appears feasible that the concerted action of the two proteins results in a splicing 
event favoring the CDV3a variant.  
 
MRG15 
PTBP1 binding to CU-RNA-T0 is of interest for the present thesis because it has 
been shown to bind MRG15 (Gonzalez et al, 2015; Luco et al, 2010). In vitro 
binding assays of MRG15 have indicated that its chromo-domain binds 
methylated lysine 36 but not lysine 4, lysine 9, or lysine 27 of histone H3 (Zhang 
et al, 2006). According to Gonzalez and colleagues, the PTBP1-MRG15 complex 
forms an adaptor that can regulate alternative splicing depending on the 
presence of H3K36me3 and absence of H3K27me3. MRG15 could not be 
detected in the mass spectrometry data likely because it is no direct interactor of 
CU-RNA-T0 but interacts on indirectly via PTBP1. In this thesis, a knockdown of 
MRG15 led to the increase in expression of both transcript variants CDV3a and 
CDV3b (Figure 37). This demonstrates its effect on processing the CDV3 pre-
mRNA but it remains elusive why the MRG15 knockdown affects both splicing 
transcripts equally. However, it has to be noted that the knockdown was not very 
efficient and a substantial level of MRG15 remained in the cells. Thus, further 
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experiments are needed to make strong conclusions about the contribution of 
MRG15 with respect to CDV3 splicing.  
 
HNRNPK 
In addition to the interaction with MRG15, the splicing regulatory protein PTBP1 
has been suggested to interact with HNRNPK (King et al, 2014), which is also 
involved in alternative splicing (Kumar et al, 2014). HNRNPK has been identified 
in two independent publications as a RepA-interacting protein (Chu et al, 2015; 
Minajigi et al, 2015). Here, HNRNPK binding to RepA was confirmed 
(Appendix 2). Minajigi and colleagues showed by knockdown studies that it is 
necessary for XIST-mediated chromatin modifications, i.e. H3K27me3, and 
polycomb targeting in mouse cells. It remains elusive how HNRNPK interacts 
with the polycomb complex to perform this function. Yet, the observation that 
HNRNPK induces H3K27me3 presents an important building block for the 
mechanism suggested in this thesis. It links the splicing machinery at the CDV3 
transcript to the H3K27me3-promoting activity of the CU-RNA-T0 that has been 
observed in living cells (Figure 23). In line with this hypothesis, it was also slightly 
enriched at the CU-RNA-T0 in comparison to CU-RNA-ΔT0 in the RNA affinity 
purification assay as determined by mass spectrometry and western blotting 
(Table 15 and Figure 36) (see also section 3.3 of the discussion). This 
observation could explain the unique H3K27me3-promoting activity of 
CU-RNA-T0. Moreover, after HNRNPK knockdown the ratio of the two CDV3 
splice variants was shifted in the same direction as after EZH2 inhibition and 
knockdown (Figure 37). This also suggests that it is involved in the regulation of 
alternative splicing at the CDV3 locus. It is noted that only the CDV3b variant was 
influenced by the HNRNPK knockdown while the CDV3a transcript variant level 
remained unchanged. One could speculate that while the CDV3a transcript 
variant does not need H3K27me3 to be expressed, the HNRNPK knockdown 
mainly affects CDV3b expression because this isoform is dependent on HNRNPK 
that putatively influences the local H3K27me3 level. Furthermore, although the 
knockdown is almost complete, the effect on the CDV3b/CDV3a ratio is relatively 
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small, which might point to the involvement of additional factors in regulating the 
local H3K27me3.  
 
DDX17 
Finally, the helicase DDX17 was identified to uniquely bind the CU-RNA-T0 and 
not the CU-RNA-ΔT0 (Figure 35 and Appendix 2). A link between splicing 
regulation and chromatin state has not been made before for DDX17. It is noted 
that DDX17 interact with the H3K27 deacetylase HDAC1 (Wilson et al, 2004). 
This activity could thus contribute indirectly to lysine 27 methylation by EZH2 by 
removing a counteracting acetylation modification (Reynolds et al, 2011).  
 
5 Model of how CDV3 balances the abundance of its splice 
variants by modifying the local chromatin signature 
The suggested complexes of PTBP1-MRG15 and HNRNPK-PTBP1, and also 
putatively DDX17-HDAC1 represent suitable candidates for linking the splicing 
machinery of the CDV3 transcript variants to reading and writing of the local 
chromatin state at the CDV3 locus. Together with the direct competition between 
U2AF2 and HNRNPC, this network of RNA and chromatin binding proteins can 
be integrated in a model of how CU-RNA-T0 balances the abundance of the 
CDV3 splice isoforms by modulating the local H3K27me3 state (Figure 40). The 
following cycling mechanism is suggested: 
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1. The active CDV3 locus carries the H3K36me3 modification as a hallmark 
of transcribed genes but lacks H3K27me3. 
2. CDV3 pre-mRNA is transcribed. 
3. The splicing regulators U2AF2 and PTBP1 in complex with MRG15 and 
HNRNPK are recruited co-transcriptionally. 
4. The recruitment of the PTBP1-MRG15 complex requires the H3K36me3 
mediated targeting of MRG15 to chromatin. 
5. CDV3 pre-mRNA is spliced in favor of the CDV3a transcript containing the 
CU-RNA-T0 element. Unless PRC2 is recruited, CDV3 pre-mRNA 
transcription starts again in the same cycle. 
6. Alternatively, the spliced but still chromatin associated CU-RNA-T0 
recruits the PRC2 complex. 
7. H3K27me3 is set by PRC2 inducing the simultaneous presences of 
H3K27me3 and H3K36me3, which inhibits the MRG15-H3K36me3 
interaction. 
8. CDV3 pre-mRNA is transcribed from the CDV3 locus that now carries 
H3K27me3 and H3K36me3. 
9. Due to the changed chromatin state, HNRNPC is recruited instead of 
U2AF2 and the MRG15-PTBP1-HNRNPK complex. 
10. CDV3 pre-mRNA is spliced in favor of CDV3b containing the CU-RNA-ΔT0 
element and CDV3 pre-mRNA transcription starts again. 
11. This splice form lacks the H3K27me3-promoting activity recruited via the 
CU-RNA-ΔT0 element. Accordingly, the transcription cycle will switch to 
producing CDV3a again, if H3K27me3 is lost spontaneously or removed 
actively. 
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Figure 40: Model of how alternative splicing at the CDV3 locus is regulated. A complex of 
PTBP1 with the CU-RNA-T0 containing transcript (CDV3a) promotes H3K27me3 via HNRNPK. 
This state favors formation of the CU-RNA-ΔT0 containing splicing variant (CDV3b), which 
lacks the ability to induce H3K27me3. Thereby a feedback loop is established linking 3’-UTR 
directed H3K27me3 modification to splicing.  
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Many of the steps in this model are substantiated by the experimental data 
provided in this thesis and further supported by publications from other groups: 
First, it is known from RNA-FISH, northern blot and RT-PCR analyses that the 
CDV3 gene is expressed in HeLa cells (Figure 18). These data also show that 
the two transcript variants, CDV3a and CDV3b, are expressed at approximately 
equal levels. Whole transcriptome data from Caudron-Herger and colleagues 
further support this finding (Caudron-Herger et al, 2011). Accordingly, there must 
be a mechanism to adjust the balance between the two splicing variants as 
suggested in the model.  
Second, it has been demonstrated that CU-RNA-T0 as part of the CDV3a 
transcript has the capability to recruit EZH2 and to induce H3K27me3 when 
tethered to the lacO arrays (Figure 23 and Figure 24). This is translated into the 
model by the fact that CDV3a, which is still chromatin tethered during the process 
of transcription, could induce H3K27me3 of the locus. It is noted that also the 
CDV3b contained CU-RNA-ΔT0 could recruit EZH2. The model suggests, 
however, that the interaction with HNRNPK is necessary for an EZH2 state that is 
capable to set the H3K27me3 modification (Chu et al, 2015; Minajigi et al, 2015). 
It could be shown here that HNRNPK binds CU-RNA-T0 stronger than to 
CU-RNA-ΔT0 (Table 15 and Figure 36) and that knocking down HNRNPK leads 
to a decrease in the abundance of CDV3b in comparison to CDV3a (Figure 37). 
Therefore the H3K27me3-promoting activity is depicted as a unique feature of 
CU-RNA-T0.  
Third, it was demonstrated that reducing the level of H3K27me3 at the CDV3 
locus by EZH2 inhibition leads to a shift in the ratio of CDV3a and CDV3b in favor 
of the CDV3a variant (Figure 30, Figure 31 and Figure 34). This suggests that 
when the CDV3 locus is not methylated at H3K27 the CDV3a transcript is 
produced.  
Fourth, the coordination of the splicing event seems to be mediated by distinct 
binding of a complex of PTBP1-MRG15 to CU-RNA-T0 and the competition 
between U2AF2 and HNRNPC as RNA affinity purification, mass spectrometry, 
and western blotting suggested. In particular, the influence of the chromatin 
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reader MRG15 has been demonstrated by the fact that its knockdown leads to a 
change in the expression levels of both CDV3b and CDV3a. Moreover, as 
discussed in detail in section 4.3, all of these proteins have previously been 
shown to contribute to alternative splicing decisions in other systems and for 
other transcripts. The fact that pre-mRNA splicing occurs mostly co-
transcriptionally, i.e. while the transcript is still associated to chromatin, is in 
agreement with this (Listerman et al, 2006; Tilgner et al, 2012).  
A number of points depicted in the model shown in Figure 40 remain speculative 
and thus require further validation. As such, additional experiments, for example 
knockdown studies showing the involvement of the splicing factors U2AF2, 
HNRNPC and PTBP1 in the splicing decision, would be insightful. The 
contribution of the H3K36me3 reader MRG15 and the H3K27me3 promoting 
protein HNRNPK also need to be further validated. HNRNPK is suggested here 
to be a crucial factor for the formation of an active EZH2 state in complex with 
RNA. It thus needs to be further investigated if HNRNPK affects the enzymatic 
activity of EZH2 when in complex with different RNAs. This could for example be 
accomplished by repeating the in vitro methylation assay conducted in this thesis 
in the presence of recombinant HNRNPK or by examining the presence of 
HNRNPK at the lacO arrays when recruiting CU-RNA-T0. 
An alternative candidate for modulating EZH2 activity is JARID2. Although the 
link between alternative splicing and JARID2 has not been made previously, 
results from other groups have shown that in vitro JARID2 can partly rescue the 
inhibitory effect of RNA on the methylation activity of EZH2 (Cifuentes-Rojas et al, 
2014). Additionally, RNA pull-down experiments conducted in this study suggest 
that JARID2 is bound by CU-RNA-T0 (Figure 28) implying that it is potentially 
also involved in modulating the function of the EZH2-CU-RNA-T0 complex. 
Further studies in living cells will help to elucidate whether JARID2 is also 
involved in the regulation of H3K27me3 at the CDV3 locus.  
Lastly, the transitions to and from the transcription cycle leading to the expression 
of CDV3b remains poorly characterized. One unanswered questions is for 
example whether there is a specific reader of the H3K27me3 replacing the 
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MRG15 as a reader for H3K36me3. Furthermore, it is unclear how H3K27me3 is 
removed before the splicing machinery switches back to producing the CDV3a 
transcript. Potentially, H3K27me3 could be actively removed for example by the 
KDM6 family of lysine demethylases (Hong et al, 2007) or it could be lost 
spontaneously, e.g. during replication where the newly incorporated histone H3 
lacks a H3K27me3 modification (Scharf et al, 2009). Since both methylation and 
demethylation are rather slow processes (Zee et al, 2010), this also raises the 
question of how quickly the switch between CDV3a and CDV3b splicing can 
occur for example in response to external stimuli.  
In summary, the model of how alternative splicing at the CDV3 locus could be 
regulated by the H3K27me3-promoting activity of CU-RNA-T0 provides new 
insights into the connection between chromatin and splicing. It includes both the 
regulation of alternative splicing events by the local chromatin modifications as 
well as the influence of splicing on the chromatin structure. It thereby proposes a 
feedback loop that serves to maintain the balance between alternative transcript 
variants of CDV3. Although not addressed in this thesis, it is conceivable that 
external stimuli altering any of the involved protein and RNA factors could shift 
the balance to render the expression ratio of the two transcript variants to a 
favorable outcome for the cell’s current state. Generally, such a mechanism could 
serve to adapt the cell’s needs by regulating the availability of transcripts that are 
distinct with respect to their 3’-UTR sequence-dependent cytoplasmic activities. 
These could for example include stability of the transcripts or potential binding 
sites for miRNAs that are distinct for the splicing variants with different 3’-UTRs 
(Figure 41). Future genome and transcriptome wide studies will show if the 
mechanism proposed here for the CDV3 locus is a mechanism that is generally 
used to regulate expression of alternative transcripts.  
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6 Conclusion and perspectives 
This work investigated a previously unknown nuclear function of the 3’-UTR of 
the CDV3 transcript. A model is proposed in which a specific sequence element 
from this 3’-UTR affects the local level of H3K27me3 and thereby regulates 
alternative splicing of the CDV3 transcript variants (Figure 40). This chromatin 
state-dependent feedback loop might regulate the 3’-UTR-dependent cellular 
stability of the CDV3 transcript. Moreover, it might provide a mechanism to stably 
maintain a given ratio between transcript isoforms in the cell.  
To further strengthen the speculative points in this model discussed above, future 
experiments could comprise the following: By systematically perturbing each of 
the involved splicing factors, their role in the hypothesized model could be 
elucidated. Furthermore, investigating the role of HNRNPK in rescuing EZH2 
activity both in vitro and in vivo would be insightful. Finally, it would be interesting 
to gain insight into the dynamics of the process to be able to assess, on which 
time scale cells can adjust their splicing decision in response to external cues. 
While these steps of the model await further analyses, the model presents a new 
function of a 3’-UTR. It demonstrated a link between the previously described 
involvement of RNA in the recruitment and activity of the PCR2 complex and the 
cross talk between alternative splicing and the local chromatin signature. It is 
proposed that the regulation of the pathway from DNA to protein via chromatin 
modifications, transcription, and alternative splicing is not restricted to specific 
Figure 41: Shifting the balance of transcript isoforms to adapt the cell’s needs by 
regulating the availability of transcripts with distinct cytoplasmic functions. For example 
transcript stability or binding sites for miRNAs could be distinct within the different isoforms. 
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groups of RNAs as introduced at the beginning (Figure 1). Instead, a cross talk 
between the RNA-mediated regulatory mechanisms is inferred from the results 
obtained here. Genome- and transcriptome-wide studies will show whether the 
proposed mechanism is also used by other transcripts, which can vary in their 
last exons to modify their 3’-UTR-dependent cellular functions.  
Understanding the complex network of alternative splicing regulation, EZH2 
activity, H3K27me3 distribution, and the influence of RNA and in particular 
3’-UTRs has a number of implications. It is important for the development of 
novel drugs for cancer therapies for the following reasons: First, the tight control 
of alternative splicing is deregulated in many cancers so that aberrant proteins 
resulting in aggressive and invasive cancer phenotypes are produced (Oltean & 
Bates, 2014).  
Second, EZH2 itself has been shown to be mutated or deregulated in many 
cancer types. Interestingly, mutations leading to the depletion of EZH2 activity 
(Nikoloski et al, 2010) as well as an increase in EZH2 activity by mutations in the 
catalytically active domain (Sneeringer et al, 2010) or its overexpression 
(Asangani et al, 2013; Kleer et al, 2003; Varambally et al, 2008; Visser et al, 
2001) have been identified. For this reason, drugs targeting EZH2 enzymatic 
activity are currently being developed and have been shown to be effective in 
influencing the global levels of H3K27me3 (McCabe et al, 2012). Future studies 
will show whether a potentially positive treatment outcome can only be attributed 
to changes in the H3K27me3 levels or whether the influence of inhibiting EZH2 is 
more far-reaching by also targeting alternative splicing as suggested here in this 
thesis.  
Third, a mutation in the gene encoding for the histone H3 variant H3.3 resulting in 
an amino acid change at position 27 from a lysine to a methionine (H3.3K27M 
mutation) was identified in glioblastoma multiforme (Khuong-Quang et al, 2012; 
Schwartzentruber et al, 2012; Sturm et al, 2012; Wu et al, 2012). This finding is of 
particular interest here because tumors with this mutation show lower overall 
H3K27me3 levels due to the fact that H3.3K27M inhibits the enzymatic activity of 
EZH2 (Bender et al, 2013; Bjerke et al, 2013; Chan et al, 2013; Lewis et al, 2013). 
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By this mutation, another way of deregulating H3K27me3 levels exists in tumors 
in addition to mutations in EZH2.  
Finally, the regulation of chromatin modifications that alter alternative splicing 
decisions might not be restricted to EZH2 itself but could potentially be expanded 
to further chromatin modifying enzymes. Genome-sequencing studies have 
reported on a large variety of mutations in genes encoding for chromatin-
modifying proteins (Plass et al, 2013). Therefore, chromatin-modifying proteins 
are emerging as targets in cancer therapeutics and the first epigenetic-based 
therapies have already been approved, which involve the inhibition of histone 
deacetylases (Helin & Dhanak, 2013; Khan & La Thangue, 2012; Wagner et al, 
2010). Most studies that investigate the potential of targeting chromatin-modifying 
proteins disregard the effect of those drugs on alternative splicing. However, it 
could turn out that their positive influence on cancer progression can, at least in 
parts, be attributed to their effect on alternative splicing.  
In conclusion, further unraveling the connections between 3’-UTRs, alternative 
splicing and RNA-mediated chromatin modifications will have far-reaching 
implications for our understanding of how cells manage to stably control the 
abundance of certain transcript variants. Thus, understanding the mechanisms 
that link alternative splicing and alterations in chromatin modifications in healthy 
and cancer cells will significantly broaden the possibilities for therapeutic 
intervention when those processes are deregulated. 
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Appendix 
 
Appendix 1: ChIP-seq of DMSO- and GSK343-treated HeLa cells. The amount of reads 
obtained from each reaction, the number of reads that mapped to the human genome, the mouse 
genome, and the number of reads that could not be mapped are depicted.  
Treatment Replicate ChIP # total reads 
# mapped 
human 
# mapped 
mouse # unmapped 
DMSO 
1 
H3K27me3 113911968 74787230 19442463 19682275 
H3 102522508 71012639 12856658 18653211 
IgG 72747831 49018820 11404975 12324036 
input 116369053 86354416 10626027 19388610 
2 
H3K27me3 79910282 47626991 18050085 14233206 
H3 97098140 65915419 13171632 18011089 
IgG 97297313 58871263 20771057 17654993 
input 88937213 66512430 7773056 14651727 
GSK343 
1 
H3K27me3 72326818 47343747 12307152 12675919 
H3 86630951 62341154 8316458 15973339 
IgG 75508616 51284152 11085523 13138941 
input 89329647 68812742 5500450 15016455 
2 
H3K27me3 84596062 57854730 11956507 14784825 
H3 94716321 70051851 7322333 17342137 
IgG 86459351 60414415 11046479 14998457 
input 94243869 72269396 5580627 16393846 
 
 
Appendix 2: RNA affinity purification and mass spectrometry of aluRNAR, CU-RNA-T0, 
CU-RNA-T2, RepA and CU-RNA-ΔT0. The peptide counts for all proteins that were identified are 
depicted. 
Protein Description beads aluRNAR T0 T2 RepA ΔT0 
NONO Non-POU domain-containing octamer-binding protein  9 17 84 117 91 65 
PTBP1 Polypyrimidine tract-binding protein 1 5 6 43 105 108 24 
ROA1 Heterogeneous nuclear ribonucleoprotein A1  1 19 60 100 54 75 
VIGLN Vigilin 0 12 65 69 81 70 
FUBP1 Far upstream element-binding protein 1 1 5 85 84 77 42 
SND1 Staphylococcal nuclease domain-containing protein 1 0 0 58 109 64 21 
HNRNPK Heterogeneous nuclear ribonucleoprotein K 1 3 57 46 71 45 
FUBP2 Far upstream element-binding protein 2 1 16 61 70 61 35 
SFPQ Splicing factor, proline- and glutamine-rich 13 21 37 65 53 32 
HNRH1 Heterogeneous nuclear ribonucleoprotein H   3 37 28 49 45 17 
ROA2 Heterogeneous nuclear ribonucleoproteins A2/B1 0 19 55 54 28 60 
K2C1 Keratin, type II cytoskeletal 1 31 47 12 20 39 23 
G3BP1 Ras GTPase-activating protein-binding protein 1 0 3 35 60 52 23 
HNRNPQ Heterogeneous nuclear ribonucleoprotein Q 1 10 36 56 41 35 
K1C10 Keratin, type I cytoskeletal 10 28 30 8 21 28 17 
LPPRC Leucine-rich PPR motif-containing protein, mitochondrial 0 0 16 45 62 14 
PABP1 Polyadenylate-binding protein 1 9 9 21 43 34 24 
U2AF2 Splicing factor U2AF 65 kDa subunit 0 0 28 47 46 6 
HNRNPD Heterogeneous nuclear ribonucleoprotein D0 0 3 16 38 43 19 
HNRNPU Heterogeneous nuclear ribonucleoprotein U 0 11 30 31 22 27 
NUCL Nucleolin 6 19 14 21 37 12 
HNRNPM Heterogeneous nuclear ribonucleoprotein M 0 0 6 43 67 5 
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Protein Description beads aluRNAR T0 T2 RepA ΔT0 
K1C9 Keratin, type I cytoskeletal 9 20 31 5 8 27 14 
HNRNPL Heterogeneous nuclear ribonucleoprotein L 0 0 18 40 12 16 
K22E Keratin, type II cytoskeletal 2 epidermal 21 32 6 12 26 15 
CSDE1 Cold shock domain-containing protein E1 0 0 22 36 11 25 
ROAA Heterogeneous nuclear ribonucleoprotein A/B  0 4 22 22 27 22 
HNRNPF Heterogeneous nuclear ribonucleoprotein F 0 25 20 32 18 11 
STRAP Serine-threonine kinase receptor-associated protein 0 0 19 34 16 21 
FUS RNA-binding protein FUS 0 0 14 32 27 14 
DAZP1 DAZ-associated protein 1 0 0 14 26 18 17 
CAPR1 Caprin-1 0 2 16 22 23 18 
PCBP2 Poly(rC)-binding protein 2 2 0 10 11 35 11 
TADBP TAR DNA-binding protein 43 0 4 14 17 19 8 
RS3 40S ribosomal protein S3 0 1 11 18 20 16 
IF2B3 Insulin-like growth factor 2 mRNA-binding protein 3 0 1 13 18 21 7 
ELAV1 ELAV-like protein 1 0 0 9 17 27 9 
TIAR Nucleolysin TIAR  0 0 13 22 22 9 
PUF60 Poly(U)-binding-splicing factor PUF60 0 0 5 23 28 3 
CELF1 CUGBP Elav-like family member 1 0 0 1 38 22 3 
RENT1 Regulator of nonsense transcripts 1 0 2 4 25 23 3 
HNRH2 Heterogeneous nuclear ribonucleoprotein H2 0 22 19 34 28 13 
DHX9 ATP-dependent RNA helicase A 0 11 8 16 11 7 
ANXA2 Annexin A2 2 1 7 16 20 11 
FUBP3 Far upstream element-binding protein 3 0 1 17 37 22 15 
ROA0 Heterogeneous nuclear ribonucleoprotein A0 0 0 15 18 14 14 
DDX5 Probable ATP-dependent RNA helicase 1 3 8 14 11 13 
KHDR1 KH domain-containing, RNA-binding, sial transduction-associated protein 1 0 2 12 14 3 9 
HNRDL Heterogeneous nuclear ribonucleoprotein D-like 0 2 13 22 22 16 
G3BP2 Ras GTPase-activating protein-binding protein 2 0 2 8 26 22 8 
IF2G Eukaryotic translation initiation factor 2 subunit 3 0 1 10 12 6 9 
ROA3 Heterogeneous nuclear ribonucleoprotein A3 0 2 10 18 7 16 
IF2A Eukaryotic translation initiation factor 2 subunit 1 0 1 13 10 6 12 
CCAR1 Cell division cycle and apoptosis regulator protein 1 0 0 2 11 20 4 
HNRH3 Heterogeneous nuclear ribonucleoprotein H3 0 2 4 13 13 7 
U2AF1 Splicing factor U2AF 35 kDa subunit 0 0 7 15 19 5 
MATR3 Matrin-3 0 1 2 16 21 2 
UBP2L Ubiquitin-associated protein 2-like 0 0 9 14 13 8 
CPSF7 Cleavage and polyadenylation specificity factor subunit 7 0 0 3 20 10 11 
CPSF5 Cleavage and polyadenylation specificity factor subunit 5 0 0 2 18 11 14 
BUB3 Mitotic checkpoint protein BUB3 0 0 8 11 12 8 
EF1A1 (+1) Elongation factor 1-alpha 1 0 2 4 14 11 8 
CSTF3 Cleavage stimulation factor subunit 3 0 0 0 19 15 0 
HNRNPR Heterogeneous nuclear ribonucleoprotein R  0 0 16 33 20 16 
RU17 U1 small nuclear ribonucleoprotein 70 kDa 0 0 10 4 0 12 
GRSF1 G-rich sequence factor 1 0 8 2 10 9 1 
SNRPA U1 small nuclear ribonucleoprotein A 0 0 16 6 2 11 
PABP4 Polyadenylate-binding protein 4 5 8 13 26 22 12 
CSTF1 Cleavage stimulation factor subunit 1 0 0 0 18 17 0 
IF2B1 Insulin-like growth factor 2 mRNA-binding protein 1 0 0 12 12 11 8 
SF01 Splicing factor 1 1 2 5 8 5 2 
MBNL1 Muscleblind-like protein 1 0 0 6 5 7 5 
PAIRB Plasminogen activator inhibitor 1 RNA-binding protein 0 0 4 11 6 6 
ILF2 Interleukin enhancer-binding factor 2 0 0 0 11 11 3 
PSPC1 Paraspeckle component 1 0 0 6 10 7 2 
ADT3 ADP/ATP translocase 3 0 1 2 9 9 7 
DDX17 Probable ATP-dependent RNA helicase DDX17 0 4 6 19 15 0 
CN166 UPF0568 protein C14orf166 0 0 0 8 8 10 
DDX3X ATP-dependent RNA helicase DDX3X 0 2 3 9 5 5 
AQR Intron-binding protein aquarius 0 2 3 13 5 1 
SMD2 Small nuclear ribonucleoprotein Sm D2 0 0 8 6 3 10 
RTCB tRNA-splicing ligase RtcB homolog 0 0 5 4 3 5 
UBP10 Ubiquitin carboxyl-terminal hydrolase 10 0 0 2 9 6 4 
SRSF1 Serine/arginine-rich splicing factor 1 0 0 5 3 8 6 
SRSF2 Serine/arginine-rich splicing factor 2 0 1 4 5 8 4 
RS10 40S ribosomal protein S10 0 0 2 5 3 4 
ILF3 Interleukin enhancer-binding factor 3 0 0 1 10 8 0 
EWS RNA-binding protein EWS 0 1 4 8 5 3 
RSMB Small nuclear ribonucleoprotein-associated proteins B and B'  0 0 6 2 1 8 
SMD1 Small nuclear ribonucleoprotein Sm D1   0 0 6 6 3 11 
RBM14 RNA-binding protein 14   0 0 3 8 10 2 
RLA0 60S acidic ribosomal protein P0   0 0 3 10 5 4 
IF2B Eukaryotic translation initiation factor 2 subunit 2  0 0 4 6 1 5 
RS2 40S ribosomal protein S2 0 0 4 4 6 5 
RL10A 60S ribosomal protein L10a 0 0 2 7 3 3 
SMD3 Small nuclear ribonucleoprotein Sm D3  0 0 11 4 3 7 
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Protein Description beads aluRNAR T0 T2 RepA ΔT0 
RS20 40S ribosomal protein S20 0 0 4 5 4 4 
GEMI5 Gem-associated protein 5 0 0 0 6 12 0 
DRG1 Developmentally-regulated GTP-binding protein 1 0 0 6 6 2 2 
PTBP3 Polypyrimidine tract-binding protein 3 0 0 0 9 17 0 
RS12 40S ribosomal protein S12 0 0 2 7 8 7 
GTPB8 GTP-binding protein 8 0 0 2 4 6 5 
RBM3 Putative RNA-binding protein 3 0 0 2 8 5 2 
IF4G1 Eukaryotic translation initiation factor 4 gamma 1 0 0 1 9 3 5 
CIRBP Cold-inducible RNA-binding protein  0 0 2 6 6 5 
PCBP1 Poly(rC)-binding protein 1  0 0 0 7 25 7 
RUXE Small nuclear ribonucleoprotein E   0 0 6 3 3 6 
NEP1 Ribosomal RNA small subunit methyltransferase NEP1  0 0 1 4 6 7 
DDX1 ATP-dependent RNA helicase DDX1  0 0 2 10 6 0 
ACTG Actin, cytoplasmic 2   1 4 1 4 3 3 
HSP7C Heat shock coate 71 kDa protein   0 0 0 6 6 2 
RBM4 RNA-binding protein 4   0 0 0 0 15 0 
RS5 40S ribosomal protein S5   0 0 4 4 4 2 
SLIRP SRA stem-loop-interacting RNA-binding protein, mitochondrial  0 0 1 4 5 3 
CSTF2 Cleavage stimulation factor subunit 2  0 0 0 6 6 0 
SRSF3 Serine/arginine-rich splicing factor 3   0 0 1 5 5 3 
SRS11 Serine/arginine-rich splicing factor 11   0 0 1 6 7 0 
SYF1 Pre-mRNA-splicing factor SYF1   0 0 0 6 1 0 
NCOA2 Nuclear receptor coactivator 2  0 2 0 0 0 0 
K2C8 Keratin, type II cytoskeletal 8  0 5 0 4 6 2 
ODB2 
Lipoamide acyltransferase component of branched-
chain alpha-keto acid dehydrogenase complex, 
mitochondrial  1 4 0 0 0 2 
SF3A1 Splicing factor 3A subunit 1   2 5 0 0 1 0 
PHB Prohibitin  0 0 0 4 1 5 
IQGA1 Ras GTPase-activating-like protein IQGAP1 0 3 0 4 0 0 
RL22 60S ribosomal protein L22  0 0 4 4 3 2 
RS9 40S ribosomal protein S9  0 0 0 2 2 3 
RBM39 RNA-binding protein 39 0 0 1 4 5 0 
MANF Mesencephalic astrocyte-derived neurotrophic factor   1 1 0 1 2 2 
RS19 40S ribosomal protein S19  0 0 1 3 3 1 
RU2A U2 small nuclear ribonucleoprotein A'   0 0 1 3 3 4 
MSI2H RNA-binding protein Musashi homolog 2   0 0 1 2 0 7 
RL12 60S ribosomal protein L12   1 1 1 3 3 3 
TIA1 Nucleolysin TIA-1 isoform p40   0 0 7 10 8 0 
TOP1 DNA topoisomerase 1   0 0 1 4 1 1 
ZN207 BUB3-interacting and GLEBS motif-containing protein ZNF207    0 0 1 3 3 2 
RAN GTP-binding nuclear protein Ran  0 0 2 3 3 2 
PPIB Peptidyl-prolyl cis-trans isomerase B   0 0 1 2 3 2 
K2C5 Keratin, type II cytoskeletal 5   7 9 0 0 4 0 
MOES Moesin 0 0 1 3 2 0 
RBM10 RNA-binding protein 10   0 0 0 1 6 1 
RS16 40S ribosomal protein S16   0 0 0 3 3 3 
SREK1 Splicing regulatory glutamine/lysine-rich protein 1  0 0 0 5 4 0 
SDOS Protein syndesmos   0 1 0 2 1 1 
RCC2 Protein RCC2   0 0 1 2 2 0 
K2C6A Keratin, type II cytoskeletal 6A   6 9 0 0 5 0 
K1C14 Keratin, type I cytoskeletal 14   8 6 0 0 0 3 
CPSF6 Cleavage and polyadenylation specificity factor subunit 6   0 0 0 9 0 0 
HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2   0 0 1 1 5 2 
RUXF Small nuclear ribonucleoprotein F   0 0 3 2 1 4 
PHB2 Prohibitin-2  0 0 0 2 2 2 
LRC59 Leucine-rich repeat-containing protein 59  0 0 0 2 1 3 
NUFP2 Nuclear fragile X mental retardation-interacting protein 2   0 0 0 2 3 1 
RBMX RNA-binding motif protein, X chromosome   0 0 0 3 0 3 
CNBP Cellular nucleic acid-binding protein  CNBP   0 0 2 0 0 5 
NCBP1 Nuclear cap-binding protein subunit 1  0 0 0 4 0 0 
PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  0 7 0 0 0 0 
ALBU Serum albumin   2 4 0 0 0 0 
F120C Constitutive coactivator of PPAR-gamma-like protein 2   0 0 0 0 1 2 
LC7L3 Luc7-like protein 3   0 0 1 1 0 7 
IF4B Eukaryotic translation initiation factor 4B   0 0 0 4 1 0 
RL11 60S ribosomal protein L11   0 0 2 2 2 2 
HNRL1 Heterogeneous nuclear ribonucleoprotein U-like protein 1   0 2 0 2 1 0 
RS4X 40S ribosomal protein S4, X isoform   0 0 0 2 1 0 
LYRIC Protein LYRIC  MTDH   0 0 0 6 0 0 
RS7 40S ribosomal protein S7   0 0 1 1 1 2 
MCM5 DNA replication licensing factor 0 1 0 2 1 0 
TCP4 Activated RNA polymerase II transcriptional coactivator p15   0 0 0 2 2 2 
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Protein Description beads aluRNAR T0 T2 RepA ΔT0 
RBM47 RNA-binding protein 47   0 0 1 3 2 0 
RS15A 40S ribosomal protein S15a  0 0 0 1 2 2 
GRP78 78 kDa glucose-regulated protein   0 0 0 3 2 1 
RS27A Ubiquitin-40S ribosomal protein S27a   0 0 0 2 1 0 
DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase  0 0 0 2 3 0 
RL9 60S ribosomal protein L9   0 0 0 2 2 0 
RUXG Small nuclear ribonucleoprotein G   0 0 1 0 0 3 
HS71A Heat shock 70 kDa protein 1A   0 0 0 5 4 0 
ZCCHV Zinc finger CCCH-type antiviral protein 1   0 0 0 1 3 0 
PURB Transcriptional activator protein Pur-beta  0 0 0 0 0 3 
RAB10 Ras-related protein Rab-10   0 0 1 2 1 0 
SC61B Protein transport protein Sec61 subunit beta  0 0 0 0 2 1 
RS28 40S ribosomal protein S28  0 0 0 1 0 2 
DHX36 ATP-dependent RNA helicase DHX36   0 0 0 2 3 0 
ZCRB1 Zinc finger CCHC-type and RNA-binding motif-containing protein 1   0 0 0 0 3 0 
ADT2 ADP/ATP translocase 2   0 0 0 8 10 6 
IMA1 Importin subunit alpha-1   0 0 0 1 2 0 
ZC3HF Zinc finger CCCH domain-containing protein 15  0 0 1 3 0 0 
IF2P Eukaryotic translation initiation factor 5B   0 0 1 3 0 0 
MCM3 DNA replication licensing factor  0 0 0 2 0 0 
K1C16 Keratin, type I cytoskeletal 16   10 0 0 0 0 0 
SYFB Phenylalanine-tRNA ligase beta subunit   0 0 0 1 2 0 
SSBP Single-stranded DNA-binding protein, mitochondrial  0 0 0 3 0 0 
PUM2 Pumilio homolog 2  0 0 0 2 0 0 
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